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Zusammenfassung 
Das bHLHZip Protein MAD1 gehört zum MYC/MAX/MAD Netzwerk von 
Transkriptionsfaktoren. Dieses Netzwerk spielt eine zentrale Rolle bei der Regulation 
verschiedener Aspekte der Zellphysiologie. MAD1 bindet mit seinem obligatorischen 
Heterodimerisierung Partner MAX an E-Box Konsensus-Motive und reprimiert die 
Transkription von Zielgenen. Diese transkriptionelle Repression basiert auf der Rekruitierung 
des mSin3 Ko-Repressor-Komplex und antagonisiert zum Teil die Funktion des 
Onkoproteins c-MYC. Die Expression der MAD Gene korreliert im Allgemeinen mit 
Differenzierungprozessen und dem Verlassen des Zellzyklus. Des Weiteren ist MAD1 an der 
Induktion von Seneszenz beteiligt und hemmt die Apoptose. Diese Funktionen stehen im 
Einklang mit dem Phänotyp, der in mad1 knock out Mäuse beobachtet wurde. Neutrophile 
Vorläuferzellen in mad1-/- Mäuse zeigen beschleunigte Zellteilungen vor der terminalen 
Differenzierung und terminal ausdifferenzierte Zellen sind sensitiver gegenüber Apoptose 
induzierenden Bedingungen.……………...………………………………..…………………………  
In der vorliegenden Studie wurde die Regulation der Expression des MAD1 Gens nach 
TGFβ1 Stimulation in der Promyelozyten Zelllinie U937 untersucht. Die Analyse TGFβ1 
assoziierter Signalwege zeigte eine kritische Rolle der MAP-Kinase p38. Die Aktivierung 
dieser Kinase ist essentiell aber nicht allein ausreichend für die TGFβ1 oder durch zellulären 
Stress vermittelte MAD1 Promotor Aktivierung. Für die effiziente Induktion der MAD1 
Expression sind zusätzliche Signale erforderlich. 
Der MAD1 Promoter ist ein CpG-Insel-Promotor ohne TATA-Box und besitzt eine Region 
hoher Sequenzhomologie, die durch eine offene Chromatinstruktur gekennzeichnet ist. Der 
proximale Promotor besitzt mehrere Transkriptionsfaktor Bindungsmotive, darunter zwei 
CCAAT- und GC-Boxen und ein E-Box-Element. Die Transkriptionsfaktoren der C/EBP 
Familien, C/EBPα und C/EBPβ sind konstitutiv am Promotor gebunden und aktivieren 
Reportergene, die vom proximalen MAD1 Promotor kontrolliert werden. In in-vitro 
Experimenten konnte gezeigt werden, dass C/EBPα und C/EBPβ als Heterodimer an die 
CCAAT-Box 1 binden. Allerdings sind beide CCAAT-Boxen für die C/EBPβ abhängige 
Aktivierung des MAD1 Promoters relevant. Ausserdem konnte gezeigt werden, dass C/EBPβ 
und SP1, ein GC-Box bindender Transkriptionsfaktor, in der Aktivierung des MAD1 
Promoters kooperieren, abhängig von jeweils einer CCAAT- und einer GC-Box. Ähnlich wie 
C/EBPα und C/EBPβ, ist SP1 konstitutiv am MAD1 Promoter gebunden. Des Weiteren 
konnte beobachtet werden, dass C/EBPα und SMAD3 in der Aktivierung des MAD1 
Promotors zusammenwirken, während andere SMAD Proteine in der Promoter-Aktivierung 
keine Rolle spielen. Dies lässt darauf schliessen, dass nicht-konventionelle TGFβ1 
Signalwege an der Regulation der MAD1 Expression beteiligt sind. Ein weiterer Faktor, der 
konstitutiv am MAD1 Promoter gebunden ist c-MYC. Die Analyse der funktionellen 
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Bedeutung von c-MYC für die MAD1 Expression zeigte, dass c-MYC als Repressor der 
C/EBPβ induzierten Aktivierung des MAD1 Promotors fungiert. Beide Faktoren interagieren 
in-vivo, wobei c-MYC die Bindung des C/EBPα - C/EBPβ Heterodimers an die CCAAT-box 1 
beeinträchtigt. Zusätzlich zu den konstitutiv gebunden Sequenz-spezifischen 
Transkriptionsfaktoren, ist der MAD1 Promoter durch den RNA Polymerase II (Pol II) 
Komplex gebunden und trägt Histonemodifikation, die mit aktiver Transkription assoziiert 
sind, unter anderem ist Histone H3 trimethyliert an Lysin K4 und stark acetyliert. Sowohl die 
Bindung des Pol II Komplexes an den MAD1 Promoter, als auch das 
Histonesmodifikationsmuster wurden durch TGFβ1 Stimulation nicht beeinflusst. Allerdings 
konnte gezeigt werden, dass die TGFβ1 Stimulation einen Wechsel in der Phosphorylierung 
der Pol II C-terminale Domäne von Serin-5 zu Serin-2 initiiert. Diese Änderung ist in der 
Regel mit einem Wechsel von der Initiation zur produktiven Elongation der Pol II assoziiert. 
Übereinstimmend mit diesem Befund konnte nach TGFβ1 Stimulation die elongierende Pol II 
innerhalb des MAD1 Gens detektiert werden. Zusammenfassend legen diese Ergebnisse 
nahe, dass der MAD1 Promotor in einem voraktivierten Zustand vorliegt, der eine schnelle 
Aktivierung und Initiation der Transkription des MAD1 Gens in Reaktion auf verschiedene 
Signale ermöglicht. 
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Abstract 
The bHLHZip protein MAD1 belongs to the MYC/MAX/MAD network of transcriptional 
regulators. This network plays a pivotal role in the regulation of different aspects of cell 
physiology. MAD1 binds with its obligatory heterodimerization partner MAX to E-box motifs 
and represses target gene transcription. This transcriptional repression bases on the 
recruitment of the mSin3 co-repressor complex and antagonizes at last in part the function of 
the oncoprotein c-MYC. The expression of MAD genes generally correlates with 
differentiation and cell cycle exit. Furthermore MAD1 is involved in the induction of 
senescence and inhibits apoptosis, which is in line with the MAD1 knockout phenotype. 
Neutrophilic progenitor cells of mad1-/- mice show accelerated cell divisions prior to terminal 
differentiation and in addition terminally differentiated cells are highly sensitive to apoptosis-
inducing conditions. 
In the present study the regulation of MAD1 expression in response to TGFβ1 was examined 
in the promyelocytic cell line U937. The analysis of the TGFβ-associated signalling pathways 
revealed a critical role of the MAP kinase p38. This kinase is necessary but not sufficient to 
activate the MAD1 promoter in response to TGFβ1 and cellular stress, indicating that 
additional signals are required for efficient MAD1 induction. The MAD1 promoter is a TATA-
less CpG island promoter containing a region of high sequence homology, which is 
characterized by an open, poorly structured chromatin. The proximal promoter possesses 
several transcription factor recognition motifs including two CCAAT- and GC-boxes and an 
E-box element. The C/EBP family members C/EBPα and C/EBPβ are constitutively bound to 
the promoter in cells and capable to activate reporter genes that are controlled by the 
proximal MAD1 promoter. In vitro C/EBPα and C/EBPβ bind as heterodimer to one of the 
CCAAT-boxes. However, for reporter gene expression both CCAAT-boxes are relevant to 
mediate C/EBPβ responsiveness. In addition C/EBPβ co-operates with SP1, a GC-box 
binding factor, in the activation of the MAD1 promoter and, consistent with this observation, 
one CCAAT- and one GC-box are critical to mediate this co-operativity. Similarly to C/EBPα 
and C/EBPβ, SP1 is constitutively bound to the MAD1 promoter. Moreover C/EBPα was 
observed to co-operate with SMAD3 in the activation of the MAD1 promoter whereas other 
SMAD proteins were inactive, indicating that a non-conventional TGFβ1-SMAD signalling 
complex is important to regulate MAD1 expression.  
Another factor constitutively bound to the MAD1 promoter is c-MYC. The analysis of the 
functional relevance of c-MYC for MAD1 expression revealed that c-MYC functions as a 
repressor of C/EBPβ-induced activation of the MAD1 promoter. Both factors interact in vivo 
and c-MYC impairs the binding of the C/EBPα-C/EBPβ heterodimer to the CCAAT-box 1. 
In addition to the constitutively bound sequence-specific transcription factors, the MAD1 
promoter is occupied by a pre-assembled Pol II complex and the promoter-associated 
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chromatin has all the hallmarks of an active promoter region. Histone H3 located at the 
MAD1 promoter is highly acetylated and carries trimethylated H3K4, modifications that are 
linked to active transcription. These modifications are not affected by stimulation with TGFβ1, 
suggesting that this cytokine regulates further downstream events relevant for the activation 
of the polymerase. TGFβ1 stimulation initiates a switch of the phosphorylation of the Pol II C-
terminal domain from Ser-5 to Ser-2. This change is typically associated with a change from 
the initiation to the productive elongation mode of Pol II. In agreement with this finding, the 
elongating Pol II progresses into the gene body and can be found associated with further 
downstream DNA regions. Together these findings suggest that the MAD1 promoter is 
assembled in a pre-activated state, which is responsive to various signalling pathways and 
which allows the rapid initiation of transcription of the MAD1 gene. 
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1 Introduction 
 
1.1 Regulation of gene expression 
1.1.1 Gene expression in eukaryotes  
All organisms exhibit generally two types of genes in their genome, non-coding RNA genes 
and protein-coding genes. In eukaryotes the majority of protein-coding genes consist of 
coding sequences, termed exons, interspersed by non-coding regions, called introns, and 
flanking untranslated regulatory DNA elements, which ensure proper regulation of 
expression. Moreover, regulatory DNA elements are located within introns and exons.   
The bulk of genes is dynamically expressed in a developmental-, a tissue- and a signal-
dependent manner. The dynamic regulation is fundamental to ensure the functional integrity 
of all cellular processes under certain physiological and environmental conditions, including 
proliferation and cell growth, differentiation, stress and external signals. The tight control of 
expression of a precise subset of genes is necessary for genotypically identical cells to 
achieve diverse cellular functions.  
Over the last decades the complexity of gene regulation has been extensively studied and 
was discovered to occur on multiple levels. All processes from the regulation of chromatin to 
the control of protein function are part of the overall process of gene expression. The 
following levels can be modulated during gene expression (Orphanides and Reinberg, 2002):  
• Chromatin accessibility/transcription 
• Post-transcriptional modifications/RNA processing 
• RNA transport 
• Translation 
• Post-translational modifications  
• mRNA degradation 
The deregulation of gene expression has most frequently serious consequences for the 
whole organism, like for instance the development of cancer. 
 
1.1.1 Generic regulation of transcription  
A critical level of transcriptional regulation occurs through the promoter of genes. It can be 
subdivided into the core and regulatory promoter elements. This organization is true in 
essence for all genes. The following chapter is concentrated on the situation as it occurs for 
protein coding genes that are transcribed by RNA polymerase II (Pol II). The core promoters 
are the DNA regions that are bound by a variety of general transcription factors (GTFs). 
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These factors are ubiquitously expressed and essential for the recruitment and the correct 
positioning of Pol II over the start site of transcription. Until now seven DNA motifs located 
within core promoter regions have been identified. These include the A/T-rich TATA box 
sequence, the initiator motif (INR) and the downstream promoter element (DPE) (Figure 1). 
These elements are not all obligatory present in all Pol II regulated promoters and, indeed, 
functional studies have confirmed that most human promoters are TATA-less (Thomas and 
Chiang, 2006). The proximal promoter region is located immediately upstream of the core 
promoter spanning roughly 500-1000 bp. This region typically contains functional cis-acting 
elements that are recognized by sequence specifically transcription factors (gene-specific 
transcription factors), which can act either as activators or repressors of transcription. The 
sequence-specific transcription factors mediate their functions through the recruitment of 
multiprotein co-activator or co-repressor complexes to their target genes (Kadonaga, 2004). 
An important consequence of the transcription factor-dependent recruitment of co-factor 
complexes is the alteration of chromatin structure and the post-translational modification of 
core histones, which either facilitates or hampers chromatin accessibility (Orphanides and 
Reinberg, 2002). The gene-specific transcription factors are generally expressed cell- or 
tissue specifically, which ensures the tight transcriptional regulation of their target genes in a 
context dependent manner.  
 
 
 
Figure 1: Simplified overview of regulatory DNA elements. These elements are located in the promoter region 
and may also be located in introns and exons 3´ of the core promoter (not shown for simplicity) and transcription 
factor complexes involved in the regulation of transcription. These complexes control Pol II function by modulating 
chromatin and determining core histone modifications. TF: transcription factor; Co-R: co-repressor complex; Co-
A: co-activator complex; TBP: TATA binding protein.  
 
In addition to the proximal promoter elements, distal enhancer, silencer and insulator 
modules are involved in the proper regulation of the transcription of many Pol II genes 
(Figure 1). Enhancer regions were first identified in the simian virus (SV) 40 polyomavirus 
and are capable to activate target gene transcription over a distance of more than 100 kb. 
Enhancer elements contain similar recognition motifs compared to proximal promoter 
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regions. Enhancers can be located 5´or 3´ of the transcriptional start site (TSS) and possess 
the ability to act bi-directionally (Blackwood and Kadonaga, 1998).  
Silencer elements down regulate target gene expression by various mechanisms, for 
instance by impairing the activity of positively acting transcription factors. Furthermore, they 
are capable to influence chromatin structure, intron-splicing and GTF assembly.  
The third long distant acting element is the insulator element. Insulator elements are involved 
in the transcriptional control, global nuclear organization and are described to play a role in 
epigenetic inheritance (Bushey et al., 2008). Two subtypes of insulators have been identified, 
firstly the enhancer blocking insulator, which disrupts the functional communication between 
enhancer or silencer elements and the promoter region, and secondly the barrier insulators 
preventing the spreading of heterochromatin. The ubiquitous Zn-finger containing CCCTC-
binding factor (CTCF) is currently the only known insulator binding protein in vertebrates.  
Another frequently appearing motif inside promoter regions are CG-rich elements termed 
CpG islands (CGIs). These CpG-rich sequences are present in constitutively expressed 
genes and overall present in 60-70% of all human promoters (Illingworth and Bird, 2009). 
While most of the CGI are un-methylated, methylation of CGI results in stable gene silencing. 
This is in contrast to CpGs that are not located in CGI and they are mostly methylated. In 
malignant cells tumour suppressor genes are frequently shut off as a result of CGI promoter 
methylation. Moreover DNA methylation is employed to inactivate one X chromosome in 
females and for genomic imprinting. More recently tissue-specific methylation patterns were 
identified, suggesting a role in the regulation of cell specificity (Illingworth and Bird, 2009). 
Generally non-CGI promoters are associated with one well-defined TSS, whereas 
transcription in CGIs promoters can be initiated from multiple start sites (Sandelin et al., 
2007).  
 
1.1.2 The RNA polymerase II transcription cycle 
The Pol II transcription cycle is an intricate multistep process, subdivided into pre-initiation, 
initiation, promoter clearance or escape, elongation and termination. Typically Pol II 
transcription starts with the binding of activated sequence-specific transcription factors at the 
proximal promoter region. These factors are capable to influence transcription by direct 
interaction with the components of the basal transcription machinery and indirectly through 
the recruitment of chromatin modifying complexes, including histone-acetyltransferases 
(HATs), histone-methyltransferase (HMTs), Mediator and ATP-dependent chromatin 
remodelling complexes (Orphanides and Reinberg, 2002) (Malik and Roeder, 2005). Both 
mechanisms are involved in the initiation of the preinitiation complex (PIC) assembly at the 
core promoter. This complex consists of Pol II and up to six general transcription factor 
complexes including TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH. The PIC ensures proper 
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positioning of Pol II at the core promoter. In that stage the PIC is bound in an inactive 
conformation (Hahn, 2004). TFIIH, a general transcription factor containing ATPase and 
helicase activity, creates negative superhelicale tension in the DNA, which denatures 11-15 
bp of DNA surrounding the transcriptional start site, generating a so-called transcription 
bubble. This remodelling process allows the single-stranded DNA template to enter the 
active cleft of Pol II resulting in the formation of an open complex (Hahn, 2004). This open 
complex conformation facilitates the synthesis of the first phosphodiester bond of RNA, 
which marks transcription initiation. Prior to productive synthesis of full-length RNAs, Pol II 
synthesises multiple short RNAs of 3-10 bases in length. This non-productive transcription is 
referred to as abortive initiation. The Pol II must undergo structural and functional maturation 
to acquire the ability of full-length RNA synthesis. The first step in this process is the 
promoter escape or clearance (Saunders et al., 2006). The promoter escape is the rate-
limiting step of transcription and occurs after synthesis of around 30 bases. During the 
escape Pol II breaks its contact with the core promoter and most components of the basal 
transcription machinery and simultaneously tightens its grip on the nascent RNA entering the 
stage of transcription elongation. Multiple factors involved in RNA processing, RNA export 
and chromatin remodelling can be recruited to Pol II during elongation (Hahn, 2004) 
(Saunders et al., 2006).  
 
1.1.3 RNA polymerase II 
The coordination of transcriptional events with RNA processing is regulated by direct 
modification of Pol II. The extended carboxy-terminal domain (CTD) of the largest Pol II 
subunit, Rpb1, is the prime target for regulatory modifications. This creates docking sites for 
several factors involved in transcriptional elongation, RNA processing and termination. The 
CTD contains multiple phosphorylation sites on its tandem heptapetide repeats, which are 
predominantly phosphorylated at Ser-2 and Ser-5. Phosphorylation at Ser-5 is catalyzed by 
Cdk7, a protein subunit of TFIIH, occurring between transcription initiation and promoter 
escape, whereas Ser-2 is mainly phosphorylated by the positive transcription elongation 
factor b (P-TEFb) subunit cyclin-dependent kinase (CDK) 9 and is predominantly found on 
the elongating Pol II (Saunders et al., 2006) (Orphanides and Reinberg, 2002).  
 
1.1.4 Gene specific transcription factors  
The importance of transcription factors is emphasized by the fact that 5% of all human genes 
are predicted to encode transcription factors (Tupler et al., 2001). Early investigations were 
focused on the specific DNA-protein interaction of transcription factors with their DNA 
consensus sequence. Three examples of consensus sequences are so-called E-box motifs 
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recognized by MYC/MAX and MAD/MAX heterodimers, CCAAT-box consensus sequences 
contacted by CCAAT/enhancer binding protein (C/EBP) transcription factors and GC-boxes 
bound by specificity transcription proteins (SP). The binding of all transcription factors is 
highly dependent on the accessibility of their specific binding site in the chromatin.  
Sequence-specific transcription factors are arranged modularly, typically possessing a DNA-
binding and a co-factor binding domain. Moreover, regulatory domains and additional 
protein-protein interaction domains are found in transcription factors. They regulate 
transcription through recruiting co-regulatory complexes. Sequence-specific transcription 
factors can stimulate transcription of one gene but repressing the transcription of another. 
These divergent activities depend on signals, which in turn define the type of the recruited 
co-regulatory complex (Orphanides and Reinberg, 2002). The activities of transcription 
factors and co-factors can be modulated through diverse post-translational modifications, 
including phosphorylation, acetylation, methylation, ADP-ribosylation, ubiquitination, 
sumoylation, and glycosylation (Boulikas, 1995) (Vervoorts et al., 2003) (Yamagata et al., 
2008) (Olabisi et al., 2008) (Kitagawa et al., 2009) (Sapetschnig et al., 2002) (Jackson and 
Tjian, 1988).  
 
1.1.5 The role of chromatin structure   
Crudely, chromatin is subdivided into the untranscribed highly dense heterochromatin and 
the euchromatin regions containing the transcribed portion of genes. Chromatin is defined as 
the packed form of DNA tightly associated with histone proteins and non-histone proteins. 
The basic unit of chromatin is the nucleosome, consisting of a 146 bp DNA fragment 
wrapped around an octameric histone protein complex consisting of two molecules H2A, 
H2B, H3, and H4. The positively charged core histone proteins are highly conserved among 
eukaryotes and possess flexible N- and C-terminal histone-tails which are subject to diverse 
post-translational modifications, such as acetylation, which affects chromatin structure and 
generates binding sites for proteins. These alterations allow the recruitment of additional 
sequence-specific transcription factors and chromatin remodelers. Chromatin modified in this 
manner is defined as active. Modulation of chromatin structure is mediated by multiple 
transcriptional co-regulator complexes, encompassing the histone-modification complexes 
and the ATP-dependent chromatin-remodelling complexes (Orphanides and Reinberg, 
2002). These complexes generally alter the structure of chromatin by modifying histones or 
ATP-dependent chromatin remodelling. The chromatin remodelling complexes locally disrupt 
or alter the association of nucleosomes by destabilizing the histone-DNA interaction. The 
remodelling of chromatin is catalyzed by three different families of chromatin-remodelling 
complexes, the SWI/SNF-, ISWI- and the Mi-2-family (Fyodorov and Kadonaga, 2001). The 
structure of chromatin influences all steps required for transcription, including DNA binding, 
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protein-protein interaction, stability, and enzymatic activity. Repression of target genes can 
be simply achieved by creating an inaccessible chromatin structure.  
1.1.6 Histone modification     
All four histone proteins can be covalently modified on multiple sites through a variety of 
complexes, including HAT complexes, HMT complexes, kinases, ubiquitin ligases, and ADP-
ribosyltransferases (Kouzarides, 2007). The post-translational modifications are most 
abundant on the N-terminal histone tails (Figure 2) and influence histone-histone, histone-
DNA and histone-protein interaction. The modification status of histones is commonly termed 
“histone code”, meaning that single or combinations of histone modifications possess distinct 
functions. An important function of these modifications is to generate binding sites for 
accessory proteins, which in turn further modulate the state of chromatin, transcription and 
post-transcriptional RNA-processing. 
 
 
 
Figure 2: Overview of histone modifications. The sequence of the N-terminal tails of the four core histones and 
modifications that have been described are shown. The globular histone body (box) and modifications that occur 
are indicated (from C.D.Allis, Epigenetics 2006). 
 
The histone-interacting proteins, which interpret histone marks, possess domains that 
specifically read individual marks or combinations thereof. For example methylated lysine 
residues are read by chromodomains, whereas acetylated lysine residues are recognized by 
bromodomains (Martin and Zhang, 2005) (Jeanmougin et al., 1997). Together the histone 
marks with the enzymes that generate/or remove these modifications and the protein that 
interpret the marks establishes a network of proteins critical to control transcription. 
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1.1.6.1 Histone acetylation 
The most extensively studied modification is the acetylation of lysine residues occurring on 
all histone tails. Histone acetylation is generally associated with active transcription. The 
acetylation is mediated by multiprotein HAT complexes, catalyzing the transfer of an acetyl-
group from the donor acetyl-coenzyme A to the ε-amino-group of lysine residues. It is 
generally agreed that the transfer of an acetyl-group partially reduces the positive charge of 
the histone proteins, which subsequently leads to a decrease in DNA packaging and thereby 
to an increase in DNA accessibility. Therefore histone acetylation opens the possibility for 
transcription factors to bind to their DNA consensus sequences and is frequently 
accompanied by chromatin remodelling (see below).  
Various HAT complex proteins have been identified in humans, including the Gcn5-related N-
acetyltransferase (GNAT) super family, the MYST proteins and the global co-activators p300 
and CREB-binding protein (CBP) (Sterner and Berger, 2000). Several HATs are also known 
to modify non-histone proteins, for instance p300/CBP is described to acetylate the 
transcription factor p53 and c-MYC (Vervoorts et al., 2003). The acetylation of histones is a 
reversible modification due to histone deacetylases (HDACs) (Sterner and Berger, 2000) 
(MacDonald and Howe, 2009). Compared to HATs, HDACs are less substrate-specific, 
except for the Sirtuins 1-3, which preferentially deacetylate lysine-16 of histone 4 (Vaquero et 
al., 2007). The deregulation of HAT and HDAC activity is linked to cancer development and 
both complexes were discovered as promising targets in drug-based cancer therapy. Giles 
and colleagues observed that alterations in the p300 gene are implicated in leukaemia and 
biallelic mutations were detected in gastric and colorectal carcinomas (Giles et al., 1998). 
Moreover, HDAC inhibitors are evaluated in clinical trials for the treatment of various 
leukaemia’s. 
 
1.1.6.2 Histone methylation  
Similar to acetylation, histone tails are targeted by HMT complexes. Based on the modified 
residue arginine or lysine, histone methyltransferases are classified as protein arginine 
methyltransferase (PRMT) and protein lysine methyltransferase (PKMT). Methylation was 
first thought to be an irreversible modification of histones. However, recent studies have 
uncovered enzymes that can demethylate lysines. The demethylation of arginines is 
generally assumed, but so far the enzymes and mechanism have not been identified.     
Arginine methylation occurs as mono- or dimethylation, catalyzed by one of six mammalian 
PRMTs (PRMT1-3, PRMT4/CARM1, PRMT5/JBP1, PRMT6) in a symmetric or asymmetric 
configuration (Kouzarides, 2007). Arginine methylation can be either repressive or 
stimulating for transcription depending on the site of modification. For example PRMT1 
methylation on histone 4 arginine 3 (H4R3), which facilitates the p300-mediated acetylation 
Introduction 
 
  8 
of H4 resulting in activation of transcription (Wang et al., 2001b). On the other hand the 
methylation of H3R2 prevents the activatory trimethylation of H3K4 and consequently 
represses gene expression (Guccione et al., 2007). 
Unlike HATs, HMTs show high substrate specificity. Methyltransferases, like mixed lineage 
leukaemia (MLL) 1-4 are capable of catalyzing mono-, di- or trimethylation by transferring a 
methyl group from S-adenosyl-L-methionine (SAM) to the ε-amino-group of lysine residues. 
Similar to the arginine modification, lysine methylation can serve as a repressive mark as 
well as an activating mark for transcription. The modification of H3K9, H3H27 and H4K20 is 
associated with transcriptional repression, whereas the methylation of H3K4, H3K36 and 
H3K79 is associated with actively transcribed genes (Kouzarides, 2007). Recent studies 
showed that the trimethylation of H3K4 is localized at the 5` end of actively transcribed 
genes, i.e. overlapping with the core promoter. H3K4me3 co-localizes with Pol ll that is 
phosphorylated at Ser-5 within the CTD. H3K4 is modified by different HMT complexes, 
including MLL1-4, SET1A/1B, ASH1 and Sc/Sp SET1. The 3`end of active genes is enriched 
in trimethylated H3K36 (Kouzarides, 2007) (Guccione et al., 2007). This modification in turn 
is associated with the elongating Pol II phosphorylated at Ser-2 within the CTD (Joshi and 
Struhl, 2005). Furthermore, trimethylated H3K36 prevents improper transcriptional initiation 
from cryptic start sites within the gene body (Joshi and Struhl, 2005) (Keogh et al., 2005) and 
monomethylated H3K4 was recently found to be enriched at enhancer regions of human 
genes (Heintzman et al., 2007). Together these findings demonstrate a potent role of specific 
histone tail methylation in the control of gene transcription.  
 
1.1.7 Chromatin remodelling 
ATP-dependent chromatin remodelling complexes utilize ATP hydrolysis to affect chromatin 
accessibility by altering the localization and composition of nucleosomes. Nucleosome 
repositioning is an important feature of all cellular processes connected to DNA, including 
replication, recombination, DNA repair and transcription. Chromatin-modifying complexes are 
subdivided into three classes based on the identity of their catalytic ATPase subunit: the 
SWI2/SNF2 complexes, the ISW1 complexes and the Mi-2 complexes. Each ATPase subunit 
assembles with additional proteins to form distinct chromatin remodelling complexes, but can 
alter chromatin structure in the absence of the remaining subunits (Narlikar et al., 2002) 
(Fyodorov and Kadonaga, 2001). Two mechanisms of ATP-dependent nucleosomal 
remodelling are currently proposed: the sliding of nucleosomes and the conformational 
change of DNA either disturbing the canonical nucleosome positioning or leading to a 
complete exchange of the nucleosome (Narlikar et al., 2002). Chromatin remodelling 
complexes are able to incorporate histone variants into specific regions of the genome 
throughout the cell cycle. H2A.Z, an evolutionarily conserved H2A variant, is localized at the 
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5' end of many non-transcribed genes and is required for proper regulation of gene 
expression. Furthermore, several studies discovered the role of chromatin remodelling 
complexes in cancer, for instance the loss of SWI/SNF function has been determine to be 
linked to malignant transformation (Reisman et al., 2009). 
 
 
1.2 The MYC/MAX/MAD network  
1.2.1 The MYC/MAX/MAD network 
The MYC/MAX/MAD network of transcriptional regulators possesses a pivotal role on the 
regulation of a wide variety of cellular behaviour, including proliferation, cell growth, energy 
metabolism, apoptosis, replication, transformation, tumourigenesis, and differentiation. MYC 
and MAD proteins fulfil antagonizing functions in the regulation of target gene transcription, 
while both bind to their obligatory heterodimerization partner MYC-associated factor x (MAX) 
(Figure 3). MAX is constitutively expressed and does not contain a co-factor interaction 
domain and is therefore transcriptionally inert. In contrast, MYC and MAD proteins are highly 
regulated. MYC is expressed in proliferating and apoptotic cells, whereas MAD proteins are 
predominantly expressed during differentiation and in non-proliferating cells.  
 
 
 
Figure 3: Simplified summary of the MYC- and MAD-dependent regulation of transcription. Both form 
heterodimers with MAX, which is necessary for the sequence-specific DNA binding. The heterodimers possess 
antagonistic function on the transcription of target genes that mediate their effects on cell behaviour. MYC and 
MAD genes and proteins are subject to a broad variety of extracellular signals that control and balance the 
activities of MYC, MAD and MAX.  
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A common structural feature of all network members is a conserved basic helix-loop-helix-
leucine zipper motif (bHLHZip), which is essential for heterodimerization and DNA binding. 
MYC/MAX as well MAD/MAX heterodimers recognize so called enhancer-box (E-box) 
CAC(G/A)TG consensus sequences that are found in a broad range of potential target 
genes. The MYC/MAX heterodimers predominantly activate whereas the MAD/MAX dimers 
repress the transcription of target genes. The malfunction of the network is highly associated 
with tumour development (Rottmann and Luscher, 2006) (Vervoorts et al., 2006).  
A more detailed insight into the biology of the MYC/MAX/MAD network will be described in 
the following section. 
 
1.2.1.1 The proto-oncogene c-MYC  
In mammals three MYC genes were identified in the early 80`s; c-MYC, N-MYC and L-MYC. 
(Nau et al., 1985) (Kohl et al., 1983). Originally c-MYC was discovered as the homolog of v-
myc (myelocytomatosis viral oncogene), a gene with transforming capacity in chicken 
(Sheiness et al., 1978). N-MYC and L-MYC were identified a few years later, associated with 
childhood neuroblastoma and small cell lung cancer (Kohl et al., 1983) (Schwab et al., 1983) 
(Nau et al., 1985). All three MYC proteins exhibit common malignant properties and are 
highly conserved, but are differentially expressed during development and expressed in 
different tissues and organs in adult organisms (Bull et al., 2001). The deletion of c-MYC or 
N-MYC but not L-MYC is lethal during early embryogenesis in mice (Grandori et al., 2000).   
The c-MYC gene is classified as an immediate early response gene, whose transcription is 
rapidly induced in response to mitogenes, growth factors and/or cytokine stimulation, even if 
protein biosynthesis is inhibited (Grandori et al., 2000) (Kelly et al., 1983) (Almendral et al., 
1988). In the absence of growth factors c-MYC expression drives cells into apoptosis 
(Prendergast, 1999). During differentiation c-MYC expression decreases consistent with the 
finding that failure in the down regulation inhibits terminal differentiation (Henriksson and 
Luscher, 1996). 
In cells c-MYC function is tightly controlled at different levels. The expression is regulated on 
the transcriptional level, through post-translational modifications effecting protein stability and 
through diverse protein interactions.  
MYC/MAX-dependent gene activation is consistent with the finding that c-MYC recruits 
multiple co-factors influencing the state of chromatin and directly activates Pol II function. 
Growth-related genes mainly connected to metabolic functions, protein synthesis, ribosome 
biogenesis and cell growth are the prevailing upregulated c-MYC target genes. Moreover, 
genes involved in cell cycle progression, genomic instability and angiogenesis are also 
stimulated (Li et al., 2007) (Poortinga et al., 2004) (Baudino et al., 2002) (Amati et al., 1993). 
Furthermore, c-MYC is involved in microRNA and non-coding RNA transcription driven by 
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Pol II (Cawley et al., 2004) (O'Donnell et al., 2005). Besides the ability to regulate Pol II 
transcribed genes, in more recent studies c-MYC was found to stimulate gene expression by 
RNA polymerase I (Pol I; ribosomal RNA) and RNA polymerase III (Pol III; tRNA, 5S rRNA) 
(Arabi et al., 2005) (Grandori et al., 2005) (Gomez-Roman et al., 2003).  
In addition to the activities described above c-MYC possesses repressive capacity which is 
found in association with the transcriptional regulator and INR binding factor MIZ-1 (Staller et 
al., 2001) (Kleine-Kohlbrecher et al., 2006). MIZ-1-bound co-activator complexes at the p21 
promoter are replaced by the DNA methyltransferase DNMT3a upon MYC/MAX interaction, 
resulting in repression through methylation of CpG dinucleotides (Adhikary and Eilers, 2005) 
(Brenner et al., 2005). Many c-MYC downregulated genes are involved in cell cycle arrest 
like p27, p21CIP1, p15INK4b, cell adhesion, and cell-cell communication (Eilers and Eisenman, 
2008). In summary these studies suggest that c-MYC stimulates proliferation by both 
activating and repressing numerous target genes. 
In quiescent cells c-MYC is not expressed. Overexpression of c-MYC in these cells induces 
G1/S transition. The influence of c-MYC on cell cycle progression is associated with the  
c-MYC-dependent up regulation of Cyclin D2, CDK4, and CDC25 expression, leading to 
activation of Cyclin E/CDK2 complexes and subsequently to S-phase entry (Henriksson and 
Luscher, 1996) (Rottmann et al., 2005).   
The capability of c-MYC to upregulate proliferation and growth-related genes and  
simultaneously downregulate genes associated with cell cycle arrest, is a crucial function of 
c-MYC in a normal physiological context but is also essential for its tumourigenic activity.   
  
1.2.1.2 The c-MYC oncogene 
The c-MYC oncogene is deregulated in a multitude of human tumours, ranging from 
hematopoietic malignancies such as Burkitt`s lymphoma (91%) to prostate cancer (70%), 
colon cancer (67%), and breast cancer (45%) (Frost et al., 2004) (Escot et al., 1986) 
(Buttyan et al., 1987) (Junttila and Westermarck, 2008). The altered regulation of c-MYC is 
triggered through chromosomal translocation, gene amplification, activation of the promoter 
(e. g. WNT signalling), and increased protein stability. One example is Burkitt´s lymphoma, a 
B-cell tumour first described in 1956, which is induced by a chromosomal translocation. This 
translocation juxtaposes the c-MYC gene with immunoglobulin loci regulatory elements, 
resulting in the inappropriate expression of c-MYC (Gerbitz et al., 1999) (Taub et al., 1982) 
(Nesbit et al., 1999). The tumourigenic function of c-MYC is confirmed in transgenic myc 
mice, which develop normally, but generate high frequently clonal tumours (Adhikary and 
Eilers, 2005). However, it should be noted that, similar to all other described oncogenes, 
deregulated c-MYC expression is not sufficient to convert rodent or human cells into tumour 
cells. To induce tumour formation c-MYC needs to co-operate with other oncogenes. 
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Prominent examples are oncogenes involved in the RAS-dependent signalling pathway. It is 
assumed that c-MYC abrogates RAS-induced senescence, whereas RAS counteracts c-
MYC-induced apoptosis. Indeed, recent findings provide evidence for this concept by 
demonstrating that c-MYC is a potent inhibitor of RAS-induced senescence. Thus, these 
findings provide an explanation for the co-operativity of c-MYC and RAS in transformation. 
 
1.2.1.3 Domain structure of c-MYC 
The c-MYC protein possesses different structural features, which can be linked to specific 
molecular functions. The highly conserved basic helix-loop-helix-zipper (bHLHZip) domain is 
located at the C-terminus. The HLHZip motif is essential for the heterodimerization with MAX 
and the basic region is indispensable for sequence-specific DNA binding (Kerkhoff and 
Bister, 1991) (Littlewood et al., 1992). The N-terminal transactivation domain (TAD) contains 
two important functional elements, which are highly conserved, the so-called c-MYC-box I 
(MBI), c-MYC-box II (MBII), and c-MYC-box III (MBIII). Both boxes are essential for the 
biological activity of c-MYC and often involved in transformation (Vervoorts et al., 2006). MBI 
is a common target of mutations in cancer and comprises two phosphorylation sites at Thr-58 
and Ser-62 (Sakamuro and Prendergast, 1999). The phosphorylation at Ser-62 and Thr-58 is 
interrelated, since phosphorylation at Ser-62 by CDKs and MAPKs primes for 
phosphorylation at Thr-58 by the glycogen synthase kinase (GSK) 3. Upon phosphorylation 
of both sites, the prolyl-isomerase PIN1 allows the protein phosphatase 2A to 
dephosphorylate Ser-62. Thr-58 phosphorylated c-MYC is targeted by the SCFFbw/CD4 E3 
ligase, which results in rapid proteasomal degradation. In recent studies it has been shown 
that the c-MYC-dependent repression of RAS-induced senescence depends on the 
phosphorylation at Ser-62 by Cyclin E/CDK2 and furthermore, that this phosphorylation plays 
an important role for c-MYC-driven transcription (Hydbring et al., 2009) (Vervoorts et al., 
2006). MBII serves as binding region for several co-factor complexes, like TRRAP 
(transformation/transcription domain associated protein), TIP60, and TRRAP/GCN5 HAT 
complexes, and SAGA, a complex containing acetyltransferase and ubiquitin ligase activity 
(Vervoorts et al., 2006) (Nikiforov et al., 2002). MBII deletion mutants fail to co-operate with 
activated RAS in the transformation of primary fibroblasts (Li et al., 1994). Herbst and 
colleagues identified a MBIII implicated in transcriptional repression and transformation and 
presumably involved in the negative regulation of apoptosis (Herbst et al., 2005). An acidic 
region of poorly defined function and two nuclear localization sequences (NLS) elements are 
located further C-terminal (Figure 4). 
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Figure 4: Schematic representation of c-MYC protein domain architecture. TAD, aa 1–150; I, II, III refer to 
the three conserved MYC boxes (aa 45–63, 129–141 and 188-199, respectively); A, acidic region (aa 242–261); 
NLS, aa 320–328; bHLHZ, aa 355–435, domain that mediates binding to MAX and sequence-specific DNA 
binding; P, main phosphorylation sites in MYC with the relevant kinases, Thr-58 phosphorylation by GSK3 
requires prior phosphorylation at Ser-62 induced by MAPK and CDKs; further phosphorylation sites, targeted by 
CK2. The region demonstrated to mediate interaction with physiologically relevant partners are indicated 
(modified from Vervoorts et al. 2006)  
 
1.2.1.4 Transcriptional regulation and DNA-binding of c-MYC 
The c-MYC protein has been reported to recruit an astonishing number of transcriptional co-
regulators. Direct interaction of c-MYC with several HAT and HMT complexes, chromatin 
remodelling complexes, the Mediator complex and the Pol II complex are thought to be 
relevant for target gene activation (Vervoorts et al., 2006) (Eilers and Eisenman, 2008) 
(Secombe et al., 2007).  
The c-MYC protein recruits HAT activity to its target genes resulting in acetylation of nearby 
histone tails of the histones H3 and H4. For instance CBP/p300 interacts directly with the  
C-terminus of c-MYC and stimulates c-MYC´s transactivation activity. In addition to the 
acetylation of histone tails, c-MYC itself is acetylated. This modification affects c-MYC 
stability, which might promote gene activation (Vervoorts et al., 2003) (Faiola et al., 2005) 
(Zhang et al., 2005). 
The two multiprotein HAT complexes GCN5/PCAF and TIP60 are recruited to c-MYC by the 
scaffolding protein TRAPP, which is a subunit of these complexes and interacts directly with 
c-MYC depending on the integrity of MBII (Bouchard et al., 2001) (McMahon et al., 1998). 
Two other components of the TIP60 HAT complex, the highly conserved ATPases TIP48 and 
TIP49 were identified as interaction partners of c-MYC (Wood et al., 2000) and both proteins 
were found in several chromatin remodelling complexes. The C-terminal domain of c-MYC 
was further found to interact with the subunit INI1/hSNF5 of the ATP-dependent SWI/SNF 
chromatin remodelling complex (Peterson and Workman, 2000). 
The MBII is also required for the interaction with the E3 ubiquitin ligase SCF/SKP2. SKP2 is 
essential for the transactivation of various c-MYC target genes. Because c-MYC is also a 
SKP2 substrate, poly-ubiquitination might be required for activation of some c-MYC target 
genes (von der Lehr et al., 2003). Another potent mechanism of c-MYC-mediated 
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transactivation is by directly interacting with the P-TEFb subunit CDK9 and with TFIIH. This 
results in the phosphorylation and activation of Pol II of the CTD residues Ser-5 and Ser-2 
(Marshall and Grana, 2006). Furthermore, c-MYC has been identified to affect the translation 
rate of a subset of mRNAs and more recently Cowling and colleague demonstrated that  
c-MYC facilitates, independent of DNA binding, mRNA cap methylation and translation (Shiio 
et al., 2002) (Cowling and Cole, 2007).   
Genomic binding studies show that 10-15% of the genomic loci are occupied by c-MYC in 
mammals. To clarify whether c-MYC binding correlates with transcriptional modulation, 
several investigators performed expression profile studies (Zeller et al., 2006) (Fernandez et 
al., 2003) and demonstrated that a high percentage of c-MYC binding sites are in the vicinity 
of transcribted genes. More direct studies corroborated that in many situations c-MYC 
functions as a transcriptional activator at these binding sites. Other apparently non-
productive c-MYC-bound sites were identified in ChIP-based experiments. Whether c-MYC is 
truly inactive at these sites or whether c-MYC regulates the transcription of miRNA and other 
RNA species or controls replication remains to be determined (Schulte et al., 2008) (Chang 
et al., 2008) (O'Donnell et al., 2005) (Gomez-Roman et al., 2003). The direct binding of  
c-MYC does not only depend on the appearance of an E-box consensus sequence but also 
on the chromatin status. While the methylation of CpG dinucleotides inhibits c-MYC binding 
to some sites, some methylation events occurring on histone tails are correlated with 
elevated c-MYC binding (Guccione et al., 2006) (Perini et al., 2005). Specifically c-MYC 
binding and methylation of H3K4 and H3K79 are correlated, whereas methylation at H3K27 
and c-MYC binding are mutually exclusive (Guccione et al., 2006).   
A multitude of interactions and modifications are involved in the c-MYC-dependent regulation 
of target gene expression. 
 
1.2.2 The MAD protein family  
The MAD proteins were originally identified as MAX interacting factors. In bacterial 
expression library screens and yeast two hybrid experiments, MAD1 and MXI1 (MAD2) were 
first found to interact with MAX followed by MAD3, MAD4, MNT and MGA a few years later 
(Ayer et al., 1993) (Zervos et al., 1993) (Hurlin et al., 1999) (Hurlin et al., 1995) (Hurlin et al., 
1997). It has been suggested that all MAD family members antagonize the function of c-MYC 
by competitive binding to MAX and by active transcriptional repression of target genes. In 
addition to MAX, MLX, Mmip1 and Mmip2 have been identified to interact with the bHLHZip 
domain of some MAD proteins but not with c-MYC (MAD1, MAD4 and MNT). MLX has been 
described to represent an alternative MAD binding partner to MAX. Since MLX also 
possesses a bHLHZip domain, the MAD/MLX heterodimers also function as sequence-
specific transcriptional regulators (Billin et al., 1999) (Meroni et al., 2000). The RING finger 
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proteins Mmip1 and Mmip2 form DNA binding deficient heterodimers with MAD proteins, 
resulting in the inhibition of MAD function (Gupta et al., 1998) (Yin et al., 1999). The four 
MAD proteins share significant sequence homology throughout the entire sequence and 
furthermore, show broad functional similarities. In contrast MNT and MGA are rather distinct 
in sequence, suggesting substantial differences in their biological function.  
While MAD1, MAD2 and MAD4 are preferentially expressed during differentiation and in non-
proliferating cells, MNT and MAX are rather equally expressed during the cell cycle and in 
resting cells. MAD3 expression peaks in S-phase, an expression profile that has not been 
evaluated functionally (Rottmann and Luscher, 2006).   
    
1.2.2.1 MAD1 
The human MAD1 gene is located on chromosome 2p12-p13 and encodes the 227 amino 
acids long MAD1 protein (Edelhoff et al., 1994). The MAD1 protein has an apparent 
molecular weight of 35 kDa and, similar to c-MYC, an extraordinary short half-life of 20-30 
min. This short half-life impedes the detection of endogenous MAD1 via western blot 
experiments.  
Generally MAD1 is expressed in cells undergoing differentiation, and in terminally 
differentiated cells, for instance resting lymphoid cells, granulocytes, keratinocytes, colonic 
epithelial cell, neuronal cells, and chronodrocytes (Queva et al., 1998) (Rottmann and 
Luscher, 2006).   
The expression of the MAD1 gene is activated in promyelocytic cell lines in response to 
various stimuli, including differentiation-inducing reagents like 12-O-tetradecanoylphorbol-13-
acetat (TPA), vitamin D3, retinoic acid (RA) and granulocyte colony stimulating factor (G-
CSF) (Larsson et al., 1997) (Larsson et al., 1994). G-CSF stimulation enhances the MAD1 
expression through the JAK/STAT as well as the RAS/RAF/ERK signalling pathway (Jiang et 
al., 2008). Additionally the cytokines transforming growth factor (TGF) β and activin A were 
shown to induce MAD1 expression in keratinocytes. Furthermore, interferon (IFN) γ 
stimulates MAD1 expression in promyelocytic cell lines. Moreover, the reagents MG132, 
cycloheximide (CHX), zinc ions and dimethylsulfoxid (DMSO) were observed to activate 
MAD1 expression in hematopoietic cell lines (Werner et al., 2001) (Larsson et al., 1994) 
(Sirinian et al., 2003) (unpublished observation). DMSO treatment of MEL (mouse 
erythroleukemia) cells elevates mad1 expression and induces differentiation (Cultraro et al., 
1997). Similarly expression of a mad1 transgene in MEL cells initiates terminal differentiation. 
However, this is the only differentiation model, in which MAD1 expression is sufficient to 
stimulate differentiation. In adipocytes and promyelocytes MAD1 expression leads to a 
differentiation delay, because additional mitotic cell divisions prior to terminal differentiation 
(Pulverer et al., 2000). This finding poses the question whether the induction of differentiation 
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is a secondary effect based on the MAD1-mediated cell cycle arrest (Rottmann and Luscher, 
2006). 
The mad1-/- mouse exhibits a rather mild phenotype possibly due to redundant function of the 
different MAD proteins. Analysis of the hematopoietic compartment revealed that 
granulocytic precursors are inhibited in cell cycle exit, resulting in enhanced proliferation and 
delayed terminal differentiation. However, the number of terminally differentiated bone 
marrow and peripheral blood granulocytes were unaffected in mad1-/- mice. The unchanged 
pool of terminally differentiated granulocytes is presumably associated with the 
compensatory increase in the sensitivity to apoptosis-inducing conditions of granulocytic 
cluster-forming cells (Foley et al., 1998). These findings further support the role of MAD1 in 
the regulation of cell cycle progression and apoptosis. 
 
1.2.2.2 MAD1 protein structure and post-translational modification 
The protein structure of the MAD1 protein is shown in Figure 5. The MAD1 protein 
possesses a N-terminal Sin3-interacting domain (SID) and a centrally located conserved 
bHLHZip domain followed by a functionally less well-defined C-terminal domain. The minimal 
SID encompasses a 13 amino acid region enriched in hydrophobic residues that forms an 
amphipathic α-helix. This hydrophobic surface seems to be essential for functional interaction 
with the paired amphipathic helix (PAH2) domain of mSin3 (Eilers et al., 1999). Further 
studies demonstrated the importance of additional residues outside the minimal SID, which 
influence binding affinities (Rottmann and Luscher, 2006). The SID bound mSin3 protein acts 
as a platform for the assembly of multi-protein complexes that include HDAC1/2 (Cowley et 
al., 2004). These HDAC-containing complexes deacetylate the surrounding histone tails, 
which alter the structure of chromatin and subsequently result in transcriptional repression. 
The introduction of amino acids disturbing the helicase and/or hydrophobic character of the 
SID abrogates the repressive function based on the inability to recruit mSin3 (Eilers et al., 
1999). The central bHLHZip domain mediates DNA binding and heterodimerization with MAX 
as mentioned above. Yin and colleagues mapped a NLS within the central loop of the 
bHLHZip domain of MAD1. Additional regions near the C- and N-termini also seem to control 
the subnuclear localization of MAD1 (Yin et al., 2001). The C-terminus is not well defined, 
only little is known about its function. In some models the C-terminus is dispensable for 
MAD1-mediated inhibition of MYC/RAS-induced transformation, in others it is not (Cerni et 
al., 1995) (Koskinen et al., 1995). Sequence alignment studies identified five homologous 
regions within the C-terminal region. The deletion of region five (the most C-terminal, 18 aa) 
eliminates the anti-proliferative effect as well as other functions of MAD1 (Rottmann and 
Luscher, 2006). Additional investigations are required to decipher in more detail the 
functional relevance of the C-terminal region of MAD1 (Figure 5).  
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Figure 5: Protein domain structure of MAD1. The N-terminal SID (mSin3-interacting domain, aa 5-21), 
important for the binding of the PAH3 domain of mSin3 and the recruitment of the mSin3-HDAC-co-repressor 
complex; the central bHLHZ domain (aa 58-150) involved in heterodimerization and DNA binding, the C-terminal 
region CT (aa 150-221) of unknown function, P indicates the phosphorylation site on Ser-145, a substrate of RSK 
and S6K (modified from Cultraro et al. 1997).  
 
Recently, Xu and colleagues showed that inhibitor of apoptosis protein (c-IAP), a RING finger 
E3 ubiquitin ligase, potentially involved in tumourigenesis, catalyzes the polyubiquitination of 
MAD1 (Xu et al., 2007). The same group identified MAD1 as a phosphorylation substrate of 
the p90 ribosomal kinase (RSK) and the p70 S6 kinase (S6K) upon serum or insulin 
stimulation. PI3K/AKT and MAPK pathways phosphorylate MAD1 at Ser-145, which 
promotes MAD1 polyubiquitination and results in its proteasomal degradation (Zhu et al., 
2008). Mutation of Ser-145 to alanine resulted in a more stable MAD1 protein with enhanced 
proliferation inhibitory activity. 
 
1.2.2.3 MAD1 target genes and biological function 
The finding that MYC/MAX and MAD1/MAX heterodimers recognize similar E-box consensus 
sequences of target genes lead to the assumption that the same genes are regulated by the 
two complexes. Among these genes are hTERT, Cyclin D2, PTEN, UBF and ODC 
(Rottmann and Luscher, 2006). The human telomerase reverse transcriptase (hTERT) is a 
subunit of the human telomerase and its transcription is antagonistically regulated by MAD1 
and c-MYC. Telomerase, a RNA-dependent DNA polymerase, elongates telomeric repeat 
sequences at chromosomal ends. This elongation process is essential to maintain genomic 
stability and integrity (Harley et al., 1994) (Rudolph et al., 1999). Telomerase activity is 
observed in 90% of all human tumours and is closely related to transformation, while normal 
tissue contains little telomerase. MAD1 was shown to repress the hTERT promoter in 
reporter gene experiments dependent on the recruitment of HDAC activity (Oh et al., 2000). 
The MAD1-mediated direct gene repression was further supported by the finding that MAD1 
directly binds to the hTERT promoter in differentiating HL60 promyelocytes (Xu et al., 2001). 
Cyclin D2, another MYC-MAD regulated gene, is repressed upon MAD1 binding. The 
repressive function of MAD1 was determined in reporter gene assays and MAD1 binding to 
the Cyclin D2 promoter was elevated in differentiating HL60 and U937 promyelocytic cell 
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lines (Bouchard et al., 2001). Consistently MAD1 binding and transcriptional inhibition of the 
Cyclin D2 gene was accompanied by the recruitment of HDAC1, and by reduced Pol II 
binding to the promoter (Bouchard et al., 2001). The repression of the Cyclin D2 gene 
emphasizes MAD1`s potential to inhibit cell proliferation, one important step for the switch 
from proliferation to differentiation (Roussel et al., 1996). Overexpression of Cyclin E/CDK2, 
a downstream mediator of c-MYC function, abolishes the MAD1 mediated inhibition of cell 
cycle progression through impairing HDAC recruitment and activity (Rottmann et al., 2005). 
These findings establish an additional antagonistic crosstalk between MAD and MYC 
proteins. 
Generally proliferation and cell growth, e.g. the increase in cell size and mass are tightly 
coupled. MAD1 is involved in the control of cell growth by repressing the Pol I transcription 
factor upstream binding factor (UBF) during terminal differentiation of granulocytes. MAD1-
deficient granulocytes display an increase in rDNA transcription and protein biogenesis 
resulting in an elevated cell volume. UBF is a key player in the regulation of rDNA 
transcription, an essential process for the maintenance of ribosome biogenesis, and is a 
target gene of c-MYC (Poortinga et al., 2004). Another aspect of cell behaviour that is 
controlled by MAD1 is apoptosis. Initial evidence was obtained from the analysis of mad1-/- 
mice, in which granulocyte precursor cells showed enhanced sensitivity to apoptosis-
inducing conditions (Foley et al., 1998). Expression of MAD1 antagonizes apoptotic signals 
and reduces the rate of apoptosis in cells substantially. Furthermore, overexpression of 
MAD1 abrogates oncogene-induced apoptosis by c-MYC and adenoviral E1a in fibroblasts 
(Gehring et al., 2000) (Bejarano et al., 2000). One gene repressed by MAD1, which 
highlights a direct link to apoptotic signalling, is the phosphatase and tensin homologue 
deleted on chromosome ten (PTEN). This gene was identified as a MAD1 target by a PCR-
select screen using an U2OS-tet-MAD1 cell line. MAD1 binding to the proximal promoter 
region and transcriptional repression of the PTEN gene was observed after induction of 
MAD1 expression (Rottmann et al., 2008). The phosphatase PTEN has been described as a 
tumour suppressor and dephosphorylates phosphatidylinositol 3,4,5-triphosphate (PIP3), a 
second messenger molecule essential for AKT recruitment and activation. Activated AKT has 
several downstream substrates including IκB kinase (IKK), a kinase of the NF-κB pathway, 
through which AKT can inhibit apoptosis (Vivanco and Sawyers, 2002) (Downward, 2004). 
The MAD1-dependent repression of PTEN expression leads to an enhanced activation of 
AKT due to the accumulation of PIP3 and subsequently to inhibition of apoptosis (Rottmann 
et al., 2008). In a recent study Chou and colleagues demonstrated a physical interaction of 
MAD1 and AKT, in addition to the above described RSK and S6K phosphorylation of MAD1 
at Ser-145 by AKT. This phosphorylation abolishes MAD1-mediated repression of hTERT 
and ODC (Chou et al., 2009). Ornithine carboxylase (ODC), the rate-limiting enzyme of the 
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polyamine biosynthesis pathway, participates in the regulation of cell growth and 
differentiation and is activated by MYC (Stenzel et al., 2004). The regulation of ODC 
transcription further supports the role of MAD1 in the control of cell growth and proliferation. 
 
 
1.3 TGFβ  
1.3.1 TGFβ cytokine superfamily 
The TGFβ cytokine superfamily of growth factors encompasses 35 structurally related 
polypeptides, including the TGFs, Activins, Nodals, Anti Muellerian Hormone (AMH), 
Myostatins, and Bone Morphogenetic Proteins (BMPs). This cytokine family mediates 
antagonistic tumour promoting as well as a tumour suppressing functions and is generally 
involved in cell proliferation, growth, differentiation, homeostasis, migration, inflammation and 
apoptosis dependent on the cellular and physiological context. In mammalian tissues TGFβ 
1-3 are ubiquitously expressed and secreted as inactive precursors named latent TGFβs (L-
TGFβ). Proteolytic cleavage by for example plasmin or matrix metalloproteinases (MMPs) or 
conformational changes, both occurring under acidic conditions, activate the precursor 
peptide. The biologically active TGFβ peptide dimerizes, binds to the receptor complex and 
initiates intracellular signalling via the SMAD and MAPK signalling pathways (Leivonen and 
Kahari, 2007). The three different isoforms TGFβ 1-3 bind to the same receptor complex and 
share 70-80% amino-acid sequence homology. Despite this sequence homology mice 
lacking one of the three isoforms develop distinct phenotypes indicating diverse biological 
functions based on distinct expression pattern (Larsson and Karlsson, 2005).    
 
1.3.2 TGFβ receptor signalling and the SMAD protein family 
1.3.2.1 TGFβ receptor 
Three types of TGFβ receptors are present on the cell surface. The receptor types I (7 
subtypes) and II (5 subtypes) propagate signals to the nucleus via phosphorylation. The 
receptor type III also known as betaglucan (Fonsatti et al., 2001) assists in TGFβ ligand 
capturing and presentation to the receptors I and II (Massague, 1998). The signalling-
associated receptors I and II are similarly organized transmembrane glycoproteins 
possessing a glycosylated extracellular domain, a short transmembrane domain and an 
intracellular serine/threonine kinase domain. The intracellular kinase domain of the receptor I 
exhibits a conserved glycine and serine (GS) -rich region, which is activated by 
transphosphorylation through the serine/threonine kinase of receptor II. This receptor is 
constitutively autophosphorylated on several lysine residues and forms after TGFβ ligand 
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binding a tetrameric receptor complex of two receptor type I and II dimers. The 
tetramerization and transphosphorylation results in activation of associated proteins and 
downstream components of the signalling pathways.  
 
1.3.2.2 SMAD protein family 
SMADs are the canonical intracellular mediators of the TGFβ signalling. The eight SMAD 
family members can be subdivided into three groups with respect to their molecular function: 
the receptor-activated SMADs (R-SMADs) composed of SMAD1, 2, 3, 5 and 8, the Co- 
common-mediator SMAD4 (SMAD4) and the inhibitory SMADs (I-SMADS) including SMAD6 
and 7 (Massague et al., 2005). A common structural attribute of all SMAD proteins is the two 
globular domains Mad homology (MH) 1 and MH2 connected through a flexible linker region. 
The MH1 domain is conserved in all R-SMADs and Co-SMAD4 and mediates DNA binding 
via a β-hairpin structure. The SMAD heterodimer recognizes and binds to the so-called 
SMAD-binding elements (SBE; 5`-GTCT-3`or 5`-AGAC-3`). TGFβ-responsive promoters 
often contain more than one SBE. 
 
 
 
Figure 6: The different SMAD protein subclasses and their structural elements. R-SMADS 1, 2, 3, 5, 8; Co-
SMAD 4; I-SMAD 6 and 7. The R-and Co-SMADs consist of two conserved globular domains MH1 and 2 (Mad 
Homology), I-SMADs 6 and 7 contain only the MH2 domain. The MH1 domain of R- and Co-SMADS possess a β-
hairpin  (hp) structure essential for DNA-binding. Multiple phosphorylation sites targeted by MAPK, CDKs and 
other kinases are located within the linker region of R-SMADs. The PY motif within the linker region of R- and I-
SMADS is recognized by SMURF ubiquitin ligases, the linker region of SMAD4 includes a NES. The basic pocket 
located in the MH2 domain enables R- and Co-SMADs to interact with the pS-x-pS motif of R-SMADS, the basic 
pocket of R-SMADS mediates the interaction with activated TGFβR I. The conserved Ser-x-Ser motif at the C-
terminus of R-SMADs is phosphorylated by the activated receptor. The hydrophobic corridor located on the 
surface of the MH2 domain of R-SMADS is involved in multiple protein-protein interaction. The SMAD4 activation 
domain (SAD) of SMAD4 mediates interactions with transcriptional activators and repressors (from Massague et 
al., 2005).  
 
The C-terminal MH2 domain is conserved in all SMAD proteins and enables miscellaneous 
protein-protein interactions. The flexible linker region of the R-SMADs possesses binding 
sites for SMAD ubiquitination-related factor (SMURF), ubiquitin ligases and several different 
kinases. The intrinsic receptor kinase phosphorylates a Ser-x-Ser motif located at the C-
terminus leading to R-SMAD activation and nuclear accumulation of the dimerized SMAD 
complex. In addition the receptor-mediated phosphorylation decreases the affinity of the 
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SMAD proteins to cytoplasmic anchor proteins like SMAD anchor for activation (SARA) 
(Tsukazaki et al., 1998) (Wu et al., 2001) and in turn increases the binding affinity for nuclear 
factors. The SMAD4 linker region contains a nuclear export signal (NES). An additional 
unique feature of SMAD4 is the SMAD4 activation domain (SAD), which serves as an 
interaction domain for transcriptional activator and repressor complexes (Figure 6) 
(Massague et al., 2005). 
 
1.3.2.3 TGFβ signalling pathways 
The members of the TGFβ cytokine superfamily mediate their effects through multiple 
receptor subtypes affecting diverse cellular processes. Figure 7 summarizes the different 
ligands with the respective signalling receptors and associated SMAD proteins. The 
TGFβ/Activin/Nodal subfamily mediates target gene regulation via SMAD2/3, whereas 
SMAD1, 5 and 8 are predominantly activated through BMP signalling (Shi and Massague, 
2003). 
 
 
 
Figure 7: Schematic summary of interactions between TGFβ ligands, TGFβ receptor I and II, accessory 
receptors, and the different SMADs as downstream effector molecules in vertebrates. R-SMADS: 1,2,3,5 
and 8; Co-SMAD 4 (from Shi and Massagues, 2003). 
 
The following chapter will mainly focus on the TGFβ-stimulated signalling. The activated 
TGFβ receptor I phosphorylates the R-SMADs on their C-termini resulting in multiple 
molecular events (Figure 8). First this modification prompts the association of the R-SMADs 
with each other. Simultaneously the phosphorylation destabilizes the SARA/SMAD 
interaction facilitating the dissociation from the receptor complex and association with the 
Co-SMAD4. SARA, a FYVE domain containing anchor protein, acts as an auxiliary protein, 
which allows a more efficient binding of SMAD2/3 to the receptor complex for 
phosphorylation. The heterodimeric SMAD complex translocates in to the nucleus and binds 
either directly to DNA or co-operates with other transcription factors to regulate target genes. 
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Alternative nuclear translocation mechanisms have been recently described for proteins of 
the SMAD family: SMAD1 and 3 enter the nucleus upon receptor-mediated phosporylation by 
direct interaction of their NLS with importin-β but not through binding to importin-α (Xiao et 
al., 2000a) (Xiao et al., 2000b). Alternatively SMAD2 and 3 interact via their MH2 domain 
directly with components of the nuclear pore complex (Xu et al., 2002). The direct interaction 
with the nuclear pore complex establishes an importin and Crm-1 independent 
nucleocytoplasmic shuttling.  
In contrast to the R-SMADs, which are predominantly located in the cytoplasm, the I-SMADs 
exhibit a primarily nuclear localization prior to activation. In response to ligand binding the  
I-SMADs translocate into the cytoplasm, where they suppress R-SMAD phosphorylation 
through competitive binding to the TGFβ receptor I.  
In addition to the pathways described above, TGFβ signals also through SMAD-independent 
pathways. These non-canonical pathways include the Rho-like GTPases, RhoA and Rac (not 
shown), the phosphatidylinositol-3-kinase/AKT, and several MAPKs (Zhang, 2009). Within 
the MAPK signalling pathway, the p38 (p38α, β, γ, δ), c-JUN N-terminal kinases (JNK) 1/2, 
and extracellular signal-regulated kinase (ERK) 1/2 can be activated in response to TGFβ 
(Leivonen and Kahari, 2007). The most extensively studied non-canonical pathway is the 
p38/JNK pathway. It becomes activated in response to TGFβ in various cell lines through the 
TGFβ receptor I. A crucial mediator of this pathway is TRAF6. In response to TGFβ, TRAF6 
is auto-polyubiquitinated through its N-terminal E3 ubiquitin ligase domain, which 
subsequently facilitates the assembly of a multisubunit protein kinase complex. The TGFβ 
activated kinase 1 (TAK1) is one of the TRAF6-activated MAP3 kinases and induces p38 
activity through an MKK3/6-dependent mechanism and JNK activation through 
phosphorylation of MKK4.  
The TRAF6/TAK1/p38/JNK pathway is required for the TGFβ-induced epithelial to 
mesenchymal transition (EMT; described below), and in conjunction with the SMAD-
dependent signalling, for the induction of apoptosis (Zhang, 2009).  
The TGFβ-dependent ERK activation occurs via phosphorylation of tyrosine residues of both 
TGFβ receptors. This phosphorylation induces the formation of a Shc/Grb2/Sos complex, 
which in turn activates membrane-bound RAS and downstream members of a signalling-
cascade that includes c-Raf, MEK and ERK. In association with SMAD-dependent signalling 
activated ERKs contribute to the regulation of the EMT (Zhang, 2009).  
TGFβ stimulation additionally activates the PI3K/AKT pathway, which also contributes to 
EMT. PI3K participates in repolarisation events and cell migration. Conversely TGFβ 
stimulation downregulates PI3/AKT signalling via SMAD-dependent expression of the lipid 
phosphatase SHIP. The activation of the PI3K/AKT pathway often antagonizes SMAD 
mediated effects, like the induction of apoptosis or growth inhibition.  This antagonism, based 
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on the interaction of AKT and SMAD3, prevent SMAD3 phosphorylation and subsequently its 
nuclear translocation (Zhang, 2009).  
Several lines of evidence demonstrate an intensive crosstalk and co-operation between 
MAPK and SMAD-dependent signalling in the TGFβ response ultimately determining cell 
fate. 
 
 
 
Figure 8: Schematic overview of TGFβ SMAD-dependent and SMAD-independent signalling. The canonical 
SMAD signalling is activated in response to TGFβ-induced tetramerization and activation of the TGFβ receptor I 
and II. After ligand binding the TGFβ receptor II phosphorylates the TGFβ receptor I, which in turn activates the 
receptor-associated SMADs 2 and 3 through phosphorylation. The phosphorylated SMAD2/3 dimerize with 
SMAD4, and translocates to the nucleus, where the SMAD-complex regulates target gene transcription alone or 
in combination with other transcription and co-factors. The JNK/p38 pathway is activated through the interaction 
of the activated receptor complex with TRAF6 leading to the K63-linked poly-ubiquitination of TRAF6. 
Polyubiquitinated TRAF6 and TAK1 activate MKK4 and/or MKK3/6, these kinases in turn activate JNK and/or 
p38. The ERK signalling is induced by phosphorylation of tyrosine residues on both receptor I and II, and/or Shc, 
which recruits Grb/Sos to the receptor complex. Grb/Sos recruitment activates the downstream kinase 
RAS/RAF/ERK signalling cascade. Activated ERK regulates target gene transcription via interaction with co-
factors and transcription factors, and/or in association with activated SMADs. The PI3K/AKT pathway can be also 
be activated in response to TGFβ. TGFβ induces AKT phosphorylation through activating PI3K probably by direct 
interaction with the receptor complex. The functional interplay of these different pathways with I-SMADs is not 
highlighted in this scheme. 
 
1.3.3 The multifunctional role of TGFβ 
The pleiotropic, partially antagonizing biological effects of TGFβ raise the question, how 
TGFβ mediates specific responses in a context-dependent manner. TGFβ is a potent 
inhibitor of G1 cell cycle progression in primary mammalian epithelial, endothelial and 
hematopoietic cells. The cytostatic response is based on a bipartite mechanism, the elevated 
expression of the CDK inhibitors p15INK4b and p21CIP1 and the concomitantly down regulation 
of c-MYC and inhibitor of differentiation/DNA binding 1 (ID1) expression. Both events occur 
P P 
P 
pY 
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in a SMAD-dependent way. Up regulation of p15INK4b and p21CIP1 is dependent on the co-
operation of the SMAD2/3/4 complex with C/EBPβ, FoxO, SP1 and MIZ-1, resulting in the 
inhibition of the CDK-mediated retinoblastoma (RB) protein phosphorylation (Gomis et al., 
2006) (Seoane et al., 2004) (Cordenonsi et al., 2003) (Feng et al., 2000) (Feng et al., 2000) 
(Seoane et al., 2001). The functional interaction of E2F4/5 and p107 with SMAD3 on the c-
MYC promoter ensures repression of c-MYC expression (Chen et al., 2002). During cancer 
progression, cells needs to overcome the TGFβ-imposed cytostatic response. In many 
human cancers TGFβ resistance results from mutations in different components of the TGFβ 
signalling pathway, like for instance the mutation in the SMAD2 encoding gene, which is 
frequently found in colon carcinomas. The most dramatic effect is observed in colon cancer 
cells with TGFβ receptor II mutations that abolish all TGFβ responsiveness (Markowitz et al., 
1995).  
In addition to growth inhibition TGFβ possesses apoptosis-inducing capacity, another 
mechanism contributing to the tumour suppressor function. In the hematopoietic system 
TGFβ induced apoptosis seems to play a crucial role in T- and B-cell homeostasis (Schuster 
and Krieglstein, 2002). Apoptosis can be induced in various cell types by different 
mechanisms involving for instance, the common SMAD signalling and the death-associated 
protein kinase (DAPK) / death domain associated protein (DAXX) pathway (Perlman et al., 
2001). 
Furthermore, TGFβ influences cell lineage commitment and terminal differentiation, for 
instance TGFβ directs mesenchymal precursor cells to differentiate into fibroblasts and 
myofibroblasts (Derynck and Akhurst, 2007). One documented mechanism how TGFβ 
modulates differentiation is the suppression of ID1 expression. ID proteins are downstream 
targets of TGFβ and BMP signalling and interfere with differentiation stimulating transcription 
factors in cell differentiation (Ruzinova and Benezra, 2003). TGFβ stimulation induces 
artificial transcription factor (ATF) 3 expression and ATF3 in turn binds and represses the ID1 
promoter in a SMAD3 dependent way (Kang et al., 2003).  
One key event essential for tumour progression, which is associated to TGFβ signalling, is 
deregulated EMT. The epithilial-mesenchymal transition is a well-organized physiological 
program during gastrulation in early embryogenesis and transiently in the process of wound 
healing. In a tumourigenic context EMT supports tumour invasion. During EMT the 
expression of E-cadherin and other components of epithelial cell junction complexes are 
down regulated, which augments a more motile and invasive phenotype. TGFβ regulates 
EMT at the transcriptional level by SMAD-dependent up regulation of high-motility group A2 
(HMGA2) resulting in Snail, Slug and Twist expression (Thuault et al., 2006). SMAD 
independent, TGFβ stimulation results in the phosphorylation of receptor-associated Par6, 
which triggers the decomposition of cell junction complexes (Ozdamar et al., 2005).  
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Besides TGFβ`s function in cell invasion, high TGFβ plasma levels are associated with 
metastasis in various human cancers including myeloma, lymphoma, breast and prostate 
cancer.   
Within the immune system TGFβ is a major suppressor of tumourigenic inflammation by 
promoting immune tolerance for example this is particularly important in the intestinal 
mucosa. Precancerous colon lesions including submucosal inflammation promote colon 
carcinoma development in TGFβ1 and SMAD3 deficient mice (Massague, 2008). This 
cytokine impairs the development, proliferation, and function of the innate as well the 
adaptive immune system. TGFβ diminishes the activity of macrophages, natural killer (NK) 
cells and effector T-cells and initiates the generation of regulatory T-cell (Massague, 2008).  
 
1.4 CCAAT/enhancer-binding protein family 
The CCAAT-enhancer-binding proteins (C/EBPs) are a family of highly conserved basic 
region leucine zipper transcription factors, comprising six members: C/EBPα, β, γ, δ, ε and ζ 
(Lekstrom-Himes and Xanthopoulos, 1998). The C/EBP proteins play a crucial role in the 
regulation of cellular proliferation and differentiation, metabolism, immune, and inflammatory 
processes, particularly in hepatocytes, adipocytes and hematopoietic cells. C/EBP proteins 
can function as tumour promoting as well as tumour suppressing factors. A common feature 
of all members of the C/EBP family is the tripartite modular composition, consisting of the C-
terminal leucine zipper domain involved in dimerization and DNA binding, a basic DNA 
binding region and an N-terminal transactivation domain (Ramji and Foka, 2002). The C/EBP 
transcription factors are capable to bind to CCAAT-box motifs present in several promoter 
and enhancer regions of target genes (Johnson and McKnight, 1989). The different 
intrafamilial homo- or heterodimers are able to recognize the identical DNA sequence motif, 
except of C/EBPζ. Furthermore, C/EBP proteins collaborate with several different bZIP and 
non-bZIP transcription factors and co-factors to direct cell fate including SP1, p300, the 
Mediator complex subunit CRSP130, SMAD4, c-MYB, c-MYC, and RB (Lee et al., 1997) 
(Schwartz et al., 2003) (Brenner et al., 2005) (Choy and Derynck, 2003) (Chen et al., 1996)  
(Tahirov et al., 2002) (Tinel et al., 2003). The most extensively studied family members are 
C/EBPα and C/EBPβ. 
 
1.4.1 C/EBPα 
C/EBPα was the first identified member of the C/EBP family in the liver (Costa et al., 1988). 
The full-length isoform, known as p42, blocks proliferation and induces differentiation of 
adipocytes, and granulocytes, whereas the isoform p30 lacking the transactivation domains 
behaves dominant negatively (Lin et al., 1993). The c/ebpα-/- mice die at birth as a 
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consequence of hypoglycaemia develop lung abnormalities and display altered hepatic 
tissue architecture (Wang et al., 1995) (Flodby et al., 1996) (Zhang et al., 1997). C/EBPα 
possesses a crucial role in the activation of lineage specific target genes like serum albumin, 
AP2, SCD1 and granulocyte colony stimulating factor receptor (Friedman et al., 1989) 
(Christy et al., 1989) (Smith et al., 1996). Furthermore, C/EBPα is implicated in the up 
regulation of miRNA223, which is involved in granulocytic differentiation (Fazi et al., 2005). 
The ability of C/EBPα to direct cell fate decision depends on the presence of collaborating 
transcription factors and co-factors. For instance MAX acts as a co-activator of C/EBPα 
during granulocyte differentiation and the repression of E2F function leads to down regulation 
of c-MYC likewise resulting in granulocytic differentiation (Zada et al., 2006) (D'Alo et al., 
2003) (Slomiany et al., 2000). The direct interaction with CDK2 and 4 impedes cell cycle 
progression and co-operation with NFκB regulates extrinsic and intrinsic apoptotic pathways 
(Wang et al., 2001c) (Wang et al., 2002) (Paz-Priel et al., 2009). The phosphorylation of 
C/EBPα at Ser-21 by ERK1/2 inhibits the C/EBPα mediated induction of granulopoiesis 
(Ross et al., 2004). Together these findings support the concept that C/EBPα is an important 
regulator of cell differentiation processes. 
 
1.4.2 C/EBPβ 
The three physiologically expressed C/EBPβ isoforms the liver-enriched transcriptional 
activator protein (LAP*, 38 kDa), LAP (35 kDa), and liver-enriched inhibitory protein (LIP; 20 
kDa), encoded from an intron-less gene on chromosome 20q13.1, are generated like 
C/EBPα from a single mRNA transcript by a leaky ribosomal scanning mechanism or 
regulated proteolysis (Descombes and Schibler, 1991) (Ossipow et al., 1993) (Welm et al., 
1999). The LAP isofrom contains the TAD and the bZIP domain, whereas the LIP isoform 
lacks the TAD. The LAP/LIP expression ratio is crucial for the biological effect of C/EBPβ. 
The N-terminal truncated LIP isoform acts as a dominant negative regulator of C/EBPβ by 
forming non-transactivating heterodimers (Descombes and Schibler, 1991).  
The c/ebpβ-/- mice are viable, but develop pleiotropic deficiencies with defects in the female 
reproductive system (Sterneck et al., 1997), in the innate immune responses (Tanaka et al., 
1995), the Th1 immune response (Screpanti et al., 1995), and in the regulation of 
differentiation and proliferation of hepatocytes, adipocytes and keratinocytes (Tanaka et al., 
1997) (Greenbaum et al., 1998) (Zhu et al., 1999) (Zhang et al., 2004).  
Similar to C/EBPα, C/EBPβ regulates a wide variety of cellular behaviour. In addition to the 
fundamental role in the regulation of differentiation and growth control, C/EBPβ was identified 
to be involved in the RB:E2F-dependent induction of senescence (Sebastian et al., 2005). 
C/EBPβ expression is up regulated in response to cytokines, mitogenes, hormones, 
nutrients, and reagents causing cellular stress, including LPS, IL6, IL1, INFγ, TNFα, 
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dexamethasone, cAMP, and glucagon (Akira et al., 1990) (Alam et al., 1992) (Cardinaux and 
Magistretti, 1996); (Matsuno et al., 1996) (Cardinaux et al., 2000) (Granger et al., 2000). 
Recently it was demonstrated in mice that C/EBPβ mRNA translation is repressed by 
miRNA-155 binding to the 3`UTR (Worm et al., 2009).   
Additionally to the transcriptional and translational regulation, C/EBPβ function is regulated 
by a number of post-translational modifications including phosphorylation, acetylation, 
methylation and sumoylation. (Nakajima et al., 1993) (Kowenz-Leutz et al., 1994) (Williams 
et al., 1995) (Pless et al., 2008) (Berberich-Siebelt et al., 2006) (Eaton and Sealy, 2003) 
(Cesena et al., 2007) (Joo et al., 2004) (Xu et al., 2003) (Shuman et al., 2004). Particularly 
interesting is the phosphorylation at Thr-235 located in the central regulatory domain and at 
Ser-64 by MAPKs, CDK2 and CDC2. These modifications induce a conformational change 
exposing the TAD domain, which leads to an exchange of components of the bound 
Mediator complex. This exchange converts the Mediator complex into its active state.  
Further modifications, modified residues and the corresponding enzymes are summarized in 
Figure 9. 
 
Figure 9: Schematic representation of the protein structure of the three different C/EBPβ isoformen LAP* 
(38 kDa), LAP  (35 kDa) and LIP (20 kDa). The TAD consists of four conserved boxes I, II, III, and IV interacting 
with the SWI/SNF co-activator complex. The central regulatory domain (RD) with three conserved boxes has 
repressing activity. The C-terminal bZIP is composed of the DNA binding domain DBD followed by the 
dimerization motif the leucine zipper. P indicates phosphorylation sites, Ser-64 is phosphorylated by MAPK, 
CDK2 and CDC2; Ser-231, Thr-235 is phosphorylated by MAPK, CDC2 and CDC2; Thr-266 is phosphorylated by 
RSK; Ser-288, Ser-325 are phosphorylated by CaMK. Both the TAD and the RD are involved in the interaction 
with the Mediator complex and p300. 
 
 
1.5 Specific Protein/Krüppel-Like Factor transcription factor family  
Members of the SP/KLF transcription factor family are highly conserved Cys2His2-type zinc 
finger proteins sharing sequence identities in the C-terminal DNA-binding domain of around 
65% (Kaczynski et al., 2003). These transcription factors bind with different affinities to GC-
and/or GT consensus sequences of promoters. The SP subfamily encompasses six 
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members SP1-6 and all family members bind preferentially to GC-box consensus sequences 
(Kaczynski et al., 2003). The founding member SP1 was first identified by Dynan and Tjian in 
the early 80`s as a transcription factor that binds to the SV40 promoter (Dynan and Tjian, 
1983). This factor was initially classified as a constitutive activator of housekeeping genes, 
but in the last two decades it became obvious that SP1 is also involved in the dynamic 
regulated transcription. The most closely related transcription factors SP1 and SP3 are 
ubiquitously expressed and involved in diverse biological processes summarized for SP1 in 
Figure 10, such as immune response, differentiation, angiogenesis, cell growth, proliferation, 
and apoptosis (Kaczynski et al., 2003) (Ming et al., 2008) (Deniaud et al., 2006) (Jones et al., 
1986) (Finkenzeller et al., 1997) (Opitz and Rustgi, 2000) (Kaczynski et al., 2003).  
 
 
 
Figure 10: SP1 interaction partners, relevant target genes and functional implications are summarized.     
 
However SP1 and SP3 capture different physiological properties best documented in 
knockout experiments. SP1 deficient mouse embryos exhibit various abnormalities with 
retarded development and died around 11 days of gestation. By contrast the sp3-/- mice died 
invariably at birth due to respiratory defects (Marin et al., 1997) (Bouwman et al., 2000). In a 
variety of human cancers SP1 is overexpressed and associated with malignant 
transformation. 
SP1 comprises two glutamine-rich TADs and activates or represses target gene transcription 
respectively depending on the interaction with co-factors, physiological stimuli and post-
translational modifications (Figure 11) (Courey and Tjian, 1988), which include 
phosphorylation, acetylation, sumoylation, ubiquitylation, poly(ADP-ribolsyl)ation (Zaniolo et 
al., 2007) and glycosylation of the SP1 factor on several different sites (Tan and Khachigian, 
2009). MAPKs-mediated phosphorylation at Thr-453 and Thr-736 is required for SP1 
transactivation activity (Milanini-Mongiat et al., 2002), whereas phoshorylation at Thr-278 and 
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Thr-739 by JNK1 protects the factor from ubiquitin-dependent degradation during mitosis in 
tumour cell lines (Chuang et al., 2008). The CK2 mediated phosphorylation at Thr-579, a 
residue located within the zinc-finger domain, impairs SP1 DNA binding capacity (Tan and 
Khachigian, 2009). Another phosphorylation, which influences SP1 DNA interaction, occurs 
at Ser-59. This serine residue is dephosphorylated by protein phosphatase 2A (PP2A) during 
interphase and increases SP1 binding to chromatin (Vicart et al., 2006). Oxidative stress 
induces SP1 acetylation resulting in enhanced DNA binding and in up regulation of target 
gene expressing (Ryu et al., 2003) (Tan and Khachigian, 2009). The p300-dependent 
acetylation that occurs in the DBD enhances (Suzuki et al., 2000), whereas the acetylation of 
K703 reduces SP1 DNA binding (Hung et al., 2006). Together these studies demonstrate a 
large variety of mechanisms that regulate SP1. However still little is known about the 
combinatorial effects of these different modifications for SP1 function.  
 
 
 
Figure 11: Scheme of the functional domains of SP1 and domain-specific interactions with general 
transcription factors, the co-activator p300 and the chromatin remodelling complex SWI/SNF. A bipartite 
inhibitory domain (ID), two serine/threonin-rich domains (ST), two glutamine-rich domains (Q), three C2H2-type 
zinc fingers (Zn) are indicated. The glutamine-rich region and parts of the ST-domains form the two TADs of SP1.  
The +/- stretch is highly charged with 12 acidic and six positive charges. P refers different phosphorylation sites, 
Ser-56 phosphorylated by ATM, Ser-59, Thr-278 substrate of JNK, Thr-453 targeted by ERK1/2, Thr-579 modified 
by CK2, Thr-736 phosphorylated by ERK1/2 and Thr-739 modified by JNK.     
 
SP1 is able co-operate with itself in case two or more binding sites are present in promoters 
(Pascal and Tjian, 1991). Beyond that SP1 competes for binding to its consensus sequence 
with other members of the SP/KLF family like SP3 and KLF9 (BTEB1) (Sogawa et al., 1993) 
(Hagen et al., 1994). In addition SP1 interacts directly with a number of different factors 
including SMAD3/4, p53, c-MYC, RB, C/EBPβ, mouse double minute (MDM) 2 and breast 
cancer associated gene (BRCA) 1(Botella et al., 2001) (Ohlsson et al., 1998) (Gartel et al., 
2001) (Chen et al., 1994b) (Lee et al., 1997) (Johnson-Pais et al., 2001) (Maor et al., 2000). 
Furthermore, components of the basal transcription machinery like TAF4, TAF7, TFIIB or 
TFIIF and TBP/TFIID are recruited to promoter regions by SP1 to stimulate transcription 
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initiation (Chiang and Roeder, 1995) (Saluja et al., 1998). SP1 also influences chromatin 
remodelling via interaction with the SWI/SNF chromatin-remodelling complex (Kadam et al., 
2000) (Kadam and Emerson, 2003). Thus SP1 has multiple mechanisms to control promoter 
activity. 
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1.6 Aim of the study 
MAD1 is involved in the regulation of a wide variety of cellular processes including 
proliferation, differentiation, transformation, and apoptosis. All biological activities of MAD1 
studies to this day are based on its function as a transcriptional repressor of target genes. In 
these findings MAD1 counteracts at last in part the function of the proto-oncogene c-MYC as 
a transcriptional activator. Previous studies mainly focused on the role of MAD1 in the control 
of cell physiology, whereas the regulation of the MAD1 gene is less well understood. Several 
extracellular signals are known to induce MAD1 expression under certain physiological 
circumstances. For instance G-CSF, the major regulator of granulopoiesis stimulates MAD1 
expression in hematopoietic HL60 and U937 cells (Jiang et al., 2008) indicating a potentially 
critical role of MAD1 in the development of cells of the immune system. Another stimulus 
known to induce MAD1 expression in a cell type specific manner is the multifunctional 
cytokine TGFβ1 (Werner et al., 2001). 
The aim of this study was to characterize the transcriptional regulation of MAD1 expression 
in response to TGFβ1 in hematopoietic cells. To unravel this mechanism this study focused 
on the identification of transcription factors acting downstream of the TGFβ1-induced 
signalling and in the regulation of histone modifications and Pol II occupancy at the MAD1 
promoter in response to TGFβ1. Furthermore, co-operative interactions of transcription 
factors involved in the induction of MAD1 transcription were analyzed in this study.  
Another aspect was to investigate the role of c-MYC as a potential regulator of the MAD1 
gene. The presence of an E-box motif within the MAD1 promoter was of particular interest 
since regulation through this DNA element may provide a mechanism to control the 
antagonism between MYC and MAD proteins. Therefore a potential role in the regulation of 
MAD1 transcription was addressed.  
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2 Materials and methods 
 
2.1 Chemicals, consumables and reagents  
2.1.1 Chemicals 
The purchased chemicals were ordered from Amersham Biosciences, AppliChem, Baker, 
Bayer, BD Biosciences, Biozym, Calbiochem, Clontech, Delta, Difco, Fluka, Hartmann 
Analytic GmbH, GE Healthcare, Gibco, Invitrogen, Invivogen, KMF, Fermentas, Merck, MP 
Biomedicals, New England Biolabs, Peprotec, Perkin Elmer, Qiagen, Riedel-de-Haën, 
Roche, Rockland, Roth, Sigma, Stratagene, USB, and Zymo Research. 
 
2.1.2 Consumables 
All used consumables were obtained from the named companies below. 
Amersham Biosciences, Ansell, Becton Dickinson, Beranek, Biometra, Bio-Rad, Brand, 
Braun, Corning, Costar, Eppendorf, Falcon, Fisher Scientific, Fuji, Greiner, Hartenstein, 
Integra Biosciences, Kimberley-Clark, Merck, Millipore, Nalgene, Nerbe Plus, Nunc, Roth, 
Sarstedt, Sartorius, Schleicher&Schuell, Stratagene, TPP, VWR, WillCo Wells. 
 
2.1.3 Oligonucleotides 
The oligonucleotides used in this study were purchased from MWG-Biotech, Germany, and 
Qiagen. 
 
Sp2    5´-AGCTGGTCGATTTGGTGAACG-3´  
15    5´-GTTGTTGGTATAGAACCAATGGG-3´ 
16    5´-TGGAAAGAGGGGGTGGAGC-3´ 
17   5´-AAGCCCTCTCCCAATCGCAC-3´ 
16   5´-TCTCTTGACAGGCCAGCTTCG-3´ 
18    5´-AGCTGGCCTGTCAAGAGAAGG-3´ 
19    5´-TGGCGGCTGCTGCTCTGC-3´ 
20    5´-TCTCTTGTCGAGCGTGGTTGC-3´ 
21    5´-AGCGGGCTCCATAGCGGGC-3´ 
23    5´-GACTATCTGGAGCGGCGGG-3´ 
CCAAT-box 1 for  5´-AGCCCTCTCCCAATCGCACAAG-3´ 
CCAAT-box 1 rev  5´-CTTGTGCGATTGGGAGAGGGCT-3´ 
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CCAAT-box 2 for  5´-CTTTGGGGGGCCAATGAGGAAC-3´ 
CCAAT-box 2 rev 5´-GTTCCTCATTGGGCCCCCCAAAG-3´ 
CCAAT-box MO for  5´-TCGAGATGGGGCAATAT-3´ 
CCAAT-box MO rev  5´-ATATTGCCCCATCTCGA-3´ 
U    5´-CCTCTTAATATACTGTCCTATGC-3´ 
U´   5´-GTCACAGCTCTCCAGAAATAGAAG-3´ 
P    5´-GTCACAGCTCCAGAAATAGAAG-3´ 
P´   5´-TTCTCTTGACAGGCCAGCTT-3´ 
G    5´-ATATTGTAGGTGACACAAACTGC-3´ 
G´   5´-ATCTCACTTGAAGCTTCCACAG-3´ 
 
2.2 Vectors and antibodies 
2.2.1 Reporter gene vectors 
pEQ176P2:  
This vector was routinely used for control transfections for CMV-containing vectors if the 
respective backbone vector for the transfected plasmid was not available. It is derived from 
pEQ176, which drives expression of ß-galactosidase under the control of a CMV promoter. 
Most of the cDNA encoding ß-galactosidase was cut out by a PvuII restriction digest (Juliane 
Lüscher-Firzlaff). 
 
pGL2-Basic-Vector:  
The vector contains an ampicillin-resistance, the luciferase gene (luc) followed by the SV40 
small T antigen intron and early polyadenylation [poly(A)] signals. The vector lacks an 
eukaryotic promoter and enhancer sequences, allowing maximum flexibility in cloning 
putative regulatory sequences (Promega). 
 
pGL2-Humad1-1282:  
The sequence of the putative human MAD1 promoter, from -1282 to +248 relative to the 
TSS, was cloned into pGL2-Basic vector with XhoI and BglII enzymes (Kolja Eckert). 
 
pGL2-Humad1-795:   
Similar to the pGL2-Humad1-1282, the sequence -795 to +248 of the human MAD1 promoter 
was cloned into the pGL2-Basic vector (Kolja Eckert). 
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pGL2-Humad1-385:  
Similar to the pGL2-Humad1-1282, the sequence -385 to +248 of the human MAD1 promoter 
was cloned into the pGL2-Basic vector (Alexandra Greindl). 
 
pGL2-Humad1-184:  
Similar to the pGL2-Humad1-1282, the sequence -184 to +248 of the human MAD1 promoter 
was cloned into the pGL2-Basic vector (Kolja Eckert). 
 
pGL2-Humad1-184A#:  
Compared to pGL2-Humad1-184, the first CCAAT-box motif was mutated (Kan Jiang). 
 
pGL2-Humad1-184B#:  
Compared to pGL2-Humad1-184, the second CCAAT-box motif was mutated (Kan Jiang). 
 
pGL2-Humad1-184E#:  
Compared to pGL2-Humad1-184, both CCAAT-box motifs were mutated (Kan Jiang). 
 
pGL2-Humad1-184SPm1#:  
Compared to pGL2-Humad1-184, the first GC-box motif was mutated (Kan Jiang). 
 
pGL2-Humad1-184SPm2#:  
Compared to pGL2-Humad1-184, the second GC-box motif was mutated (Kan Jiang). 
 
pGL2-Humad1-184SPm1+2#:  
Compared to pGL2-Humad1-184, both GC-box motifs were mutated (Kan Jiang). 
 
pXHmintk-184-58:  
The portion from -184 to -58 of putative human MAD1 proximal promoter was cloned into the 
pXHmintk-luc vector by using XhoI and HindIII enzymes (Marie Henriksson).  
 
pGL3:  
The pGL3 Basic vector contains an ampicilin resistance, a synthetic poly(A) 
signal/transcriptional pause site for background reduction, a SV40 late poly(A) signal and the 
luciferase gene (Promega).  
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pGL3SBE:  
12 repetitive SMAD binding sites were cloned into the pGL3 luciferase vector (kindly gift from 
Prof. Heinrich). 
 
pBlueskript:  
This vector was routinely used to fill up transfections to an equal DNA content (Stratagene). 
 
2.2.2 Eukaryotic expression vectors 
pEQ176:  
This vector was routinely used for reporter gene assay.  pEQ176 constitutively expresses ß-
galactosidase under control of a CMV promoter (Firzlaff et al., 1991).  
 
pCB6+-C/EBPβ:  
The cDNA of C/EBPβ was cloned into pCB6+ vector by using HindIII and EcoRI enzymes. 
The expression of C/EBPβ is under the control of the CMV promoter (Oelgeschlager et al., 
1996). 
 
pCB6+-C/EBPα:	  	  
The cDNA of C/EBPα was cloned into pCB6+ vector by using HindIII and EcoRI enzymes. 
The expression of C/EBPα is under the control of the CMV promoter (Oelgeschlager et al., 
1996). 
 
pCDNA3+-C/EBPε: 
A 1.2-kb cDNA encoding full-length human C/EBP-epsilon was cloned into pcDNA3 under 
the control of CMV promoter (Verbeek et al., 1999).   
 
pCL-neo-HA-SP1:  
The full length SP1 cDNA was cloned into pCI vector (kindly gift from H. Rotheneder (Wien, 
Austria). 
 
pCI-neo-HA-SP1-N:  
This construct expresses the N-terminal part of SP1 lacking the DNA binding domain, from 
amino acid 8 to 618 (kindly gift from H. Rotheneder, Wien, Austria). 
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pCGN-HA-MYC: 
 The cDNA of the human c-MYC (2 to 439 aa) was cloned into the pCGN-HA vector by using 
XbaI and BamHI. pCGN is a CMV promoter driven expression vector, and expresses an HA-
tag fusionprotein (kindly gift from Tansey (Salghetti et al., 1999)). 
 
pCGN-HA-Myc∆N2:  
The cDNA of human c-MYC encoding amino acid 147 to 429 was cloned into the pCGN-HA 
vector (kindly gift from Tansey (Salghetti et al., 1999)). 
 
pCGN-HA-Myc∆C3:  
The cDNA of human c-MYC encoding amino acid 1 to 221 was cloned into the pCGN-HA 
vector (kindly gift from Tansey (Salghetti et al., 1999)). 
 
pcDNA3-SMAD2:  
This construct expresses human SMAD2 under the control of a CMV promoter (kindly gift 
from Prof. Heinrich, Aachen).  
 
pcDNA3-SMAD3:  
This construct expresses human SMAD3 under the control of a CMV promoter (kindly gift 
from Prof. Heinrich, Aachen).  
 
pcDNA3-SMAD4:  
This construct expresses human SMAD4 under the control of a CMV promoter (kindly gift 
from Prof. Heinrich, Aachen).  
 
TGFβR1ca:  
Was previously described in (Abdollah et al., 1997). 
 
TGFβR1wt:  
Was previously described in (Abdollah et al., 1997). 
 
pSuper-shC/EBPβ:  
This vector was derived from pSuper by insertion of the hybridized oligo shC/EBPβ between 
the BglII and HindIII sites. The construct drives the expression of shRNA designed for 
targeting the C/EBPβ mRNA. 
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pSuper-c-MYC #4:  
This vector was derived from pSuper by insertion of the hybridized oligo sh-c-MYC between 
the BglII and HindIII sites. The construct drives the expression of shRNA designed for 
targeting the c-MYC mRNA (Juliane Lüscher-Firzlaff). 
 
pSuper-rAsh2m = pSuperAsh(rat)f#5:  
This vector was derived from pSuper by insertion of the hybridized oligo shASH2 between 
the BglII and HindIII sites. The construct drives the expression of shRNA designed for 
targeting the rat ASH2 mRNA. Due to sequence mistakes this shRNA is not functional and 
served as control shRNA (Juliane Lüscher-Firzlaff).   
 
2.2.3 Antibodies 
Antigen Company Cat.no. Application 
α-Histone3 H3 acetyl Upstate 06-599 ChIP 
α-H3K4me3 Abcam 8580-50 ChIP 
α-Pol II N20 Santa Cruz Biotechnology SC-899 ChIP 
α-Pol II CTD 
phosphoserine 2 H5 
Covance MMS-129R ChIP 
α-Pol II CTD 
phosphoserine 5 H14 
Covance MMS-134R ChIP 
α-alpha Tubulin B-5-1-2 Sigma T-5168 WB 
α-Actin MP Biomedicals 69100 WB 
α-C/EBPα 14AA Santa Cruz Biotechnology SC-61 ChIP, EMSA, WB 
α-C/EBPβ C19 Santa Cruz Biotechnology SC-150 ChIP, EMSA, WB 
α-C/EBPβ-P (Thr235) Cell Signaling 3084S WB 
α-SP1 PEP2 Santa Cruz Biotechnology SC-59 ChIP 
Α-SP1 Upstate 07-124  
α-p38 H147 Santa Cruz Biotechnology SC-7149 WB 
α-p38-P (Thr180/Tyr182) Cell Signaling 9216 WB 
α-p300 C20 Santa Cruz Biotechnology SC-585 ChIP 
α-ERK1 C16 Santa Cruz Biotechnology SC-93 WB 
α-ERK1/2-P E4 Santa Cruz Biotechnology SC-7383 WB 
α-SMAD3 Cell Signaling 9513 WB 
α-SMAD3-P (Ser423/425) 
C25A9 
Cell Signaling 9520 WB 
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2.3 Prokaryotic stains and culture 
2.3.1 Escherichia coli strains 
DH5α:  
F-φ80dlacZΔM15Δ(lacZYA-argF) U169 recA1 endA1 hsdR17(rk-mk+) phoA supE44λ- thi-1 
gyrA96 relA1 (Invitrogen) 
 
XL10-Gold:  
Tetr D(mcrA)183 D(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1, recA1 gyrA96 relA1 lac 
Hte [F’ proAB lacIqZDM15 Tn10 (Tetr) Amy Camr] (Invitrogen) 
 
TOP/10/P3:  
F-mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 recA1 araD139 Δ (araleu) 7697 galU 
galK rpsL endA1 nupG P3: KanR AmpR TetR (Invitrogen)  
 
2.3.2 Culture medium 
LB medium:  
1%  (w/v) trypton  
0.5%  (w/v) yeast extract  
1%  (w/v) NaCl (pH7.0) 
 
Agar plate (amp):  
LB medium 
1.5%  (w/v) bacto agar (Difco) 
100 µg/ml  ampicillin  
 
Agar plate (kan):  
LB medium 
1.5%  (w/v) bacto agar (Difco) 
100 µg/ml kanamycin 
 
2.4 Work with prokaryotic cells 
2.4.1 Transformation 
A 200 µl aliquot of chemical competent E. coli cells was thawed on ice. 100 µl of the cells 
were mixed with 500 ng – 800 ng vector DNA in a 1.5 ml tube and incubated for 30 min on 
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ice. Heat shock was performed at 42 °C for 45 s and immediately placed on ice for 2 min. 
Subsequently 1 ml of pre-warmed LB medium was added to the bacteria suspension and the 
culture was shaking incubated at 37°C for 30 min on a thermal block. After the expiration of 
the incubation time the cells were pelleted by centrifugation, resuspended in 100 µl LB 
medium and 10 µl plated on an agar plate containing the required antibiotics. The plates 
were incubated at 37°C overnight. 
 
2.4.2 Plasmid mini-preparation and maxi-preparation  
The maxi preparation were performed following the manufacturer`s instructions using the 
Macherey Nagel Maxi preparation Kit.    
The Fermantas or Zypy mini preparation kit was used for small scale purification of plasmid 
DNA.  
 
2.5 Eukaryotic cells and culture conditions 
2.5.1 Cell lines and primary cells 
Cell line Description Growth medium 
HEK293 
ATCC CRL-1573 
The HEK293 cell line is an hypotriploid adherent 
cell line derived from human embryonic kidney 
cells (HEK), transformed Adenovirus 5 DNA 
(Integration site chromosome 19q13.2). 30% of the 
cells exhibit a modal number of 64 chromosomes, 
4.2% are higher ploid. 
DMEM (Gibco) 
4.5 g/l glucose, 
10% FCS 
(Gibco);  
Pen/Strep 
(Seroted) 
10.000 units/ 
10.000 µg/ml 
HEK293T HEK293T cells are a derivative of HEK293 cells 
that stably express the large T antigen of SV40.  
Plasimds containing the SV40 origin are replicated 
to a copy number of between 400 -1000 plasmids 
per cell within 293T, and therefore express the 
large T antigen at a higher level. HEK293T cells 
were made in Michelle Calos' laboratory at 
Stanford and are resistant to G418. 
DMEM (Gibco) 
4.5 g/l glucose, 
10% FCS (v/v) 
(Gibco);  
Pen/Strep 
(Seroted) 
10.000 units/ 
10.000 µg/ml 
HeLa 
ATCC CCL-2 
HeLa cells are adherent human epithelial cells from 
a fatal cervical adenocarcinoma transformed by 
human papillomavirus 18 (HPV18, Henrietta Lacks, 
1951). 100% of the cells are aneuploid and 98% 
contain a small telocentric chromosome. The p53 
expression levels were reported to be low whereas 
pRB expression levels are normal. 
DMEM (Gibco) 
4.5 g/l glucose, 
10% FCS (v/v) 
(Gibco);  
Pen/Strep 
(Seroted) 
10.000 units/ 
10.000 µg/ml 
U937 
ATCC CRL-
1593.2 
U937 cells were derived from the pleural effusion 
of a patient with histiocytic lymphoma in 1974 by 
Sundstorm and Nilsson. Phorbol esters, vitamin 
D3, gamma interferon, tumour necrosis factor and 
RPMI 1640 
(Gibco), 10% 
FCS (v/v) 
(Gibco);  
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retinoic acid are potent to induce terminal 
differentiation in this promyelocytic cell line.  
Pen/Strep 
(Seroted) 
10.000 units/ 
10.000 µg/ml 
HDF 
F335 
HDF are primary human dermal fibroblast isolated 
from a foreskin of a 5 year old boy  
DMEM (Gibco) 
w/o phenolred 
4.5 g/l glucose, 
glutamax, 10% 
FCS (v/v) 
(Gibco);  
Pen/Strep 
(Seroted) 
10.000 units/ 
10.000 µg/ml 
 
2.5.2 Culture conditions 
All listed eukaryotic cells were cultured in the appropriated culture medium (shown in the 
table above) at 37°C in humid atmosphere with 5% CO2. 
 
2.5.3 Materials for cell culture 
Penicillium/Streptomycin (Seromed)  10.000  units/10.000 µg/ml 
Trypsin/EDTA (Seromed)   0.5/0.02%  (w/v) in PBS 
Fetal Calf Serum (FCS, Gibco) 
 
PBS 
140 mM  NaCl 
 2.6 mM  KCL 
    2 mM  Na2HPO4 
           1.45 mM  KH2PO4 
 
Tissue culture dishes (Sarstedt) Ø 6 cm, 10 cm, 15 cm  
Tissue culture flask (Sarstedt, Falcon): volume 100, 250, 1000 ml 
Tissue culture plates (TPP): 6-well , 12-well   
 
2.5.4 Cryo-conservation and thawing of eukaryotic cell lines and primary cells  
For the cryo-conservation of eukaryotic cells, logarithmic growing adherent cells were 
trypsonized (5-10 min at 37°C) and harvested in 10 ml culture medium. The cell suspension 
was centrifuged at 1300 rpm at 4°C for 5 min. The cell pellet is resuspended in 1 ml 
FCS/10% DMSO (v/v) at a density of 5x106 – 107 cells/ml and transferred into a cryo tube. 
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For slowly cooling the cryo tubes were first stored in an isolated box at -80°C for 2 d, and for 
long-term storage transferred into the -150 °C freezer. 
For thawing cells, the cryo tube was incubated at 37°C, immediately after melting the cell 
suspension was transferred into a 15 ml tube containing 10 ml pre-warmed cell culture 
medium, and centrifuged at 1300 rpm for 5 min. The pelletized cells were resuspended in 10 
ml pre-warmed culture medium and transferred into an appropriate culture dish or flask.      
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2.6 General moleculare methodes 
2.6.1 DNA agarose gel electrophoresis 
DNA agarose gel electrophorese was modified from Sambrook et al.,1989. Double strand 
DNA was separated by preparative or analytical agarose gel electrophoration. According to 
the expected DNA fragment size gel electrophoresis was performed in 1-4% agarose 
supplemented with Ethidiumbromide (0.1 mg/ml). The bands were visualized using a UV 
transluminator at 302 nm, and the DNA fragment size was determined by using a DNA 
marker.     
 
DNA loading buffer 
 50 mM  Tris-HCL pH 8 
 50 mM  EDTA 
    50% (v/v)  glycerin 
 0.25% (w/v)  bromophenol blue 
 0.25% (w/v)  xylene cyanol 
 
TBE  
 89 mM  Tris-HCL pH 8 
 89 mM  boric acid 
   2 mM  EDTA 
 
DNA ladder 1 kb (Fermentas) 
Agarose Low EEO (Sigma) for 1-2% gels 
NuSieve GTG Agarose (Biozym Scientific) for 3-4% gels  
 
2.6.2 Gel extraction of DNA  
Agarose gel separated DNA fragments were recovered using the GeneJET™ Gel Extraction 
Kit (Fermentas). After gel electrophoresis the Ethidiumbromid stained DNA fragments were 
visualized via UV-light and the appropriated DNA fragment was excised using a scalpel, 
weighted in a 1.5 ml reaction tube and recovered according the manufacturer`s instruction. 
 
2.6.3 Enzymatic digestion of vector DNA  
Routinely 0.5-1 µg of vector DNA was digested in 20 µl reaction volume using restriction 
enzymes (Fermentas or NEB) under the appropriated buffer and temperature conditions 
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usually 37°C for 1 h. Double digests were performed by adding both restriction enzymes in 
Magic buffer. Adequate DNA digestion was analyzed by DNA agarose gel electrophoration. 
 
10x Magic buffer 
 200 mM  Tris pH 7.5 
 700 mM NaCl 
 200 mM  KCl 
 100 mM  MgCl2 
  0.5 mM  spermine 
         0.125 mM  spermidine 
 
2.6.4 DNA ligation 
Prior DNA ligation the linearized vector was dephosphorylated at 5`-phosphate groups by 
incubation with calf intestine alkaline phosphatase (Fermentas) at 37°C for 1 h. Vector and 
insert DNA was mixed at the appropriated vector/insert ratio and ligated using the T4 DNA 
ligase (Fermentas). Sticky end ligation was carried out at RT for 1-2 h. The ligated DNA was 
transformed into competent E. coli XL10 or DH5α.  
 
Calf Intestine Alkaline Phosphatase (Fermentas) 
T4 DNA ligase (Fermentas) 
 
2.6.5 Generation of pSuper-based shRNA vectors 
The online available program siDirect (genomics.jp/sidirect) was used to design shRNA 
oligonucleotides targeting a specific sequence and analyzed via the BLAST algorithm. The 
oligonucleotides were solved in TE buffer at 4°C. For hybridization the oligonucleotides were 
heated up to 98°C and slowly cooled down to RT. The hybridized oligonucleotides were 
cloned into pSuper vector (Brummelkamp et al., 2002) linearized with BglII and HindIII.  
 
sense 
5`GAT CCC C agcacagcgacgagtacaa (target sequence) TTC AAG AGA gattgtactcgtcgctgtgc 
(complementary sequence) TTT TTG GAA A´3 
 
antisense 
5`AGC TTT TCC AAA AA (target sequence) TCT CTT GAA complementary sequence 
GGG`3 
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2.6.6 Total RNA prepreparation 
The RNAeasy Mini Kit (Qiagen) was used for total RNA extraction, according the 
manufacturer`s instruction. The cell lysates were homogenized using the RNeasy Mini 
QIAShredder Kit. Qiagen DNase treatment was optional performed during RNA purification 
to avoid genomic DNA contamination using RNase Free DNase Set (Qiagen), therefore the 
DNase solution was directly pipeted on the column matrix and incubated at RT for 15 min.  
The RNA concentration was measured at 260/280 nm with the Nanodrop 100 UV/VIS 
Spectrophotometer (Peqlab/Thermo Scientific). The total RNA were directly used, then 
stored at -80°C and thawed on ice.   
 
2.6.7 cDNA synthesis 
During cDNA synthesis, the reverse transcriptase was used to transcribe RNA into cDNA 
(complementary DNA). The cDNA synthesis was performed using the Transcription First 
cDNA Synthesis Kit from Roche or the QuantiTect Reverse Transcription Kit For cDNA 
Synthesis from Qiagen. 500 ng -1 µg total RNA was used for cDNA synthesis according the 
Manufactur`s instruction. The cDNA was stored at -20°C.       
 
Transcription First cDNA Synthesis Kit (Roche) 
1 µg total RNA, 2 µl randome hexamer primer and x µl RNase free water (up to 13 µl) were 
incubated at 65°C for 10 min for primer annealing. Subsequently 4 µl 5x Reverse 
Transcriptase buffer, 0.5 µl Protector RNase Inhibitor, 2 µl dNTP mix and 0.5 µl Reverse 
Transcriptase were added to the RNA sample (total volumen 20 µl) and incubated at RT for 
10 min. For the synthesis reaction the samples were incubated at 55°C for 30 min and 
afterwards heat inactivated at 85°C for 5 min.  
 
QuantiTect Reverse Transcription Kit For cDNA Synthesis (Qiagen) 
The QuantiTect Reverse Transcription Kit For cDNA Synthesis (Qiagen) contained an 
additional step to get rid of genomic DNA contamination, this comprised 2 min incubation 
step at 42°C with the 2 µl DNA Wipeout buffer. The cDNA synthesis reaction was incubated 
at 42°C for 20-30 min. The reaction was heat inactivated at 95°C for 3 min.  
  
5`RACE 
For rapid amplification of cDNA-ends (5`-RACE) the 5`/3`-RACE-Kit (Roche) was used 
following the manufacturer’s protocol. 
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2.6.8 RT-PCR (real time polymerase chain reaction) 
The realtime PCR reaction was performed using the LightCycler (Roche) or the Rotorgene 
(Corbett Life Science). 
 
LightCycler 
Three step protocol 
 10 µl  SYBRgreen Ready Mix (Qiagen) 
   6 µl  RNase/DNase free H2O 
   2 µl  template cDNA  (undiluted, or 1:10 diluted in RNase free H2O) 
   2 µl  QantiTect primer assay (Qiagen)  
 
RT-PCR program 
 95°C  15 min initial denaturation 
 94°C  15 s 
 60°C  20 s 
 72°C 20 s 
The fold induction was calculated the program RelQant 
 
Rotorgene RT-PCR 
Two step RT-PCR protocol 
5 µl  SybrGreen Mix Universal Mastermix (Diagenode) 
3 µl  RNase/DNase free H2O 
1 µl  QantiTect primer assay (Qiagen) or  
1 µl  template cDNA (undiluted, or 1:10 diluted in RNase free H2O) 
 
RT-PCR program 
 95°C  15 min initial denaturation 
 95°C  15 s 
 60°C   60 s 
       60-95°C, melting hold s on the first step, hold 5 s on next steps 
 
The β-glucuronidase gene was used as house keeping gene for standardization. The fold 
induction was calculated via ΔΔCT calculation; the value of duplicates was averaged from 
each treated sample and each time point. 
Formula 2 -ΔΔCT 
 
 
40 cycles 
40 cycles 
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Three step protocol 
5 µl SybrGreen Mix Universal Mastermix (SensiMix) 
2 µl RNase/DNase free H2O 
2 µl template ChIP  
1 µl primer  
 
RT-PCR program 
 95°C 10 min initial denaturation 
 95°C 15 s 
 60°C 30 s 
 72°C 15 s 
60-95°C, melting hold s on the first step, hold 5 s on next steps  
 
2.7 Transient transfection 
2.7.1 Calcium phosphate transfection 
The transient transfection method bases on the precipitate formation of calcium-phosphate-
DNA complexes, which are endocytosed by the adherent cells. The calcium-phosphate 
transfection was modified from the protocol previously described by Chen and Bousset 
(Chen and Okayama, 1988) (Bousset et al., 1994). The method was used to transfect 
adherent cell lines including HEK293, HEK293T and HeLa. 
The day prior transfection the cells were seeded at a density of 1x106 cells on a 10 cm plate 
and 0.8-1.5x105 cells on 6 well plate. According the experiment 20 µg (10 cm plate) or 3-5 µg 
(6 well plate) total DNA was diluted in 500 µl/100 µl 250 mM CaCl2 solution. Subsequently 
the same volume (500 µl/100 µl) 2x Hebs buffer was added drop wise to the sample, mixed 
by flipping and incubated at RT for 10 min. Following the incubation time the solution was 
carefully pipeted onto the cell monolayer. The plates were slewed and incubated at 37°C and 
5% CO2. HeLa cell were transfected overnight, HEK293 and HEK293T cells for 6 h. 
Referring to the incubation time the medium was discard and the cells were washed with 
HEPES buffer and incubated at RT for 10 min. Subsequently fresh culture medium was 
added and the cells were incubated up to 48-72 h prior harvesting at 37°C and 5% CO2.  
 
 
 
 
 
 
40 cycles 
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2x Hebs buffer 
274 mM NaCl 
  42 mM  HEPES 
 9.6 mM KCl 
 1.5 mM  Na2HPO4 
 pH 7.1 
 
250 mM CaCl2 
 
HEPES buffer 
142 mM  NaCl 
  10 mM  HEPES 
 6.7 mM  KCl 
 pH 7.3 
 
2.7.2 Reporter gene assay 
Reporter gene assays are an established method to investigate the promoter regulation of 
eukaryotic genes. Therefore putative promoter elements are cloned into a construct 
containing an easily detectable gene product (luciferase), whose expression is than 
controlled by the promoter elements. Increased luciferase expression in the transiently 
transfected cells correlates with an increase in the luciferase activity in the cell lysate. The 
transfection efficiency was detected by co-transfecting the constitutively expressed β-
galactosidase expression construct, due to variable transfection efficiencies β-galactosidase 
expression was used for normalization. Empty vectors of the different expression constructs 
and the pBlueskript construct were used to achieve a constant total DNA content of 3 µg and 
5 µg (shRNA) per well (6 well plate). The transfected cells were harvested after 42 h of 
incubation, therefore the cell monolayer was washed 1x with PBS and lysed in 150-200 µl 
Extraction buffer for 10 min. The cells were scraped into a 1.5 ml reaction-tube and 
centrifuged at 16000 x g at 4°C for 15 min. The supernatant was used for the following 
luciferase- and β-galactosidase-measurements. 
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vector µg DNA/ well (6 well plate)  
reporter- luc-construct            1µg 
TGFβ receptor constructs        0.5 µg 
transcription factor constructs       0.5 µg 
β-galactosidase construct 0.2-0.5 µg 
shRNA pSuper constructs          3 µg 
(optional) pH2B-YFP       0.2 µg 
  
Luciferase-assay 
To measure the luciferase activity 20 µl of each cell lysate were mixed with 100 µl Measuring 
buffer in a 96 well plate. 35 µl luciferin solution was automatically injected into each well to 
start the enzymatic reaction. The luciferase activity respectively the quantity of emitted 
photons within a 5 s period was measured using the bioluminator (ELISA-Reader Victor2).  
 
β-galactosidase assay 
For the β-galactosidase measurment 20 µl cell lysate were mixed with 100 µl Z-buffer and 25 
µl ONPG (o-Nitrophenyl-β-D-galactopyranosid)-solution in a 96 well plate. The reaction batch 
was incubated at RT for 10-30 min, once the approach turned yellow the reaction was 
stopped via adding 65 µl Na2CO3.The level of colouration was determined photometically at 
405 nm in the bioluminator. Each experiment was preformed in three independent replicates 
and measured in duplicates. 
 
5 x Extraktion buffer:  
25 mM  Tris pH 8 (containing H3PO4) 
  2 mM  EDTA 
10% (v/v)  glycerin 
  1% (v/v)  Triton X-100 
10 mM  DTT (add freshly) 
 
Measuring buffer 
25 mM  glycin 
15 mM  MgSO4 x 7H2O 
  5 mM  ATP, pH 7 (add freshly) 
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Luciferin-solution 
25 mM  luciferin 
25 mM  NaOH 
storage at -20°C  
 
Z buffer 
60 mM  Na2HPO4 (waterfree) 
40 mM  Na2HPO4 x H2O 
10 mM  KCl 
  1 mM  MgSO4 
50 mM ß-Mercaptoethanol (add freshly) 
 
reaction stop reagent 
1 M Na2CO3 
 
substrates 
4 mg/ml ONPG diluted in Z buffer 
luciferin solution (see above) 
 
2.8 Cell lysate preparation for immunoprecipitations (IP), western blotting 
and electrophoretic mobility shift assay (EMSA) 
2.8.1 Frackelton buffer for EMSA lysates and Co-IP lysates 
 
10 mM  Tris-HCL  pH 7.05 
50 mM  NaCl 
30 mM  Na4P2O7 
50 mM  NaF 
   5 µM  ZnCl2 
  1 % (v/v) Triton X-100 
10 % (v/v)  glycerol 
freshly added protease and phosphatase inhibitors  
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EMSA lysates 
              100 µM  Na3VO4 
   150 µM  benzamidin 
           0.025 U/ml  α-macroglobulin (Roche) 
               2.5 µg/ml  leupeptin   
    14 µg/ml  aprotinin 
 
One 10 cm plate of transiently transfected HEK293T cells were harvested 48 h post-
transfection. First the cell monolayer was washed twice with PBS, and then lysed in 400 µl 
icecold Frackelton buffer on ice for 10 min. Thereafter the cells were scraped into a 1.5 ml 
reaction-tube and centrifuged at 16000 x g for 20 min at 4°C. The supernatant was 
transferred into a new 1.5 ml reaction tube, and shock-froozen in liquid nitrogen (when not 
directly used). The EMSA lysates were stored at -80°C and thawed on ice for usage.   
    
Co-IP lysates 
100 µM  Na3VO4 
500 µM  Pefabloc (Roche) 
150 µM  benzamidin 
  10 mM  sodium ß-glycerophosphate  
         0.025 U/ml  α-macroglobulin (Roche) 
 2.5 µg/ml  pepstatin A 
 2.5 µg/ml  leupeptin 
  14 µg/ml  aprotinin 
 
After 42 h post-tranfection the cells of each 10 cm plate were washed 1x with PBS prior lysis 
in 1 ml Frackelton buffer. The cells were incubated for 10 min on ice, afterwards sharped into 
a 1.5 ml reaction tube, and centrifuged at 16000 x g at 4°C for 20 min. The supernatant was 
transferred into a new tube and directly used for the CoIP experiment.    
 
RIPA lysates  
10 mM  Tris-HCl, pH 7,4 
50 mM  NaCl 
  5 mM  Pefablock 
   1% (w/v)  NP-40 
   1% (w/v)  Desoxycholat 
0,1% (w/v)  SDS 
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0,5% (w/v)  aprotinin 
2.8.2 Preparation of proteins from total RNA preparation flow through  
The total RNA preparation flow through was mixed with 2-volume aceton and incubated for 
15 min on ice. The protein precipitates were pelleted by centrifugation at 16000 x g at 4°C for 
15 min. The protein pellets were dried to remove most of the aceton and solved in 20 - 100 µl 
Urea buffer.    
 
Urea buffer 
 9 M  Urea 
 4% (w/w)  CHAPS 
 1% (w/w) DTT  
 
2.8.3 Freeze-thaw lysis  
This extraction procedure was described previously (Rudolph et al., 1999), and was used to 
generate highly concentrated cell extracts for western blotting of low-abundant proteins. The 
cells (107 cells/preparation) were pelleted by centrifugation, the culture medium was removed 
and the cells were washed twice with ice-cold PBS. The cell pellet was resuspended in 20 - 
30 µl FT lysis buffer by pipeting up and down. The lysates were froozen in liquid nitrogen, 
thawed on ice and mixed by vortexing. The freeze-thaw cycles were repeated five times. The 
thawed lysates were incubated with 250 U Benzonase (Merck) at RT for 10 min to digest the 
DNA.  An equal volume of 2x Sample buffer was added to the lysates, heated up to 95°C for 
10 min and immediately loaded on a polyacrylamid gel. 
 
FT lysis buffer 
 600 mM KCL 
   20 mM  Tris-Cl pH 7.8 
    20%   glycerol 
   10 µg/ml  leupeptin 
   10 µg/ml  pepstatin A 
  14 µg/ml  aprotinin  
            0.4 mg/ml  Pefabloc (Roche)  
 
2.8.4 Denaturing discontinuous polyacryamide gele electrophoresis (SDS-PAGE) 
The discontinuous SDS-PAGE was modified from Laemmli (Laemmli, 1970) using a 5% 
stacking gel and a 10-12.5% separating gel. This method is used to separate mixtures of 
Materials and methods 
  52 
proteins according to their molecular weight. SDS, a negatively charged detergent, binds 
quantitatively to the hydrophobic region of the protein molecule and applies a negatively net 
charge to the protein. In addition, reducing agents such as β-mercaptoethanol is added to 
break any S-S linkages. The protein mixture was heated up to 95°C and immediately loaded 
onto a polyacrylamid gel. The solely proteins are separated according their molecular weight 
by electrophoretically enforced migration through a polyacrylamid matrix towards the anode.   
 
2x/4x Sample buffer 
             160 mM    320 mM  Tris pH 6.8 
 100 mM    200 mM  β-Mercaptoethanol 
   20%     40% (v/v)  glycerol 
   10%       8% (w/v)  SDS 
0.25%    0.5% (w/v)  bromophenol blue 
 
Laemmli Running buffer  
   25 mM  Tris base 
 250 mM  glycine 
  0.1% (w/v)  SDS 
 
Protein Ladder  
PageRuler Prestained Protein Ladder, 11-170 kDa (Fermentas) 
 
2.8.5 Western blotting 
The western blot method was modified from Towbin (Towbin et al., 1979). The proteins 
separated by SDS-PAGE were electrophoretically transferred onto a nitrocellulose 
membrane in Semi-dry transfer buffer; during this transfer the proteins are partially renatured 
due to the removal of at least most of the SDS. The partial renaturation allows the 
immunodetection of proteins by using specific antibodies. For the semi-dry transfer of 
proteins the gel and nitrocellulose membrane were placed between buffer soaked Whatman 
papers and placed in a blotting camber between two electrode plates. The transfer was 
performed for 1.15 h at 1.5 mA per cm2 of membrane area. To control adequate protein 
transfer to the membrane, the membrane was stained with Ponceau for 2-3 min, afterwards 
washed twice with dH2O.  
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Semi-dry transfer buffer 
  25 mM  Tris base 
192 mM  glycine 
20% (v/v)  methanol 
0.2% (w/v) Ponceau S in 3% (v/v) TCA 
 
2.8.6 Immunodetection  
Subsequent to the protein transfer, the nitrocellulose membrane was incubated in TBS-
T/BSA or skim milk at RT for 30 min, to achieve blocking of unspecific binding sites on the 
membrane. After blocking the membrane was washed three times with TBS-T or PBS-T at 
RT for 5 min. The membrane was incubated with the primary antibody, diluted in PBS-T or 
TBS-T at 4°C overnight or at RT for 2 h. Prior incubation with the horseradish peroxidase 
conjugated secondary antibody, the membrane was washed three times with PBS-T or TBS-
T at RT for 5 min. The secondary antibody targets the invariable region of the primary 
antibody and was diluted in Blocking buffer and incubated at RT for 45 min. After incubation 
the membrane was washed at least three times with PBS-T or TBS-T at RT for 5 min. Finally 
addition of a chemiluminescent substrate allows immunodetection of the proteins of interest. 
The substrate is enzymatically turned over by the horseradish peroxidase, this reaction emits 
light, which was directly detected by a highly sensitive computer-assisted camera system 
(LAS-3000, Fuji).     
 
PBS-T 
PBS 
0.05% (v/v) Tween-20 
TBS-T 
  TBS 
0.05% (v/v) Tween-20 
 
Blocking buffer  
PBS-T 
5% (w/v) skim milk powder 
or 
TBS-T 
 5% (w/v) BSA 
 
ECL solution (Pierce) 
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SuperSignal West Femto Maximum Sensitivity Substrate (Pierce) 
2.8.7 Stripping of western blot membranes 
The nitrocellulose membrane was incubated in 0.5% H2O2 shaking at RT for 1 h. Afterwards 
the membrane were washed 3 three times with PBS-T. 
 
Stripping solution 
   1 ml 30%  H2O2 
 59 ml  H2O 
 
2.8.8 Immunoprecipitation  
Protein A Sepharose “4 fast flow” (Amersham Pharmacia) was swelled in PBS, washed 
several times with PBS and stored in PBS 0.1% (w/v) natriumazid at 4°C. The Protein A 
Sepharose was used for immunoprecipitations (IPs) with polyclonal antibodies, and washed 
three times in Frackelton buffer prior IP. For IP, 1 ml of Frackelton cell lysates were 
incubated with 2 µg specific antibody and 15-20 µl Protein A Sepharose rotating at 4°C 
overnight. The Protein A Sepharose was washed three times with ice cold Frackelton buffer, 
and pelleted at 2561 x g at 4°C for 1 min. The pellet was resuspended in 20-30 µl 2x Sample 
buffer. The IPs were separated by SDS-PAGE and detected via western blotting. 
 
2.8.9 Electrophoretic mobility shift assay  
Each Oligonucleotide was solved in H2O at a concentration of 50 ng/ml. 
 
Oligonucleotide labelling 
          100 ng  Oligonucleotide (100 pmol/ml) 
10 U   T4 Polynucleotide Kinase (Fermentas, 10 U/µl)  
  2 µl   10x Reaction buffer A (forward reaction, Fermentas)  
30 µCi  γ32P-ATP (370MBq  (10mCi)/ml, Hartmann Analytic) 
nuclease free H2O up to 20 µl 
 
The labelling reaction was incubated at 37°C for 30 min, and subsequently heated up to 
95°C for 5 min. For oligonucleotide annealling the reaction was slowly cooled down to RT 
around 3 h. 
 
Oligonucleotide purification 
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The radiolabeled oligonucleotides were separated on a 20% DNA-polyacrylamid at 400V for 
purification. The bands corresponding to radiolabeled oligonucleotides were detected by 
autoradiography, cut out and transfered into a screw tube. The radiolabeled oligonucleotides 
were recovered by shaking in 1 ml of 50 mM NH4 bicarbonat at 37°C overnight. The 
supernatant was transfered into a new tube and lyophilized to a remaining volume of 200 µl. 
For DNA precipitation the solution was mixed with 2 µl MgCl2 (1 M), 20 µl NaCl2 and 1.5 ml 
EtOH and stored at -20°C overnight. The precipitated oligonucleotides were pelleted by 
centrifugation at 16000 x g at 4°C for 30 min. The pellet was dried and solved in 30-50 µl 
H2O. 
 
Gel for oligonucleotide purification (20%) 
  12.5 ml  30%:0.8% Acryl/Bisacrylamid 
  1.87 ml  10x TBE 
    4.3 ml  H2O 
18.75 µl  TEMED 
   28.5 µl APS (20%) 
  
EMSA  
The protein-DNA complexes were seperated on a 5% native polyacrylamid gel, prior sample 
loading , the gel was pre-electrophoresed at 400V at 4°C for 30-60 min. 
 
EMSA reaction mix 
      3 µl  Frackelton lysates 
      2 µl  poly dI-dC (1mg/ml) 
 12.5 µl  GS reaction buffer 
      5 µl  BSA (10 mg/ml) or antibody 
     3 µl  radiolabeled oligonucleotide 
 
The reaction mix was incubated on ice for 10 min prior addition of the radiolabeled 
oligonucleotide. After addition of the radiolabeled oligonucleotide the reaction mix was 
incubated at 30°C for 30 min. Immediately after incubation 5 µl GS Dye was added and the 
reaction mix was loaded on a 5% native polyacryamid gel. The protein DNA complexes were 
electrophoretically separated at 400V, <20 mA at 4°C for 3-4 h. The gel was transferred to 
thick Whatman paper and placed on a vacuum dryer overnight. The dried gel was exposed to 
X-ray films at -80°C.       
 
 
Materials and methods 
  56 
 
  
GS running buffer (final use 0.5% GS running buffer) 
 50 mM  Tris 
 50 mM  boric acid 
 10 mM  EDTA-Na2  
  
GS reaction buffer 
 20 mM  Hepes pH7.3 
 50 mM  KCl 
   3 mM  MgCl2 
   1 mM  EDTA 
   8%   glycerin 
   1 mM  β-Mercaptoethanol 
 10 mM  DTT 
 
GS-Dye 
 0.25% (w/v) bromophenol blue  
 0.25% (w/v)  xylene cyanol 
 GS reaction buffer 
 
EMSA gel (5%) 
 11.25 ml  30%:0.8% Acryl/Bisacrylamid 
   6.75 ml  5x GS running buffer 
   49.3 ml  H2O 
   67.5 µl  TEMED 
 102.6 µl APS (20%) 
 
2.8.10 Chromatin immunprecipitation (ChIP) 
Suspension cells: 5-2.5 x 107 cells/ml per IP. 
U937 cell were cultured in a spinner flask to a maximal density of 106 cells/ml. Following 
treatment the cultured cells were centrifuged in a 500 ml cup at 1500 rpm at 4°C for 10 min, 
once washed with icecold PBS and resuspended in icecold RPMI medium without FCS at a 
density of 106 cells/ml.  
 
Fixation 
Adherent cells 
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The cells were placed on ice, the culture medium was removed and the cells were washed 
twice with ice cold PBS. The cells were fixed by adding 1% Formaldehyd/PBS and incubation 
at RT for 5 min. The fixation solution was removed and the cross-linking reaction was 
stopped through addtion of 0.125 M glycin/PBS at RT for 5 min. The cells were washed twice 
and scraped in PBS.        
 
Suspension cells  
For fixation the cell suspension were slowly swirled on ice, and 1/10 volume of the fixation 
solution were slowly added to the cell suspension and incubated for 20 min. The cross-
linking reaction were stopped by adding glycine to a final concentration of 0.125 M, the 
suspension was mixed until all glycine was soluble, and further incubated swirling on ice for 
10 min. 
 
Adherent and suspension cells 
Subsequently the cell suspension was centrifuged, once washed with icecold PBS at a 
density of 2.5 x 106 cells/ml, and resuspended in 5 ml Washing solution A per 108 cells. The 
cells were incubated at RT for 15 min on a tiliting shaker, centrifuged, resuspended in 
Washing solution B and incubated under the same conditions. Accordingly the cells were 
centrifuged and resuspended in icecold ChIP RIPA buffer at a density of 5 x 107 cells/ml. The 
cell lysates were stored at 4°C overnight or immediately used for sonification. For sonification 
the lysates partitioned in equal aliquotes with a maximun volume of 5 ml in a 15 ml tube. The 
lysates were sonicated 6 to 8 times for 1 min on ice (Branson Sonifier, cell disrupter B15, 
50% output, 0.5 cycle, microtip). The aliquotes were centrifuged in 1.5 ml reaction tubes at 
16000 x g at 4°C for 30 min. The supernatant was unified in new tube and immediately used 
for the immunoprecipitation or stored at -80°C. 20 µl lysate were seperated for total 
chromatin preparation.  
 
Immunoprecipitation  
Immunoprecipitations were performed with 2 µg antibody per 1 ml ChIP RIPA lysate rotating 
at 4°C overnight without beads. 15-20 µl Protein A or G Sepharose (beads) were used per 
IP. First the beads were washed twice with cold ChIP RIPA buffer and pre-incubated in ChIP 
RIPA buffer containing poly dI-dC (final) and BSA (final) rotating at 4°C for 2 h. The beads 
were washed twice in ChIP RIPA buffer, resuspended in 100 µl ChIP RIPA buffer and added 
to the lysates. The IPs were incubated rotating at 4°C for 1.5 h. For background minimization 
the beads were washed 3 times with 1.5 ml ChIP RIPA buffer (the first washing step was 
incubated for 10 min at RT), 1 time with 1.5 ml High-Salt buffer, 2 times with 1.5 ml ChIP 
RIPA buffer and 1 time with 1 ml TE buffer. During washing the IPs were centrifuged at 2000 
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rpm for 1 min. The TE buffer was removed completely and the beads were resuspended in 
52 µl Elution buffer. For elution the beads were mixed at 1400 rpm at RT for 10 min. 50 µl 
eluate was transferred into a new reaction tube. 
 
DNA preparation     
For DNA preparation 149 µl TE buffer, RNaseA (final 50 µg/ml) and poly dI dC (final 1 µg/ml) 
were added to the eluates (50 µl). For total chromatin preparation 30 µl Elution buffer, SDS 
(final 1%), 149 µl TE buffer, RNaseA (final 50 µg/ml) were added to the total chromatin (20 
µl). IPs and total chromatin were incubated at 37° for 30 min. Proteinase K (final 500 µg/ml) 
were added to both, the samples were mixed and incubated at 37°C overnight. The cross-
link was reversed by incubating the IPs and the total chromatin at 65°C for 6 h. The DNA was 
purified by Phenol/Chloroform/Isoamylalcohol (PIC 25/24/1) extraction. First one volume of 
PIC was added, mixed and centrifuged at 16000 x g at RT for 10 min. The supernatant was 
transfered into a new reaction tube, and mixed with 1 volume Chloroform/Isoamylalcohol for 
the second extraction. For DNA precipitation 3 volume EtOH, 1/10 volume 3 M NaAc pH 5.2, 
glycogen (final 20 µg) were added to the supernatant, mixed and stored at -20°C overnight 
and additional 1 h at -80°C. The precipitated DNA was pelleted by centrifugation at 16000 x g 
at 4°C for 20 min and washed once with 500 µl icecold 70% EtOH. The DNA pellet was dried 
at 30°C. The IP-DNA-pellet was solved in 50 µl and the total chromatin was solved in 20 µl 
TE buffer at 4°C overnight.  
To control adequate sonification 2 µl of total chromatin was mixed with 10 µl TE buffer and 2 
µl 10x DNA loading buffer and separated by gel electrophoresis in 0.8% agarose gels.  
 
PCR 
PCR reaction mix:  
     3 µl  10x Hotstar PCR buffer (Qiagen) 
     3 µl  dNTP mix (4 x 2 mM, final 4 x 0.2 mM)  
     3 µl   primer mix (reverse and forward each 10 µM, final each 1 µM) 
   18 µl   PCR-water  
  0.5 µl   Hotstar Taq Polymerase (Qiagen, 5U/ml, final 2.5U/reaction) 
 2.5 µl   DNA template (IP undiluted, total chromatin pre-diluted, according the 
DNA concentration)    
mixed carefully 
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PCR-reaction conditions: 
 95°C  15 min initial denaturation 
 94°C  20 s 
 60°C  20 s 
 72°C  20 s 
 72°C  7 min final elongation 
 
Gel electrophoresis 
15 µl   PCR reaction mix 
   2 µl   0x DNA loading buffer 
 2%   agarose gel / TBE/ EtBr   
run shortly 
 
2.8.11 RE-ChIP 
The first immunoprecipitation was performed as described above until the last ChIP RIPA 
buffer washing step. The ChIP RIPA buffer was removed and 50 µl Release buffer was 
added. The beads were incubated at 37°C shaking for 30 min. After pelleting the supernatant 
was transferred into a new reaction tube and mixed with 950 µl RIPΔSDS and Iodoacetamid. 
The second immunoprecipitation was performed according the protocol for immuno-
precipitation described above.    
 
Reagents 
 
Fixation solution  
 0.1   M  NaCl 
   1 mM  EDTA 
0.5 mM EGTA 
 50 mM  Tris-HCl, pH 8  
11%   Formaldehyde (added before use) 
 
Washing solution A  
 10 mM  Tris-HCl, pH 8 
1 0 mM  EDTA 
0.5 mM  EGTA 
0.25%   Triton X 100 
28-32 cycles 
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  0.5%   aprotinin (added before use) 
  1 mM  Pefa-Block (added before use) 
 
Washing solution B  
  0.2 M  NaCl 
10 mM  Tris-HCl, pH 8 
  1 mM  EDTA 
          0.5 mM  EGTA 
0.5%   aprotinin (added before use) 
1 mM   Pefa-Block (added before use) 
 
TE buffer  
10 mM  Tris-HCl, pH 7.5 
  1 mM  EDTA 
RNase-free H2O 
 
Elution buffer  
1%   SDS 
1 mM   DTT 
TE buffer 
 
High Salt buffer  
     2 M  NaCl 
10 mM  Tris-HCl, pH 7.5 
  1 mM  EDTA 
   1%   NP40 
0.5%   DOC 
 
CHIP RIPA buffer  
150 mM  NaCl 
  10 mM  Tris-HCl, pH 7.5 
    1 mM  EDTA 
     1%   NP40 
  0.1%   DOC 
  0.1%   SDS 
  0.5%   aprotinin 
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Release buffer  
 1%  SDS 
 10 mM  DTT (added before use) 
 TE buffer 
 
RIPΔSDS 
 150 mM  NaCl 
  10 mM  Tris, pH 7.5 
       1%  NP40 
       1%  DOC 
0.053%  SDS 
    0.5%  aprotinin 
1 mM EDTA 
 
Iodoacetamid 1 M in 10 mM Trisbase, final 1 mM (before use)   
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3 Results 
3.1 Induction of MAD1 expression in response to TGFβ1  
MAD1 expression is closely linked to terminal differentiation, regulation of proliferation and 
apoptosis in different cell types. The induction of MAD1 expression was demonstrated in 
response to differentiation inducing stimuli like G-CSF and TPA in the promyelocytic cell lines 
U937 and HL60 (Jiang et al., 2008). An additional context, in which MAD1 expression was 
shown to be enhanced, is the TGFβ-induced differentiation of keratinocytes. TGFβ is a 
pleiotropic cytokine with potent growth inhibitory function in mammals. MAD1 was suggested 
to be involved in the cessation of cell proliferation in differentiating keratinocytes in response 
to TGFβ (Werner et al., 2001).  
To determine whether the MAD1 expression is regulated in response to TGFβ1 stimulation in 
hematopoietic cells, the human promyelocytic cell line U937 was used to address this issue. 
Proliferating U937 cells were stimulated with TGFβ1, total RNA isolated at the indicated time 
points and analyzed by quantitive RT-PCR. Following TGFβ1 treatment the MAD1 
expression increased 5 to 6-fold reaching a maximum between 2 to 3 h (Figure 12A). U937 
cells were pre-treated with the protein synthesis inhibitor cycloheximide (CHX) to clarify 
whether the induction of MAD1 expression upon TGFβ1 treatment was a direct effect. 
However, as demonstrated in Figure 14A, addition of cycloheximide was sufficient to 
enhance MAD1 expression in these cells. To verify, that the TGFβ1-dependent induction of 
MAD1 expression also correlates with an increase in MAD1 protein levels, whole cell extracts 
of U937 cells stimulated with TGFβ1 were generated and analyzed by western blotting. Due 
to the short half-life of the MAD1 protein the detection of endogenous MAD1 by western 
blotting is difficult, thus highly concentrated protein extracts were generated and analyzed. 
Consistent with the induction of MAD1 expression the amount of MAD1 protein increased in 
response to TGFβ1 treatment. Endogenous MAD1 was detectable after 4 to 5 h of 
stimulation and was further elevated after 24 h of stimulation (Figure 12B). The identity of the 
MAD1 protein was controlled by treating U937 cells with the proteasomal inhibitor MG132. 
The MAD1 protein is rapidly degraded by 26S proteasomal degradation and was stabilized 
by addition of MG132 for 5 h (Figure 12B). Moreover, MAD1 expression was found to be 
substantially induced in response to MG132 (Figure 12C), suggesting that MAD1 expression 
is activated in response to cellular stress. In conclusion, the results indicate that MAD1 
expression is upregulated in response to TGFβ1 treatment correlating with an increase of 
endogenous MAD1 protein. 
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Figure 12: Induction of MAD1 expression and MAD1 protein in response to TGFβ1 and MG132 in U937 
cells. A. Exponential proliferating U937 cells were treated with 2.5 ng/ml of TGFβ1. The kinetics of MAD1 
expression in response to TGFβ1 was analyzed by quantitative RT-PCR at the indicated time points. The mean 
values ± SD of three independent experiments are shown. B. The induction of MAD1 expression correlates with 
an increase in MAD1 protein levels. U937 cells were treated with TGFβ1, whole cell lysates were generated at the 
indicated time points and analyzed for endogenous MAD1 protein by western blot. MG132 (10 µM, 5 h) treated 
U937 cells were used as a positive control. C. Total RNA was isolated from U937 cells treated with 10 µM MG132 
for 5 h. After reverse transcription the cDNA was analyzed by quantitative RT-PCR. Displayed is one of two 
independent experiments and similar results were obtained in HeLa cells (data not shown).  
 
 
3.2 TGFβ1-activated signalling pathways involved in the induction of MAD1 
expression  
TGFβ ligand binding initiates the formation of a tetrameric TGFβ receptor complex, which in 
turn activates intracellular signalling cascades. These include the canonical SMAD pathway 
and different MAPK pathways. In order to address the signalling pathways involved in the 
TGFβ1-mediated induction of MAD1 expression, different inhibitors were applied to block 
selectively different components of these receptor-signalling pathways. Exponentially 
proliferating U937 cells were pretreated with the different inhibitors prior to the addition of 
TGFβ1 and the relative MAD1 expression was measured by quantitive RT-PCR. p38 was 
inhibited by SB203580, which reduced TGFβ1-induced MAD1 expression by 50% (Figure 
13A and B). In contrast the inhibition of JNK1/2 and 3 via SP600125 resulted in an increase 
of MAD1 expression. The TGFβ receptor I inhibitor SB505124 almost completely abolished 
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the TGFβ1-induced MAD1 expression, whereas inhibition of the ERK pathway by the MEK1 
inhibitor PD98059 did not affect MAD1 expression in response to TGFβ1 (Figure 13A).  
The TGFβ1-induced phosphorylation of SMAD3, ERK and p38 and their selective inhibition 
were determined by western blot analysis (Figure 13B). All three pathways were already 
active in non-treated cells. SMAD3 phosphorylation at Ser-423/425 was induced upon 
TGFβ1 stimulation and selectively reduced by SB505124 treatment correlating with the 
reduction of MAD1 expression. Similarly phosphorylation of p38 at Thr-180/182 increased 
following TGFβ1 treatment. The selective p38 inhibitor SB203590 led to a reduction in p38 
phosphorylation to a level comparable to the phosphorylation status detected in non-treated 
U937 cells. Remarkable is the high p38 phosphorylation level observed in cells treated with 
the TGFβ receptor I inhibitor SB505124. This inhibitor abrogated the TGFβ1-dependent 
MAD1 expression. This suggested that the activity of p38 is essential but not sufficient for the 
induction of MAD1 expression by TGFβ1. ERK1/2 were already highly phosphorylated in 
non-treated U937 cells, which was completely blocked by PD98059. In response to TGFβ1 
no additional increase in their phosphorylation status was detectable. The unchanged MAD1 
expression upon MEK1 inhibition implies an ERK-independent regulation of the MAD1 
promoter in response to TGFβ1. In conclusion these results indicate that the p38 pathway is 
critical for the activation of MAD1 expression in response to TGFβ1. Whether the activation 
of SMADs is relevant remains open. An interesting possibility is that the p38 pathway and 
SMADs co-operate in the TGFβ1-dependent activation of MAD1 expression.  
 
 
Figure 13: Inhibition of TGFβ1 induced signalling pathways affecting the activation of MAD1 expression in 
promyelocytic U937 cells. A. U937 cells were treated for 40 min prior addition of 2.5 ng/ml TGFβ1 with the p38 
inhibitor SB203580 (10 µM), the JNK inhibitor SP600125 (10 µM), the TGFβ receptor I inhibitor SB505124 (5µM) 
and the MEK1 inhibitor PD98059 (100 µM), respectively. The MAD1 expression was assayed after 2 h of TGFβ1 
stimulation by quantitative RT-PCR. The displayed data are mean values ± SD of three independently performed 
experiments. B. Induction and inhibition of the TGFβ1-associated signalling pathways were controlled in U937 
cells by western blotting. U937 cells were handled as described in A. Whole cell extracts were generated and 
probed for the indicated proteins respectively their phosphorylation status.  
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3.3 The role of p38 signalling in the induction of MAD1 expression 
To verify the influence of p38 signalling in the activation of MAD1 expression, MAD1 
expression was analyzed in cycloheximide (CHX) treated U937 cells by quantitative RT-
PCR. Cycloheximide has previously been shown to activate the p38 pathway (Itani et al., 
2003). This cycloheximide-induced activation of the p38 pathway could be confirmed by 
western blot analysis of p38 phosphorylation on Thr-180/Tyr182 (Figure 14B) (Ahmed et al., 
2002). Cycloheximide treatment leads to an approximately 2-fold induction of MAD1 
expression in U937 cells and was reduced around 60% through inhibition of p38 signalling by 
SB202190 (Figure 14A). This inhibitor completely abolished p38 phosphorylation in U937 
cells as demonstrated in Figure 14B. The entire block of p38 phosphorylation did not 
correlate to the same extent with the reduction of MAD1 expression, leading to the notion 
that p38 signalling is only partially involved in the induction of MAD1 expression.  
 
 
 
Figure 14: The role of p38 signalling in the induction of MAD1 expression in U937 cells. A. MAD1 
expression was examined in cycloheximide (CHX), DMSO and CHX+SB202190 a selective p38 inhibitor treated 
U937 cells. Total RNA was isolated and analyzed by quantitative RT-PCR. The results shown are mean values ± 
SD of three independent experiments B. Whole cell extracts were isolated and probed for phosphorylated p38 
and total p38 in response to CHX (25 µM) or CHX +SB202190 (10 µM) treatment by western blotting. α-Tubulin 
was detected as a loading control. 
 
3.4 The MAD1 locus  
The transcribed region of the MAD1 locus spans 23 kbp consisting of 6 exons located on 
chromosome 2 (Figure 15A). Two TSS`s (transcriptional start site) were identified by 5`RACE 
and were further verified by quantitative PCR analysis of the primary single strand 5`RACE 
products (Jiang et al., 2008). The single strand templates were amplified by using the 
reverse primer Sp2 combined with different forward primers, covering a 800 bp region 
surrounding the mapped TSS (Figure 15C). Consistent with the first TSS identified by 
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5`RACE a boost in the amount of product amplification was detectable between the forward 
primer 18 and 19 surrounding the first TSS. More product was generated by using primer 20 
as compared to primer 19, whereas a slight decrease in product formation was observed with 
the primer 21, may due to marginal differences in primer efficiency. Primer 22, located in 
close proximity to the translational start site, revealed a slight increase in product formation 
compared to primer 20 (Figure 15B). In conclusion these results support the findings 
obtained by the 5`RACE experiments of one major TSS within the MAD1 promoter 
accompanied by an additional 3` located second TSS.   
  
 
 
Figure 15: Mapping of the transcriptional start site within the MAD1 promoter. A. Schematic overview of the 
human MAD1 locus. The genomic organization was deduced from comparing the cDNA to the genomic clone 
HTGS Acc. No. AC019206. The ATG start codon is indicated in exon 1. The TAA stop codon is indicated in exon 
6. E, exon sequences. B. The primary 5`-RACE products were amplified with the indicated forward primers and 
the Sp2 reverse primer by quantitative PCR. The amount of product obtained with forward primer 15 was set as 1. 
Mean values ± SD of two independent experiments performed in duplicates are displayed. C. Schematic 
presentation of the primer combination used for the mapping of the TSS. 
 
3.5 Organization of the MAD1 promoter 
 In previous studies the putative MAD1 promoter region has been identified and cloned into 
the pGL2 firefly luciferase reporter gene construct (referring to the -1282 to +248), in order to 
characterize the G-CSF dependent regulation of the MAD1 promoter (Jiang et al., 2008). To 
determine the G-CSF responsive region within the MAD1 promoter truncated promoter 
fragments were also cloned into the pGL2 firefly luciferase reporter gene construct (Figure 
16A). The MAD1 promoter is a TATA-less CpG island promoter containing a non-typical INR 
element and no DPE. Sequence alignment studies of the primary 5´sequence depicted a 
GC-rich region of 400 bp revealing high degree of sequence homology between mouse and 
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human, this region was accordingly termed homology region (Jiang et al., 2008). 
Nucleosomal protection assays were performed to evaluate the chromatin organization within 
the MAD1 promoter region. These studies suggested a weakly organized chromatin structure 
over the core of the homology region. This was based on either the low appearance of 
nucleosomes or poor nucleosomal positioning (Jiang et al., 2008). Within the cloned region 
several consensus sequences have been identified including an E-box, GC-boxes and 
CCAAT-boxes, using the MultiTF program indeed no potential SMAD binding site. The 
MultiTF program uses the Mulan alignment, which identifies conserved transcription factor 
binding sites by comparing consensus sequences provided from the ECR (Evolutionary 
Conservation of Genomes)-Browser  (Figure 16). 
 
 
 
 
 
Figure 16: Schematic presentation of the MAD1 promoter region. A. Promoter fragments cloned into the 
pGL2 luciferase reporter gene construct. B. Potential transcription factor binding sites are indicated.  
 
 
3.6 MAD1 promoter activation in dependency of transcription factor binding  
3.6.1 The role of C/EBP proteins in the regulation of the MAD1 promoter   
The sequence alignment studies revealed two CCAAT-boxes localized within the homology 
region of the MAD1 promoter, which are potential C/EBP protein binding sites. In previous 
studies C/EBP proteins were shown to play an important role in mediating TGFβ signals 
during monocytic differentiation and in the coordination of the TGFβ-induced cytostatic 
response by repressing c-MYC and activating p15INK4b expression (Pan et al., 1999) (Gomis 
et al., 2006). To address the role of C/EBP proteins in the regulation of the MAD1 promoter 
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in human cells, HeLa cells were transiently transfected with reporter gene constructs 
containing the -184 to +248 or the -1284 to +248 MAD1 promoter fragment and expression 
constructs encoding C/EBP family members. Two of three tested C/EBP proteins, i.e. 
C/EBPα and β but not ε, were capable to transactivate both MAD1 promoter constructs. Co-
transfection of the C/EBPα encoding construct activated the -1284 to +248 MAD1 promoter 
fragment around 6-fold and the -184 to +248 MAD1 promoter fragment around 7-fold 
compared to their basal activity (Figure 17). C/EBPβ co-expression enhanced the basal 
activity of the -1284 to +248 MAD1 promoter fragment around 8.5-fold and activated the 
truncated promoter fragment around 6-fold, whereas C/EBPε only slightly increased the 
MAD1 promoter activity (Figure 17). The comparable transactivation of both reporter gene 
constructs in response to C/EBPα and C/EBPβ supports the perception that the C/EBP cis-
acting elements are located between -184 to +248 bp within the MAD1 promoter.  
 
 
 
Figure 17: Activation of the MAD1 reporter constructs in response to three different C/EBP proteins in 
HeLa cells. A. and B. HeLa cells were co-transfected with the indicated reporter gene constructs and three 
different C/EBP protein encoding vectors respectively. The promoter-less pGL2 construct served as negative 
control and its activity was set as 1. The luciferase activity was normalized to β-galactosidase activity expressed 
from a cotransfected vector. The displayed results are the mean value ± SD of three independent experiments.  
 
To verify the relevance of C/EBPβ in the activation of the MAD1 promoter, pSuper-based 
shRNA targeting all isoforms of C/EBPβ was used to knock down endogenous C/EBPβ. The 
shRNA targeting C/EBPβ was tested in HeLa cells and confirmed to reduce efficiently the 
level of endogenous C/EBPβ (Figure 18B), while the control shRNA did not affect the 
C/EBPβ protein level. The knockdown of endogenous C/EBPβ reduced the basal activity of 
the -184 to +248 reporter gene construct by around 40% compared to HeLa cells transfected 
with the control shRNA (Figure 18A). This result further supports the assumption that 
C/EBPβ is involved in the regulation of the MAD1 promoter.  
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Figure 18: Knockdown of endogenous C/EBPβ reduced the basal activity of the -184 to +248 reporter gene 
construct. A. Reporter gene assays were performed in HeLa cells by co-transfecting the -184 to +248 reporter 
gene construct and a pSuper-based shRNA targeting C/EBPβ or a control shRNA. The shown results represent 
the mean value ± SD of three independent experiments. B. The efficiency of the shRNA targeting all isoforms of 
C/EBPβ was examined in HeLa cells by immunoblotting. C/EBPβ-specific antibodies were used to detect 
endogenous C/EBPβ proteins in whole cell lysates. 
 
3.6.2 Relevance of the CCAAT-box motifs within the MAD1 promoter region 
In previous studies the two CCAAT-box motifs, localised at -113 to -109 (referred CCAAT-
box 1) and -72 to -68 (referred to CCAAT-box 2) relative to the first TSS within the homology 
region of the MAD1 promoter (Figure 19A), were mutated (Jiang et al., 2008).  
 
 
 
 
 
 
Figure 19: Relevance of the two CCAAT-
box motifs of the MAD1 promoter for the 
C/EBPβ-dependent transactivation in 
HeLa cells. A. Position of the CCAAT-box 
motifs within the MAD1 promoter region B. 
The C/EBPβ-mediated relative activation of 
the indicated MAD1 promoter constructs 
were analyzed in reporter gene assays 
performed in HeLa cells. The relative 
luciferase activity was normalized to the β-
galactosidase activity. The promoter-less 
pGL2 construct served as negative control 
and was set to 1. The displayed diagram 
summarizes mean values ± SD of three 
independent experiments. 
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To clarify whether these two CCAAT-box elements are involved in C/EBPβ induced reporter 
gene activation in human cells, reporter gene assays were performed using MAD1 promoter 
constructs, where both CCAAT-boxes were mutated either individually or in combination. 
Disruption of CCAAT-box 1 led to a strong reduction in the C/EBPβ induced activation as 
compared to the wild type construct. Moreover, mutation of CCAAT-box 2 or mutation of both 
CCAAT-box motifs almost completely abolished the responsiveness to C/EBPβ (Figure 19B). 
These results indicate that both CCAAT-box elements are relevant for the C/EBPβ-
dependent MAD1 promoter activation.  
 
3.6.3 C/EBPβ binds to the MAD1 promoter in vivo 
The results obtained in the reporter gene assays revealed that C/EBPβ is capable to 
transactivate the MAD1 promoter construct in HeLa cells. To determine whether C/EBPβ 
binding to the MAD1 promoter is regulated in response to TGFβ1 in cells, U937 cells were 
stimulated with TGFβ1 for 1.5 h, cross-linked and lysed under stringent conditions. 
Subsequent to cell preparation, the DNA-protein-complexes were immunoprecipitated with 
specific antibodies targeting the C/EBPβ. The co-immunoprecipitated DNA was analyzed by 
PCR using the primer pair P, which amplifies a region within the homology region.  
 
 
 
 
3.6.4 C/EBPβ binds as a C/EBPβ-C/EBPα heterodimer to CCAAT-box 1 in vitro 
To validate the binding of C/EBPβ to the CCAAT-box motifs of the MAD1 promoter 
electrophoretic mobility shift assay (EMSA) were performed. To determine the DNA binding 
activity of C/EBPβ cell extracts of either mock-transfected or C/EBPβ over expressing 
A 
Figure 20: C/EBPβ binds to the MAD1 promoter 
in cells. A. Schematic presentation of the 
positioning of primer sets used for ChIP PCR 
relative to the first and major TSS. B. C/EBPβ 
binding to the MAD1 promoter was determined in 
response to TGFβ1 in U937 cells by ChIP assay. 
U937 cells were treated with 2.5 ng/ml TGFβ1 for 
1.5 h. The displayed experiment is representative 
of three independent experiments with a similar 
outcome.  
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HEK293 cell extracts were incubated with [32P]-labelled CCAAT-box 1 or CCAAT-box 2 
probes and separated by non-denaturating polyacrylamide gel electrophoresis. The 
oligonucleotide CCAAT-box-MO was previously described to bind C/EBPβ specifically and 
served as positive control (Oelgeschlager et al., 1995). Neither CCAAT-box 1 nor CCAAT-
box 2 formed specific DNA-protein complexes with C/EBPβ. In contrast the CCAAT-box-MO 
formed specific complexes with C/EBPβ, which could be super shifted with a C/EBPβ- but 
not with a C/EBPα-specific antibody (Figure 21). Remarkably and in contrast to the ChIP 
experiments these results demonstrate that C/EBPβ is not sufficient to bind to the CCAAT-
box elements in vitro. This suggests that additional factors are required to enhance or co-
operate with C/EBPβ DNA binding activity. 
 
 
 
Generally C/EBP proteins gain DNA binding activity through homodimerization or 
heterodimerization with other C/EBP family members. In order to address whether C/EBPβ 
binds to the CCAAT-box elements as a heterodimer with C/EBPα, HEK293 cell extracts 
containing over expressed C/EBPα and C/EBPβ were analyzed for DNA binding activity to 
the CCAAT-box oligonucleotides by EMSA. In the C/EBPα-C/EBPβ containing extracts a 
DNA-protein complex was detectable, which could be either super shifted with a C/EBPβ-
specific antibody as well as with a C/EBPα-specific antibody (Figure 22A). In contrast no 
complex formation could be observed with the CCAAT-box 2 or control oligonucleotide 
(Figure 22B). These findings demonstrate that C/EBPα or C/EBPβ homodimers are not 
sufficient to bind to the CCAAT-box elements inside the MAD1 promoter and only C/EBPα-
Figure 21: C/EBPβ does not possess DNA binding 
activity to the CCAAT-box elements. Mock - 
transfected or C/EBPβ - transfected HEK293 cell extracts 
were incubated with [32P]-radiolabelled oligonucleotids 
derived from the MAD1 promoter or as a positive control 
with the CCAAT-box-MO. Half of the samples were pre-
incubated with 2 µg C/EBPβ or α specific antibodies as 
indicated. The mixtures were separated on a 5 % non-
denaturing polyacrylamide gel at 400 V at 4°C for 3 h 
The reaction was analyzed by autoradiography. The gel 
was exposed for 19 h at -80°C. One of three experiments 
is shown. 
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CEBPβ heterodimers possess DNA binding activity to CCAAT-box 1. Regarding to the 
results achieved from the reporter gene assays, revealing an essential role of the CCAAT-
box 2 element, further studies are necessary to clarify whether C/EBPα or C/EBPβ are able 
to bind to the CCAAT-box 2 consensus sequence in co-operation with either other C/EBP 
family members or possibly other transcription factors.   
 
 
 
Figure 22: Binding of C/EBPα-C/EBPβ heterodimers to the CCAAT-box 1. A. The C/EBPα-C/EBPβ DNA-
binding activity to CCAAT-box 1 was investigated by EMSA. The HEK293 cell extract over expressing C/EBPβ-
C/EBPα formed slow migrating complexes with radiolabeled CCAAT-box 1. The complexes could be super shifted 
with a C/EBPα- as well as C/EBPβ-specific antibody. The control oligonucleotide showed no complex formation. 
B. CCAAT-box 2 was neither bound by C/EBPα or C/EBPβ homodimers respectively nor C/EBPα-C/EBPβ 
heterodimers. Similar results were obtained in three independent experiments.   
 
 
3.6.5 C/EBPα-C/EBPβ heterodimers bind to the MAD1 promoter in vivo, but do not 
co-operate in the MAD1 promoter activation 
Since C/EBPβ-C/EBPα heterodimers were discovered to possess DNA-binding activity to 
CCAAT-box 1 in vitro, a RE-ChIP assay was performed in U937 cells to confirm the C/EBPβ-
C/EBPα binding specificity to the MAD1 promoter in vivo. Cross-linked U937 cell were 
sheared and first immunoprecipitated with a C/EBPβ-specific antibody. Subsequently the 
protein-DNA complexes were released, divided into three samples and prepared for the 
second immunoprecipitation using parallel C/EBPα- and C/EBPβ-specific antibodies or for 
control Protein A Sepharose. The enriched DNA was analyzed by quantitative PCR using the 
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primer set P, which amplifies, within the homology region. The RE-ChIP assay revealed a 5-
fold enrichment of promoter DNA bound by C/EBPβ and a 2.3-fold enrichment of C/EBPα 
bound promoter DNA (Figure 23A), thus confirming C/EBPα-C/EBPβ heterodimer binding to 
the MAD1 promoter.  
To examine whether C/EBPα and C/EBPβ also co-operatively transactivate the MAD1 
promoter, reporter gene assays were performed. Therefore HeLa cells were co-transfected 
with the -184 to +248 reporter gene construct and C/EBPα and C/EBPβ encoding vectors. 
Both C/EBP proteins were capable to activate the MAD1 promoter construct as 
demonstrated before, but did not co-operate (Figure 23B). 
 
 
 
Figure 23: C/EBPα-C/EBPβ heterodimers bind to the MAD1 promoter in vivo, but do not co-operate in the 
promoter activation. A. The co-operative binding of C/EBPα and C/EBPβ to the MAD1 promoter was confirmed 
by RE-ChIP experiments. A C/EBPβ-specific antibody was used for the first immunoprecipitation; the DNA-protein 
complexes were released from the antibodies. The second immunoprecipitations were performed with Protein A 
Seharose as negative control and C/EBPα- or C/EBPβ-specific antibodies. The isolated promoter DNA was 
analyzed by quantitative PCR using the primer set P amplifying within the homology region of the MAD1 
promoter. The signal intensities of C/EBPβ or C/EBPα were normalized to the negative control. Depicted are the 
findings from a single experiment. B. The co-operativity of C/EBPβ and C/EBPα were examined by reporter gene 
assays, therefore HeLa cell were co-transfected with the -184 to +248 reporter gene construct and C/EBPβ and 
C/EBPα encoding constructs. C/EBPβ and C/EBPα did not co-operate in the activation of the MAD1 promoter 
construct. The displayed experiment is the mean values ± SD of three independent experiments. 
 
3.6.6 The MAD1 promoter is co-operatively activated by C/EBPβ and SP1   
Several co-operative interactions of C/EBP proteins with other transcription factors have 
been reported to regulate different target promoters. In addition to the CCAAT-box elements 
located within the homology region of the MAD1 promoter, two GC-box elements were 
identified via sequence analysis (Jiang et al., 2008). Thus the presence of the two CCAAT-
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box motifs in close proximity to two GC-box elements raised the question, whether these cis-
acting elements are functionally linked in the regulation of the MAD1 promoter. In order to 
assess the ability of C/EBPβ to enhance the MAD1 promoter activation by interacting with 
transcription factors binding to the GC-box consensus sequences, the co-operativity of 
C/EBPβ and SP1 were tested in reporter gene assays. The -184 to +248 MAD1 promoter 
construct, comprising both CCAAT-box motifs alternated by the two GC-box elements, was 
co-transfected with C/EBPβ and SP1 encoding constructs into HeLa cells. The activity of this 
construct was increased marginally by over expression of SP1, whereas over expression of 
C/EBPβ enhanced the relative luciferase activity as observed before. Importantly co-
expression of C/EBPβ and SP1 stimulated the promoter activity co-operatively (Figure 24A).  
 
 
 
Figure 24: SP1 enhances the transactivation capacity of C/EBPβ in transiently transfected reporter gene 
assays. A. HeLa cells were co-transfected with the -184 to +248 reporter gene construct and C/EBPβ and/or SP1 
expression vectors. The displayed data are mean values ± SD of three independent experiments. B. A dominant 
negative SP1 mutant was tested for its transactivation potential without or in combination with co-expression of 
C/EBPβ in HeLa cells.  The results represent mean values ± SD of three independent experiments.   
 
The relevance of SP1 for the activity of C/EBPβ to transactivate the MAD1 promoter 
construct was further supported by co-expressing dominant negative SP1 proteins. The 
dominant negative SP1 mutant, which lacks the DNA binding domain reduced the basal 
activity of the -184 to +248 promoter construct by about half and abolished the C/EBPβ 
mediated (Figure 24B). Taken together, these results demonstrate a co-operative interaction 
of C/EBPβ and SP1 in the MAD1 promoter activation. The DNA binding activity of SP1 
appears to be necessary for the C/EBPβ mediated promoter activation, further suggesting 
that SP1 binds directly the promoter region rather than being recruited by C/EBPβ.  
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3.6.7 Importance of the CCAAT-box and GC-box motifs for the co-operative promoter 
activation 
The functional relevance of GC-box and CCAAT-box elements for the co-operative regulation 
by C/EBPβ and SP1 of the MAD1 promoter was further analyzed by using different point 
mutated reporter gene constructs (Figure 25A). The data obtained in reporter gene assays 
performed with the CCAAT-box 1 mutated construct showed little relevance of this element, 
although the experiments with this reporter gene construct were quite variable. The CCAAT-
box 2 mutated construct showed a marginal reduction in the basal promoter activity, while 
the C/EBPβ-SP1-mediated activation was abrogated entirely (Figure 25B).  
 
 
 
 
 
 
 
Figure 25: Cis-acting elements involved in the co-operative C/EBPβ-SP1 promoter activation. A. Schematic 
presentation of the CCAAT-and GC-box motifs within the MAD1 promoter region. B. and C. HeLa cells were co-
transfected with the indicated reporter gene constructs and expression vectors encoding C/EBPβ and SP1 
expression construct. The promoter pGL2 vector served as a negative control and its activity was set to 1. The 
results represent the mean values ± SD of three independent experiments.   
 
To elucidate the role of the two GC-box elements, reporter gene assays were performed 
using GC-box mutated reporter gene constructs. Individual mutation of either GC-box 1 or 2 
or combined mutation of both GC-box motifs did not affect the basal MAD1 promoter activity 
appreciably. However, the C/EBPβ-SP1-induced co-operative activation of reporter gene 
constructs containing a mutated GC-box 2 or mutation of both GC-box elements were 
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strongly reduced, whereas the role of GC-box 1 was not obvious (Figure 25C). Similar results 
were observed with the triple mutated construct, possessing mutation in both CCAAT-box 
motifs and GC-box 1 (data not shown). In conclusion, GC-box 2 and CCAAT-box 2 are cis-
acting elements required for the co-operative activation induced by C/EBPβ-SP1, whereas 
GC-box 1 and CCAAT-box 1 appear less relevant in this contest. 
 
3.6.8 SP1 is constitutively bound to the MAD1 promoter in vivo 
To obtain direct evidence of in vivo interaction of SP1 with the MAD1 promoter and whether 
this is regulated by TGFβ1, non-treated and TGFβ1 treated U937 cells were analyzed by 
ChIP. The transcription factor SP1 was bound, similar to C/EBPβ, constitutively to the 
homology region of the MAD1 promoter, whereas only slight background signals were 
observed in the gene body. TGFβ1 did not alter SP1 occupancy on the MAD1 promoter 
significantly (Figure 26B). These findings further support the involvement of SP1 in the 
regulation of the MAD1 promoter.   
 
 
 
 
3.6.9 c-MYC is involved in the regulation of the MAD1 promoter 
Given the fact that the MAD1 promoter contains an E-box consensus sequence and that 
several studies demonstrated TGFβ1-dependent repression c-MYC a question arising was   
whether c-MYC might be involved in the regulation of MAD1 expression in response to 
TGFβ1. To determine whether c-MYC and MAX interact with the E-box motif located within 
the MAD1 promoter in vivo, TGFβ1 treated or untreated U937 cells were used for ChIP 
analysis. The cross-linked chromatin was immunoprecipitated with c-MYC- and MAX-specific 
Figure 26: SP1 binds to the MAD1 promoter in 
vivo. A. Schematic presentation of the positioning 
of primer sets used for ChIP PCR relative to the 
first and major TSS. B. U937 cells were treated 
with 2.5 ng/ml TGFβ for 1.5 h, cross-linked and 
examined for SP1 promoter binding by ChIP. The 
isolated DNA was analyzed by PCR using the 
primer set P amplifying within the homology region 
and the primer set G amplifying inside the gene 
body as negative control. Comparable results 
were obtained with a second SP1 specific 
antibody (not shown). 
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antibodies or Protein A Sepharose alone for control. A strong MAD1 promoter signal was 
observed in the MAX immunoprecipitation independent of TGFβ1 treatment, while the signal 
obtained from c-MYC immunoprecipitation was weaker, but similarly detectable in non-
treated and treated TGFβ1 cells. The amount of c-MYC and MAX bound to the promoter 
region remained almost constant upon TGFβ1 stimulation, while only faint background bands 
were visible using the upstream amplifying primer set U (Figure 27). This demonstrates that 
c-MYC and MAX are constitutively bound to the MAD1 promoter in vivo. 
 
 
  
 
3.6.9.1 c-MYC impairs the C/EBPβ induced promoter activation 
To elucidate the role of c-MYC in the MAD1 promoter regulation, reporter gene assays were 
performed in HeLa cells with the -1282 to +248 reporter gene construct encompassing the  
E-box motif. c-MYC did not impair the basal promoter activity, but indeed reduced the 
C/EBPβ enhanced reporter gene activation by around 65% (Figure 28A). To verify whether 
the reduction of the C/EBPβ-induced promoter activation is dependent on the E-box, the -184 
to +248 reporter gene construct was used in a similar experiment. Independent of the E-box 
motif, c-MYC co-expression reduced C/EBPβ mediated transactivation, but led to a less 
strong reduction of only 30% (Figure 28B).    
 
Figure 27: In vivo binding of c-MYC and MAX to the 
MAD1 promoter in U937 cells. A. Schematic 
presentation of the positioning of primer sets used for 
ChIP PCR relative to the first and major TSS. B. ChIP 
assay was performed in non-treated and TGFβ1 (1.5 
h) treated U937 cells and the chromatin was 
immunoprecipitated with c-MYC- or MAX-specific 
antibodies or Protein A Sepharose only. The isolated 
DNA was analyzed by PCR with the indicated primer 
sets. The c-MYC ChIP assay was performed three 
times with a similar outcome.    
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Figure 28: c-MYC impairs the C/EBPβ induced promoter transactivation. A. and B. HeLa cells were 
transiently transfected with the -1284 to +248 or the -184 to +248 reporter gene construct and c-MYC and 
C/EBPβ expressing constructs. The pGL2 vector possessing no promoter was used as a control and its activity 
was set to 1. Both displayed experiments are mean values  ± SD of three independent experiments.     
    
The influence of endogenous c-MYC on the C/EBPβ induced transactivation was examined 
in reporter gene assays using the E-box-less -184 to +248 construct. HeLa cells were 
transfected with the C/EBPβ encoding construct and either a pSuper based shRNA vector 
targeting endogenous c-MYC or a pSuper based control shRNA. 
 
 
 
Figure 29: Knockdown of endogenous c-MYC enhances the C/EBPβ induced reporter gene activation. A. 
Reporter gene assays were performed in HeLa cells by co-transfection of C/EBPβ and control shRNA or shRNA 
targeting c-MYC and the E-box-less -184 to 248 reporter gene construct. Displayed are mean values ± SD of 
three independent experiments. B. To test the knock down efficiency, HeLa cells were transiently transfected with 
the control shRNA and the c-MYC specific shRNA, total RNA was isolated 48 h post-transfection and analyzed by 
quantitative RT-PCR.  
 
The reduction of endogenous c-MYC additionally enhanced the transactivation capacity of 
C/EBPβ on the -184 to +248 promoter fragment as compared to transactivation observed in 
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cells transfected with the control shRNA (Figure 29A). Similar to the MAD1 protein c-MYC is 
rapidly degraded impeding its detection by western blotting. Therefore the knockdown 
efficiency of the c-MYC specific shRNA was tested at the mRNA level in HeLa cells by 
quantitative RT-PCR (Figure 29B). Taken together, these results demonstrate that c-MYC 
binds to the MAD1 promoter in vivo, but beyond that c-MYC is able to influence the MAD1 
promoter activation in an E-box-independent manner by impairing the C/EBPβ-dependent 
transactivation.  
 
3.6.9.2 C/EBPβ and c-MYC interact in vivo 
Thus far the findings obtained in the reporter gene assays support the notion that the E-box-
independent influence of c-MYC on the MAD1 promoter is dependent on the inhibition of 
C/EBPβ-induced transactivation. One possible explanation how this might occur is through 
an interaction of c-MYC and C/EBPβ. To elucidate this HeLa cells were transiently 
transfected with an HA-tagged c-MYC and a C/EBPβ encoding vector. The cell extracts were 
used in a co-immunprecipitation experiment with C/EBPβ specific antibodies. The co-
immunoprecipitation demonstrates that over expressed C/EBPβ and c-MYC interact in vivo 
(Figure 30).  
 
 
 
To map the region of c-MYC required for the C/EBPβ interaction the c-MYCΔN2 (147-439aa) 
mutant encompassing the acidic region and the bHLHZip motif and the c-MYCΔC3 (1-221aa) 
mutant comprising the TAD and the three-conserved c-MYC boxes were used. The  
c-MYCΔN2 mutant is not capable to transactivate target genes, whereas the c-MYCΔC3 
mutant possesses no DNA-binding activity and is not competent to form heterodimers with 
MAX. HeLa cell extracts over expressing C/EBPβ and the HA-tagged c-MYC mutants were 
immunoprecipitated with a C/EBPβ specific antibody. C/EBPβ specifically interacted with the 
C-terminal region of c-MYC. A slight signal of the c-MYCΔC3 (1-221aa) could be detected in 
Figure 30: C/EBPβ and c-MYC interact in vivo. 
Co-immunprecipitation was performed with HeLa 
cell extracts overexpressing C/EBPβ and/or c-
MYC. Overexpressed C/EBPβ was immuno-
precipitated with a C/EBPβ specific antibody. The 
immunoprecipitates were separated by 10% SDS-
PAGE and transferred to a nitrocellulose 
membrane. The membranes were probed with 
specific antibodies detecting C/EBPβ and the HA-
tag. The whole cell extracts were similarly 
analysed and additionally probed for β-actin as a 
loading control. The experiment was performed 
three times with a similar outcome.  
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the C/EBPβ over expressing extracts either as a result of unspecific binding or a weak 
C/EBPβ interaction (Figure 31).    
 
 
 
3.6.9.3 c-MYC influences the DNA-binding capacity of the C/EBPα-C/EBPβ 
heterodimers 
To determine how the interaction of c-MYC and C/EBPβ may influence the capacity of  
C/EBPβ to activate the MAD1 promoter fragment, the effect of c-MYC on the C/EBPβ DNA-
binding affinity to the CCAAT-box 1 were examined by EMSA. HEK293 cell extracts over 
expressing either C/EBPα and C/EBPβ or C/EBPα, C/EBPβ and c-MYC (Figure 32B) were 
incubated with the radiolabeled CCAAT-box 1. In both extracts a slow migrating complex was 
detected, which was sensitive to both C/EBPα- and C/EBPβ-specific antibodies. The 
formation of these protein-DNA complexes was strongly inhibited by co-expression of c-
MYC. The competition assay confirmed the strong reduction of C/EBPβ-C/EBPα-DNA-
complex formation in the c-MYC comprising extracts (Figure 32). Thus, these findings 
suggest, that c-MYC influences the C/EBPβ-dependent transactivation, either by preventing 
the C/EBPα-C/EBPβ heterodimer formation or by reducing the DNA-binding the heterodimer. 
 
Figure 31: C/EBPβ interacts with the c-
terminal region of c-MYC in vivo. HeLa cells 
were transiently transfected with a C/EBPβ and 
HA-tagged c-MYCΔN2 or c-MYCΔC3 
expressing constructs. The HeLa cells were 
harvested 42 h post-transfection in 1 ml 
Frackelton lysis buffer and used in a IP 
performed with a C/EBPβ specific antibody.  
Total cell extracts and IPs were separated by 
SDS-PAGE and analyzed by western blotting. 
The membranes were probed with C/EBPβ, an 
α-Tubulin and an HA specific antibody. The 
experiment was performed twice with a similar 
outcome. 
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Figure 32: c-MYC reduces the DNA-binding affinity of C/EBPα-C/EBPβ heterodimers to the CCAAT-box 1. 
A. The EMSA was performed with either C/EBPα and C/EBPβ or C/EBPα, C/EBPβ and c-MYC over expressing 
cell extracts and the CCAAT-box 1 oligonucleotide. The slowly migrating protein-DNA complex could be 
specifically super shifted with a C/EBPβ and a C/EBPα specific antibody; no super shift was observable with a c-
MYC-specific antibody. The competition assay was performed with increasing amounts of unlabelled CCAAT-box 
1, which was titrated to the EMSA reaction mix (middle lanes). B. C/EBPβ, C/EBPα and HA-MYC were over 
expressed in HEK293 cells. Total cell extracts were separated by SDS-PAGE and analyzed by western blotting 
with the indicated antibodies. 
 
Taken together the results reveal that C/EBPβ and C/EBPα activate the MAD1 promoter and 
bind as heterodimers to the CCAAT-box 1 motif but do not synergistically transactivate the 
MAD1 promoter. However, a co-operative interaction in promoter activation could be 
observed between C/EBPβ and SP1 and their respective binding sites. In particular CCAAT-
box 2 and GC-box 2 were critical to activate the MAD1 promoter by these transcriptional 
regulators. Furthermore, the C/EBPβ induced activation is dependent on the DNA binding of 
SP1.   
c-MYC binds to the MAD1 promoter in vivo and is indeed able to reduce the C/EBPβ-
mediated promoter activation. This function is independent of the E-box motif. c-MYC 
interacts with C/EBPβ in vivo and impairs the DNA-binding activity of the C/EBPα-C/EBPβ 
heterodimer to the CCAAT-box 1.  
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3.7 The role of TGFβ associated signalling in the activation of the MAD1 
promoter 
3.7.1 The synthetic SBE reporter gene construct is activated by SMAD proteins and 
the constitutively active TGFβ receptor I  
The TGFβ receptor I and SMAD encoding vectors were functionally tested in reporter gene 
assays using a synthetic TGFβ responsive reporter gene construct, which contains 12 
SMAD-binding elements (SBE). The TGFβ receptor I encoding constructs were analyzed for 
their capacity to transactivate the SBE reporter gene construct (Figure 33A). TGFβ signalling 
requires TGFβ receptor I and TGFβ receptor II, which form a tetrameric receptor complex 
after TGFβ ligand binding, to efficiently induce TGFβ signal transduction. Mutation of T204 
located in the glycine-serine-region of the receptor to an acidic residue (T204D) constitutively 
activates the TGFβ receptor I (TGFβRca) and induces the receptor-associated signalling 
cascades independent of the TGFβ receptor II (Wieser et al., 1995). This receptor enhanced 
the promoter activity around 5-fold, whereas the wild type TGFβ receptor I (TGFβR) did not 
increase the basal activity of the SBE promoter construct (Figure 33A).  
 
 
 
 
Figure 33: The SBE-luc reporter gene construct is activated in response to TGFβ signalling and over 
expression of SMAD2/3/4. A. and B. HeLa cells were transiently transfected with the pGL3SBE reporter gene 
construct and vectors expressing either the constitutive active TGFβ receptor I (TGFβRca) or the wild type TGFβ 
receptor I (TGFβR). In B. SMAD2/3/4 encoding vectors were co-transfected. The luciferase activity was 
normalized to the β-galactosidase activity and the promoter-less pGL3 vector was used as control and its activity 
was set to 1. Displayed are mean values ± SD of three independent experiments.  
 
 
In a similar experiment the SMAD encoding constructs were analyzed for their capacity to 
transactivate the synthetic promoter construct. Co-expression of SMAD2/3/4 efficiently 
activated the SBE promoter construct and a further increase was observed by co-expression 
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of the TGFβRca I. These results confirmed the functionality of the TGFβR I as well as the 
SMAD expressing constructs, which were further used to investigate the TGFβ1-dependent 
regulation of the MAD1 promoter. 
 
3.7.2 The constitutively active TGFβ receptor I does not activate the cloned MAD1 
promoter constructs  
In order to identify the TGFβ responsive region within the MAD1 promoter, the -1282 to +248 
and three truncated promoter constructs were transfected into HeLa cells and analyzed for 
their TGFβRca responsiveness. The different promoter regions cloned into the pGL2 
luciferase vector are shown in Figure 34A. None of the promoter constructs were significantly 
activated in response to either over expression of the TGFβR I wild type or the TGFβRca I 
(Figure 34B). These findings indicate that the TGFβ responsive region is not located within 
the cloned promoter region or that additional factors are required to activate the MAD1 
promoter in response to TGFβ signalling.  
 
 
Figure 34: The constitutively active TGFβ receptor I does not activate MAD1 promoter constructs. A. 
Schematic presentation of the MAD1 promoter constructs transiently transfected into HeLa cells. B. The indicated 
MAD1 promoter constructs were co-transfected with the constitutively active or the wild type TGFβ receptor I 
constructs. The luciferase activities of the different reporter gene constructs were normalized to the β-
galactosidase activities. The results represent the mean value ± SD of three independent experiments.    
 
 
 
 
 
B 
A 
Results 
  84 
3.7.3 SMAD3 increases the MAD1 promoter activity 
Although the -1282 to +248 promoter fragment does not possess any predicted SMAD 
consensus sites it is possible that SMAD protein were limiting in the experiments described 
above. Therefore reporter gene assays were performed with SMAD2, 3 and 4 encoding 
constructs and the TGFβ receptor I expression constructs. The -1282 to +248 reporter gene 
was 5-fold activated by SMAD3, whereas neither SMAD2 and 4 nor the constitutively active 
TGFβ receptor I possessed transactivation capacity. Co-expression of the constitutively 
active or the wild type TGFβ receptor I did not further enhances the SMAD3-induced 
transactivation. Unexpectedly, over-expression of the constitutively active TGFβ receptor I 
indeed tended to reduce the SMAD3-dependent activation. The combined expression of 
SMAD2, 3 and 4 stimulated the MAD1 promoter construct less effectively than SMAD3 
alone, but again co-expression of the TGFβRca I had no further effect (Figure 35).   
 
 
 
Figure 35: Influence of SMAD proteins and TGFβ receptor signalling on the MAD1 promoter activation 
HeLa cells were transiently co-transfected with the -1282 to +248 reporter gene construct and the indicated 
expression constructs. The luciferase activities were normalized to the β-galactosidase activities. The results 
presented are mean values ± SD of three independent experiments.   
 
Despite the lack of SMAD binding motifs, the -1284 to +248 MAD1 promoter region is 
activated by SMAD3. To identify the SMAD3 response region a series of MAD1 deletion 
promoter constructs were analyzed for their transactivation in response to SMAD3 over 
expression. SMAD3 activated all four reporter gene constructs, however the activation of the 
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-385 to +248 and the -184 to +248 promoter fragment was less prominent (Figure 36). These 
results did not allow making predictions about possible SMAD3 responsive regions in the 
MAD1 promoter. Nevertheless, the region with the CCAAT- and GC-box motifs is still 
responsive and comprises SMAD3 responsive element. 
 
 
 
Figure 36: SMAD3 transactivates the different MAD1 promoter constructs. The basal luciferase activity of 
the indicated MAD1 promoter constructs was compared to the relative luciferase activity induced by over 
expression of SMAD3. The luciferase activity was normalized to the β-galactosidase activity. Displayed are mean 
values ± SD of three independent experiments.    
 
3.7.4 SMAD3 acts as a co-activator of C/EBPα 
SMAD proteins require additional transcription factors to efficiently activate gene expression. 
Putative co-operative interaction of SMAD3 with transcription factors, constitutively bound to 
the MAD1 promoter region, was investigated in reporter gene assays. HeLa cells were 
transiently transfected with C/EBPα and SMAD3 encoding vectors, and both were shown to 
stimulate the -1282 to +248 and -184 to +248 promoter construct reporter gene construct 
individually. Co-expression of SMAD3 increased the C/EBPα mediated transactivation 
synergistically (Figure 37A and B). Similar observations were made with a -184 to -58 
promoter fragment cloned upstream of the minimal thymidin kinase (minitk) promoter, which 
drives luciferase expression, to test, whether this promoter region possesses enhancer 
function dependent on C/EBPα and SMAD3 (Figure 37C). The activation of the MAD1 
promoter induced by C/EBPβ and/or SP1 was not enhanced by co-expression of SMAD3 
(data not shown). In conclusion these findings suggest that SMAD3 acts as a co-activator of 
C/EBPα.  
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Figure 37: C/EBPα and SMAD3 transactivate the -1282 to +248 and the -184 to +248 MAD1 promoter 
construct and -184 to +58 minitk reporter gene construct co-operatively. A. and B. HeLa cells were 
transiently transfected with either the -1282 to +248 promoter or the -184 to +248 promoter construct and C/EBPα 
and SMAD3 encoding vectors. The luciferase activities were normalized to the β-galactosidase activities. The 
results shown in A. are mean values ± SD of two independent experiments. B. Represents the mean values ± SD 
of three independent experiments. C. The activation of the -184 to -58 minitk reporter gene construct was 
analyzed in response to C/EBPβ and SMAD3 co-expression in HeLa cells. The minitk vector was used as 
negative control and its activation was set as 1. These results are mean values ± SD of three independent 
experiments.       
 
In summary the studies demonstrate that co-expression of the constitutively active TGFβ 
receptor I is not sufficient to activate the proximal MAD1 promoter and furthermore, does not 
enhance the SMAD3 induced transactivation. Individually over expressed SMAD3 
transactivates the proximal promoter and additionally possesses the capability to co-operate 
with C/EBPα in the proximal promoter activation. 
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3.8 Histone modifications, p300 recruitment and Pol II occupancy on the 
MAD1 promoter in response to TGFβ1  
Histone modifications such as acetylation and trimethylation of histone 3 lysine 4 (H3K4) are 
well-characterized histone marks associated with actively transcribed genes. Chromatin 
immunoprecipitation (ChIP) experiments were performed to examine the histone 
modifications and the Pol II recruitment to the MAD1 promoter in U937 cells upon TGFβ1 
stimulation. Independent of TGFβ1 stimulation the homology region within the MAD1 
promoter and the region inside the gene body were highly acetylated on histone 3. 
Accompanying the occurrence of histone H3 acetylation, the ChIP analysis revealed 
increased binding of the histone acetyltransferase p300 to the homology region of the MAD1 
promoter in response to TGFβ1 (Figure 38B.) The second histone modification linked to 
active transcription examined in response to TGFβ1 was the trimethylation on H3K4. 
Similarly to the acetylation on histone H3, high levels of H3K4 trimethylation were already 
detectable within the MAD1 promoter region in untreated U937 cells. No significant increase 
in trimethylated H3K4 could be observed in response to TGFβ1 stimulation (Figure 38C).  
 
 
 
Figure 38: Histone modifications, p300 binding and Pol II loading to the MAD1 promoter before and after 
TGFβ1 stimulation in U937 cells. A. Schematic representation of the positioning of primer sets used for ChIP 
PCR amplification relative to the first and major TSS. B. and C. Proliferating U937 cells were treated with or 
without 2.5 ng/ml TGFβ1 for 1.5 h. After cross-linking and preparation, the modification status of histone H3 and 
the presence of p300 and Pol II on the MAD1 promoter were assessed by ChIP. For control the 
immunoprecipitations were performed with Protein A Sepharose without antibody. The precipitated and input DNA 
was analyzed by PCR using the indicated primer sets. Both experiments were performed similarly three times 
with the same outcome.  
 
To further evaluate the activation status of the MAD1 promoter, Pol II loading in the absence 
and presence of TGFβ1 was examined. In the absence of TGFβ1 the MAD1 promoter was 
already occupied by Pol II and the level of Pol II loading remained constant on the promoter 
region upon TGFβ1 stimulation (Figure 38C). Neither H3K4me3 nor Pol II binding were 
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detectable within the upstream located control region. The pre-assembly of the Pol II 
complex and the appearance of histone marks that are linked to transcriptional activation 
prior to stimulation supports the notion that the MAD1 promoter is arranged in a pre-activated 
state. This is characterized by an open and highly accessible chromatin structure of the 
homology region. 
Since no TGFβ1-dependent changes in the histone modification pattern and the Pol II 
loading on to the promoter were apparent in U937 cells, the Pol II CTD phosphorylation was 
investigated upon TGFβ1 stimulation by ChIP assay. The phosphorylation of the CTD 
residue Ser-2 marks the elongating polymerase and the phosphorylation occurring on Ser-5 
is essential for the recruitment of mRNA capping enzymes to promoter. U937 cells were 
stimulated with TGFβ1 and immunoprecipitations was performed with antibodies detecting 
the phosphorylated CTD residues Ser-2 and 5 on Pol II. The promoter region was occupied 
by Pol II independent of TGFβ1 stimulation as demonstrated before. However, Pol II 
association within the gene body increased upon TGFβ1 stimulation, which correlates with 
increased MAD1 expression. In response to TGFβ1 treatment, a shift from preferentially CTD 
Ser-5 phosphorylation to CTD Ser-2 phosphorylation was detected on the promoter region 
and inside the gene body, further supporting the assumption of an increase in elongating Pol 
II upon TGFβ1 treatment (Figure 39).  
   
 
 
Figure 39: Phosphorylation on the CTD residues Ser-2 and 5 in response to TGFβ1 stimulation. U937 cells 
were treated with 2.5 ng/ml TGFβ1 for 20 and 40 min before cross-linking. Pol II loading and the phosphorylation 
of the CTD residues ser-2 and 5 were examined on the MAD1 promoter region and within the gene body in non-
treated and treated cells. Displayed is one representive experiment.  
 
3.8.1 The MAD1 promoter is arranged in a “pre-activated” state in primary non-
hematopoietic cells.  
To clarify whether the “pre-activation” status of the MAD1 promoter occurs specifically in 
hematopoietic U937 cells comparable experiments were performed in primary human dermal 
fibroblasts (HDF) isolated from the foreskin of a 5 years old boy. HDFs are TGFβ responsive 
Results 
  89 
but MAD1 expression was not affected (data not shown). MAD1 is described to be most 
highly expressed in non-proliferating cells, therefore the MAD1 promoter status of logarithmic 
proliferating HDFs was compared to HDFs cultured under serum-deprived condition. Pol II 
and H3K4me3 were present on the promoter region and the gene body in proliferating and 
non-proliferating cells. However, Pol II loading accumulated upon serum starvation on the 
promoter and downstream in the gene body, suggesting an increase in elongating Pol II. 
Consistent with these findings the abundant trimethylation on H3K4 slightly increased on the 
promoter region and to a higher extent inside the gene body (Figure 39). This experiment 
revealed that the MAD1 promoter is highly trimethylated on H3K4 and occupied by Pol ll in 
primary non-hematopoietic cells.   
 
 
Figure 40: Trimethylation of H3K4 and Pol II loading on the MAD1 promoter in primary human dermal 
fibroblasts. Logarithmic proliferating or serum starved (48 h) HDFs were determined for Pol II occupancy and 
H3K4me3 on the MAD1 promoter by ChIP assay. The depicted experiment was performed twice with a similar 
outcome. 
 
In conclusion these results provide evidence for the hypothesis that the MAD1 promoter is 
arranged in a “pre-activated state” in primary and cancerous cells. This state is characterized 
by the presence of pre-assembled Pol II and histone modifications that are linked to active 
transcription. 
 
 
3.9 Cellular response of U937 cells to TGFβ1  
The exposure of cells to TGFβ1 can trigger a variety of cellular responses including 
differentiation, inhibition of cell proliferation and apoptosis. To characterize the TGFβ1-
induced response in U937 cells, the effect of TGFβ1 on cell proliferation was analyzed by 
counting TGFβ1 treated or non-treated U937 cells cultured in medium supplemented with 
10% FCS over a period of 48 h. Despite TGFβ1 treatment the cells continued proliferation 
comparable to non-treated U937 cells. This result indicates that U937 cells are resistant to 
the proliferation inhibitory effect of TGFβ1 (Figure 41A).  
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Another described function of TGFβ signalling is its influence on cell viability. In a cell type 
and context specific manner TGFβ is able to provide signals for either promoting cell survival 
or stimulating apoptosis. To explore whether the cellular viability of U937 cells is affected by 
TGFβ1, U937 cells were incubated in the presence or absence of TGFβ1 under serum-
deprived culture conditions over a period of 120 h. The number of viable cells was 
determined by CASY measurement and thryphan blue staining. Within the first 72 h under 
growth factor deprivation no changes in cell viability of were observed. At 96 h of serum 
starvation slight differences in cell viability between both groups were verifiable, the viability 
of untreated U937 cells dropped around 17%, whereas the viability in TGFβ1-stimulated cells 
was decreased about 9%. A comparable tendency was observed after 120 h of serum 
withdrawal, where 71% of non-treated cells and 79% of TGFβ1 treated cells were viable 
(Figure 42B). Such findings suggest that TGFβ1 slightly enhances cellular viability under 
serum-deprived conditions and may act as a survival supportive factor under certain 
physiological conditions in U937 cells.  
 
 
 
Figure 41: Influence of TGFβ1 treatment on cellular behaviour of promyelocytic U937 cells. A. The effect of 
TGFβ1 on proliferation of U937 cells. U937 cells were initially diluted to a density of 105 cells/ml and incubated 
with 2.5 ng/ml TGFβ1 over a period of 48 h. The number of cells was determined at the indicated time points by 
CASY measurement. B. TGFβ1 signalling affects cell viability of U937 cells under serum-deprived culture 
conditions. 105 cells/ml U937 cells were cultured in serum-deprived RPMI 1640 cell culture medium for 120 h in 
the absence or presence of TGFβ1 (2.5 ng/ml). Cell viability was discriminated at the indicated time points by 
CASY measurement and controlled by trypan blue staining. Both experiments presented are mean values ± SD of 
three independent experiments, the significance of the experimental results was determined by the Student’s t 
test (2-sided); *P< 0.0001; ** P< 0.001.  
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4 Discussion 
The MYC/MAX/MAD network of transcriptional regulators tightly controls the expression of a 
wide variety of target genes in order to direct cell fate and influence cell behaviour. This 
network is functionally associated and regulated by cytokine signalling. MAD1 is involved in 
the molecular switch from proliferation to differentiation, the induction of senescence and the 
inhibition of apoptosis under certain physiological conditions. MAD1 acts as a repressor of 
target gene transcription, thereby antagonizing at least in part the functions of MYC. Previous 
studies mainly focused on the role of MAD1 in the control of cell behaviour, while only little is 
known about the transcriptional regulation of MAD1 expression. 
 
4.1 MAD1 expression is induced upon TGFβ1 stimulation in promyelocytic 
cells  
In the promyelocytic cell line U937 MAD1 expression is upregulated in response to TGFβ1 
correlating with an increase in MAD1 protein levels (Figure 12). This is consistent with recent 
findings from Wu and colleagues investigating MAD1 expression upon TGFβ1-induced 
senescence in U937-myc6, HL60 and ML-1 cells (Wu et al., 2009). In addition to the 
observations in hematopoietic cells, MAD1 expression is induced in response to TGFβ1 in 
keratinocytes and epithelial cells. Similarly, the expression of the MAD family members MXI1 
(MAD2) and MAD4, but not MAD3, were upregulated in response to TGFβ in epithelial and 
hematopoietic cells (Werner et al., 2001) (Siegel et al., 2003) (Wu et al., 2009). The TGFβ1-
induced MAD1 expression has diverse biological consequences, for instance the induction of 
differentiation, but all base on its function as a transcriptional repressor of target genes. For 
instance MAD1 expression has been linked to the induction of senescence in myeloid cells 
by binding to the Cyclin D2 and hTERT promoter and repression of their expression (Wu et 
al., 2009). In keratinocytes MXI and MAD4 downregulate ID2 expression upon TGFβ 
stimulation, which is an important step during the TGFβ-induced cytostatic response (Siegel 
et al., 2003).  
In this study the cellular response of U937 cells to TGFβ1 was determined over a period of 
48 h, within this period the cells continued their exponential proliferation (Figure 41). Recent 
studies revealed that in U937-myc6 the onset of G1 cell cycle arrest was rather slow and was 
observed only after 72 to 96 h after addition of TGFβ1 (Wu et al., 2009). To clarify whether 
TGFβ1 treatment induces a rather slow cytostatic response in U937 cells longer periods of 
treatment need to be analyzed.  
Apoptosis is another cellular process that is regulated by both TGFβ signalling and MAD1. 
MAD1 inhibits Fas-induced apoptosis by repressing PTEN expression (Rottmann et al., 
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2008). This inhibitory effect is in line with the mad1-/- phenotype. In neutrophils of the animals 
an enhanced sensitivity to apoptosis inducing conditions was observed (Foley et al., 1998). 
The impact of TGFβ1 stimulation under serum-deprived condition were analyzed in U937 
cells over a period of 120 h revealing that TGFβ1 stimulation had slight effects on cell 
viability (Figure 41). After 96 h TGFβ1 treated cells exhibited an enhanced survival rate 
suggesting that TGFβ1 signalling may support cell survival through the anti-apoptotic 
function of MAD1. In a similar experiment the knockdown of endogenous MAD1 unravelled 
that MAD1 expression is critical for cell survival under certain physiological conditions 
including serum deprivation. These findings demonstrated that MAD1 expression is 
upregulated in response to TGFβ1 in U937 cells, which did not immediately result in G1 cell 
cycle arrest. But the TGFβ1-induced MAD1 expression may support cell survival under 
apoptosis inducing conditions.  
 
4.2 TGFβ-associated signalling pathways involved in the induction of MAD1 
expression  
Several pathways, including the canonical SMAD, the RAS/RAF/ERK and the p38/JNK 
pathway are described to be activated in response to TGFβ. The binding of TGFβ initiates 
the tetramerisation of TGFβ receptor complex (TGFβRI and TGFβRII), which results in the 
transphosphorylation of the TGFβRI and the activation of the receptor-associated signalling 
cascades. In U937 cells the p38 and the SMAD pathway were activated in response to 
TGFβ1. In contrast the RAS/RAF/ERK pathway was active in untreated U937 cells and no 
additional increase was observed in response to TGFβ1 (Figure 13). To identify the TGFβ1-
induced signalling pathways involved in the regulation of MAD1 expression inhibitors were 
used to block the different pathways selectively. Inhibition of the p38 pathway reduced MAD1 
expression around 50% (Figure 13). However the increased p38 activity in response to other 
inhibitors like the TGFβRI inhibitor SB505124 was not sufficient to enhance MAD1 
expression independent of an activated TGFβRI (Figure 13).  
These findings indicate that the p38 pathway is involved in the TGFβ1-dependent 
stimulation, but additional signals seem to be required for significant MAD1 expression. 
Similarly, CHX-induced p38 activation correlated with increased MAD1 expression, but 
blocking of p38 reduced MAD1 expression by 50% (Figure 14), further supporting the notion 
that the p38 pathway activates MAD1 expression in conjunction with other signalling 
pathways. The TGFβ1-dependent activation of p38 occurs independently of SMAD but 
requires the TGFβ-activated kinase-1 (TAK1) (Yamaguchi et al., 1995). TAK1 is an ubiquitin-
dependent kinase generally activated by stress signalling and cytokines, including TGFβ, 
TNF and IL1. In a TRAF6-dependent manner TAK1 phosphorylates MKK3/6, which act 
directly upstream of p38 (Wang et al., 2001a). The molecular mechanism of the 
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TAK1/TRAF6 activation by the TGFβR complex is not fully understood. Recent studies 
reported a direct physical interaction of TAK1/TRAF6 and the TGFβRII, which seems to be 
critical for the interaction with the TGFβRI. The kinase activity of the TGFβRI is not essential 
for the interaction with TRAF6 but is required for TRAF6 polyubiquitination and subsequently 
for the activation of the downstream signalling cascades (Yamashita et al., 2008). These 
findings indicate that both TGFβ receptors are required for the sufficient activation of 
TAK1/TRAF6. The results obtained in reporter gene assays performed to identify the TGFβ1-
responsive region within the proximal promoter revealed that constitutive signalling through 
the TGFβRI was not sufficient to transactivate the MAD1 promoter (Figure 34). This either 
suggests that additional components are required for sufficient MAD1 induction, for instance 
the TGFβRII to enable the interaction of TRAF6/TAK1 with the TGFβ receptor complex 
and/or SMADs or the TGFβ1 responsive region is located in a more distal region relative to 
the core promoter. However bioinformatic analysis did not provide any evidence for distally 
located enhancer elements or other highly conserved regions that might function in the 
control of the MAD1 promoter. Since the signals may be received by non-canonical response 
elements, more open approaches will be required to clarify how the TGFβ1 signal activates 
the MAD1 promoter. Such studies may involve ChIP-on-chip analysis or Chromosome 
Conformation Capture assays. In addition to the activation of the MKKs, TAK1 
phosphorylates IκB kinases (IKKs), which activate the NFκB pathway. One of the IKKs, IKKα 
was recently shown to induce MAD1 expression in a SMAD3-dependent fashion during 
TGFβ-induced keratinocyte differentiation (Descargues et al., 2008). Taken together these 
findings provide evidences that TAK1 activation is critical for the MAD1 induction and may 
stimulate expression through a functional interplay of the p38 and IKKα pathway. Although 
TGFβ induces p38 signalling independent of SMADs, the TRAF6/TAK1-p38 cascade 
frequently converges with the SMAD-dependent pathway to regulate cellular responses to 
TGFβ. SMAD3 was observed to activate the MAD1 reporter gene construct (Figure 35), but 
co-expression of SMAD2/4 and the TGFβRca did not enhance further promoter activity 
(Figure 35). It rather reduced the SMAD3-mediated induction suggesting that the MAD1 
promoter is not activated by the trimeric SMAD2/3/4 complex. This in turn is consistent with 
the previously described IKKα-SMAD2/3 mediated MAD1 induction in keratinocytes 
(Descargues et al., 2008). However further inhibitor and knockdown experiments need to be 
performed to verify the crosstalk of the TGFβ-linked signalling pathways converging on the 
MAD1 promoter.   
 
4.3 The human MAD1 promoter 
The MAD1 promoter was identified in previous studies (Jiang et al., 2008). Comparism of the 
sequences upstream of the translation initiation codon identified a region that revealed an 
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high degree of sequence homology between rat, human and mice. This region appears to 
contain the core promoter of the MAD1 gene. The MAD1 promoter is a TATA and DPE-less 
CpG island promoter containing a non-typical INR element (Jiang et al., 2008). INR elements 
are recognized by the TFIID subunits TAF1 and TAF2, which are essential for the correct 
positioning of the Pol II complex. The INR element and the major transcriptional start site are 
located within the homology region supporting the notion that the core promoter is located 
within this homology region. An additional transcriptional start site was mapped further 
downstream, which is consistent with genome wide studies demonstrating that CpG island 
promoters possess more than one transcriptional start site (Sandelin et al., 2007). 
Nucleosome protection assays disclosed a region of approximately 400 bp of chromatin, 
which is highly accessible to nuclease treatment and directly overlaps with the homology 
region. The high accessibility to the nuclease treatment indicates that this region contains 
poorly positioned or low numbers of nucleosomes, which predisposes this region for 
transcription factors to bind (Jiang et al., 2008). These findings provide further evidence that 
the core and the proximal promoter are located within this region. Several potential 
transcription factor-binding sites were identified within this region, including two CCAAT-box 
motifs and two GC-boxes.   
 
4.4 C/EBPs are involved in the regulation of MAD1 expression 
Previous investigations performed in the rabbit-derived kidney cell line RK13 revealed that 
both CCAAT-box motifs are relevant for the G-CSF and C/EBP-induced transactivation of the 
MAD1 reporter gene constructs. The CCAAT consensus sequence serves as recognition 
motif for several transcription factors, including YB-1, NF-Y, and C/EBPs. YB-1 and NF-Y 
proteins were analyzed for their capability to transactivate the MAD1 promoter construct, 
however none of these transcription factors significantly enhanced the MAD1 promoter 
activity (data not shown).   
The third family of CCAAT-recognizing factors are C/EBPs, a family of basic leucine zipper 
transcription factors that control the expression of a variety of target genes involved in 
proliferation, differentiation, immune response, and apoptosis (Pal et al., 2009). Four 
members (α, β, δ and ε) of the C/EBP family are expressed in myeloid cells (Friedman, 
2002). Previous findings, which demonstrated that C/EBPs are direct targets of TGFβ 
signalling in the induction of G1 cell cycle arrest in breast cancer cells and during monocyte 
differentiation, implicated C/EBP proteins in the TGFβ1-induced MAD1 expression (Pan et 
al., 1999) (Gomis et al., 2006).  
Indeed two of three (α, β and ε) tested C/EBP family members, C/EBPα and C/EBPβ, 
possess the capacity to activate the MAD1 promoter constructs in human cells (Figure 17). 
The C/EBPβ-mediated activation of the MAD1 promoter was confirmed in the knockdown 
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studies. A decrease of endogenous C/EBPβ reduced the activity of the MAD1 reporter gene 
construct (Figure 18). C/EBPβ does not possess a critical role in myeloid development, but is 
essential for the regulation of cell survival. Recent studies revealed that C/EBPβ-deficient 
neutrophils undergo enhanced apoptosis. This phenotype is in line with the mad1-/- 
phenotype, and the anti-apoptotic function of the MAD1 protein (Akagi et al., 2008) (Foley et 
al., 1998) (Gehring et al., 2000) (Rottmann et al., 2008). Furthermore, C/EBPβ was recently 
shown to positively regulate TGFβ1 promoter activity. Interestingly, the expression of SMAD3 
and SMAD4 impairs the activity of C/EBPβ on the TGFβ1 promoter by direct interaction. This 
interaction reduces the association of C/EBPβ with the promoter region (Abraham et al., 
2009). In earlier studies SMAD3/4 were described to inhibit adipocyte differentiation by 
repressing C/EBP-induced transactivation of the PPARgamma2 and leptin promoter (Choy 
and Derynck, 2003).  
The binding of C/EBPβ to the MAD1 promoter was analyzed by ChIP. Constant amounts of 
C/EBPβ were bound to the promoter independent of TGFβ1 stimulation. However, it remains 
to be determined, whether TGFβ1 induces posttranslational modifications of C/EBPβ, for 
instance via the p38 pathway, which are required for the recruitment of co-factors like p300 
or subunits of the Mediator complex (Schwartz et al., 2003) (Mo et al., 2004).  
The two CCAAT-boxes within the MAD1 promoter are critical for the C/EBPβ-induced 
activation (Figure 19), but both represent only “half-sites”. One question therefore was, which 
C/EBP complexes can bind to these sites, also because both C/EBPα and C/EBPβ were 
identified at the promoter in ChIP assays. EMSA studies revealed that C/EBPβ homodimers 
are not capable to bind to the CCAAT-boxes of the MAD1 promoter. Only C/EBPα-C/EBPβ 
heterodimers possess DNA binding activity to the CCAAT-box 1 (Figure 21 and 22). In 
contrast none of these complexes was bound to CCAAT-box 2. The co-operative binding of 
C/EBPα and C/EBPβ was validated in cells by RE-ChIP experiments (Figure 23). 
Nevertheless, the mutation of CCAAT-box 2 substantially reduced the C/EBPβ-induced 
transactivation demonstrating that this motif possesses a critical role in the C/EBPβ-
dependent regulation of the MAD1 promoter in cells. It needs to be addressed whether 
C/EBPβ is capable to bind to this motif in co-operation with other transcription factors, for 
instance SP1, which co-operates with C/EBPβ in the MAD1 promoter activation as described 
below. Another possible interaction partner is C/EBPγ, an ubiquitous expressed C/EBP 
family member which is described as the predominant heterodimerization partner for other 
C/EBPs (Parkin et al., 2002). Taken together, these results indicate that C/EBPα and 
C/EBPβ are able to transactivate the MAD1 promoter, but are only capable to bind as a 
heterodimer to the CCAAT-box 1. The sufficient activation of the MAD1 promoter by C/EBPβ 
depends on the integrity of both CCAAT-box motifs.   
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Of note is the finding that all three isoforms of C/EBPβ bind as heterodimers to the CCAAT-
box 1 (Figure 22). The three different isoforms LAP*, LAP and LIP are generated from a 
single mRNA transcript by translation from alternative start sites, a process controlled by 
PKR and mTOR signalling (Calkhoven et al., 2000). The LAP isoforms act as transcriptional 
activators, whereas the LIP protein lacks the TAD and represses target gene transcription. 
The polyclonal C/EBPβ antibody used in the ChIP analysis did not allow distinguishing 
between different promoter bound C/EBPβ isoforms. Due to this finding it would be 
interesting to investigate, whether TGFβ1 stimulation leads to changes in the LIP/LAP 
expression ratio and subsequently to changes in the promoter occupancy of the different 
isoforms. The LIP/LAP ratio is crucial for the maintenance of normal growth and 
development, and indeed, unbalanced expression of these two proteins is associated with 
aggressive forms of breast cancer (Zahnow, 2009) (Kowenz-Leutz and Leutz, 1999).  
 
4.5 The role of SP1 in the activation of the MAD1 promoter 
A common feature of all four MAD genes is, that these promoters are TATA-less and GC-rich 
(Benson et al., 1999) (Fox and Wright, 2003) (Kime and Wright, 2003) (Jiang et al., 2008). 
SP transcription factors bind preferentially to GC-rich promoter regions, where they are 
targeted by signal transduction pathways or act as basal transcription factors. At least two 
GC-boxes are, similarly to the CCAAT-box motifs, located within the highly accessible 
homology region of the MAD1 promoter. SP1 was previously described to possess a crucial 
role in the regulation of MXI1 expression (Benson et al., 1999) and was further found to 
regulate the p21 promoter in a TGFβ-dependent manner (Koutsodontis et al., 2002). ChIP 
analysis discovered that SP1 was associated with the MAD1 promoter in the absence of 
TGFβ signalling and that no significant changes were measurable in response to TGFβ1. 
SP1 had only marginal effects on the MAD1 promoter but co-operated with C/EBPβ in the 
induction of the MAD1 promoter constructs (Figure 24). These findings are consistent with a 
basal activity of SP1, as described for many other for GC-box-bound SP transcription factors 
(Antequera, 2003) (Suske, 1999). However, the results obtained in reporter gene assays 
using a dominante negative SP1 mutant lacking the DNA-binding domain, decreased the 
basal promoter activity slightly and abrogated the C/EBPβ-induced transactivation. This 
suggests that DNA-bound SP1 is crucial for the activating function of C/EBPβ (Figure 24). 
Mutagenesis of the CCAAT- and GC-boxes strongly suggests that the CCAAT-box 2 and the 
GC-box 2 are indispensable for co-operative promoter activation. To clarify the relevance of 
the CCAAT-box 1 and GC-box 1 further investigations are required (Figure 25). The protein-
protein interaction and functional co-operativity of SP1 and C/EBPβ has been observed 
before in the regulation of the IL10 promoter (Liu et al., 2003). This collaboration may 
facilitate the binding of co-factor complexes, including CBP/p300, the chromatin-remodelling 
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complex SWI/SNF- or the Mediator complex. Individually C/EBPβ and SP1 were previously 
found to interact with these complexes (Schwartz et al., 2003) (Suzuki et al., 2000) (Hung et 
al., 2006). Furthermore, SP1 is capable to recruit TAF4 to target gene promoters, which is a 
subunit of the basal transcription factor TFIID (Furukawa and Tanese, 2000) (Chen et al., 
1994a). TFIID is important for the proper positioning of the Pol II complex over the 
transcriptional start site. Due to the finding that the MAD1 promoter is already occupied by 
the Pol II complex prior to stimulation, SP1 may play a role in keeping the MAD1 promoter in 
a pre-assembled state. To address this question further studies need to be performed, which 
determine the level of promoter-bound Pol II in cells expressing low levels of SP1.     
 
4.6 c-MYC influences the MAD1 promoter activation by interacting with 
C/EBPβ 
In addition to the CCAAT- and GC-boxes located within the homology region, the MAD1 
promoter contains an E-box consensus sequences upstream of the homology region. ChIP 
analysis revealed that c-MYC and MAX are constitutively bound to the MAD1 promoter in 
cells (Figure 27). This finding is particular interesting because of the fact that MYC/MAX and 
MAD/MAX heterodimers possess antagonizing functions in the regulation of target gene 
expression. This raised the question, whether the MAD1 promoter is regulated by its 
antagonist c-MYC or by itself through a negative feedback loop. In contrast to the MAD 
proteins, c-MYC is preferentially expressed in proliferating cells and is downregulated in 
response to TGFβ signalling in epithelial cells during TGFβ1-induced G1 cell cycle arrest 
(Gomis et al., 2006). The influence of c-MYC on the MAD1 promoter was determined in 
reporter gene assays using an E-box containing and a truncated, E-box-less promoter 
fragment (Figure 28). The basal activities of both promoter constructs were not significantly 
regulated by the over expression of c-MYC but c-MYC reduced the C/EBPβ-mediated 
transactivation. This repression was independent of the E-box (Figure 28). One explanation 
might be that c-MYC interacts with C/EBPβ in vivo. An interaction of the two proteins was 
detected in co-immunoprecipitations (Figure 30 and 31). Whether this interaction is direct or 
indirect needs to be verified in glutathione-S-transferase (GST) pull down assays. In EMSAs 
co-expression of c-MYC impaired the binding of the C/EBPα-C/EBPβ heterodimer to the 
CCAAT-box 1. Whether c-MYC prevents the DNA binding by impairing the formation of the 
heterodimer or through inhibition of its DNA binding activity needs to be clarified in future 
experiments. Furthermore, it would be interesting to examine the amount of promoter-bound 
C/EBPβ in c-MYC over expressing cells. In support of a functional interaction, v-MYC was 
identified to inhibit C/EBPβ activity by impeding the C/EBPβ-mediated phosphorylation of 
p300 (Steinmann et al., 2009). These findings suggest that c-MYC is involved in the 
regulation of MAD1 expression by interacting with C/EBPβ. 
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Previous studies investigating the TGFβ-dependent regulation of the p15INK4b gene showed 
that c-MYC represses target gene transcription via binding to INR elements by interacting 
with the zinc-finger protein MIZ-1 (Staller et al., 2001). In proliferating cells the murine mad4 
promoter is repressed by the binding of the MYC/MIZ complex to the INR element (Kime and 
Wright, 2003). Sequence alignment studies revealed that the MAD1 promoter contains a 
non-typical INR element (5´-ACACTCCG). Interesting to investigate will be whether MIZ-1 is 
bound to the MAD1 promoter by ChIP and whether c-MYC is able to repress the C/EBPβ 
induced promoter activation by using an INR mutated MAD1 promoter construct. Due to the 
finding that no obvious changes were detectable in the occupancy of c-MYC, MAX and 
C/EBPβ at the MAD1 promoter in response to TGFβ1, it will be necessary to analyze ChIP 
experiments by quantitative PCR, which allows detecting slight differences in promoter 
binding. To detect changes in promoter binding in the early phase of MAD1 induction it will 
be interesting to analyze early time points of MAD1 stimulation.  
 
4.7 The MAD1 promoter is arranged in a pre-activated state 
Previous studies analyzing the chromatin structure revealed an open and highly accessible 
chromatin structure, which overlaps with the homology region (Jiang et al., 2008). 
Interestingly, C/EBPα and β as well as SP1, MYC, and MAX were constitutively bound to the 
MAD1 promoter region in cells and no significant changes appeared in response to TGFβ1 
(Figure 20, 23, 26, 27). Similarly histone modifications linked to active transcription, i. e. the 
acetylation of histone H3 and the trimethylation of H3K4, were present at the promoter in the 
absence of TGFβ1 treatment (Figure 38). No significant changes were detectable upon 
TGFβ1 stimulation (Figure 20,23,26, 27, 38). Overall the findings provide further evidence 
that the MAD1 promoter is assembled in a pre-activated state, which was further supported 
by the finding that the pre-assembled Pol II complex is bound to the promoter in the absence 
of TGFβ1 stimulation (Figure 38, 39). These findings are in agreement with recently 
published observations. Genome wide expression analyzes in combination with ChIP-on-
Chip assays demonstrated that most of the protein-coding genes are occupied by a poised 
Pol II complex and nucleosomes with trimethylated H3K4 and acetylated H3K9 and K14 
(Guenther et al., 2007) (Margaritis and Holstege, 2008). Guenther and colleagues reported 
that many inactive genes exhibiting transcriptional initiation marks truly initiate transcription 
without productive elongation. These observations imply that for the class of pre-assembled 
genes the rate-limiting step of transcription is neither the recruitment of the transcription 
machinery nor the initiation but rather the switch to productive elongation. Genes arranged in 
a pre-activated state are mostly developmental control genes and genes responding to 
extracellular signals (e.g. TGFβ) (Price, 2008).  
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The CTD residue Ser-5 was already phosphorylated in unstimulated cells, which suggests 
that the promoter completed the state of initiation. One hallmark of transcriptional elongation 
is the phosphorylation of the CTD residue Ser-2, which marks the elongating Pol II. This 
phosphorylation is mediated by the CDK9, a subunit of P-TEFb (Sims et al., 2004). In 
response to TGFβ1 stimulation the phosphorylation of the CTD shifted from Ser-5 to Ser-2 
implying that Pol II entered the state of productive elongation (Figure 39). Increasing 
amounts of Pol II inside the gene and the increase in RNA levels upon TGFβ1 stimulation 
further suggested the transition to productive elongation (Figure 12 and 39). This switch 
could be further verified by nuclear run on assays to determine changes in the rate of 
elongation. In conclusion these observations support the hypothesis that the MAD1 promoter 
is arranged in a pre-activated state through the constitutively binding of specific transcription 
factors and the pre-assembly of the Pol II complex. Particularly interesting would be to 
investigate whether the P-TEFb, the negative elongation factor (NELF) and the DRB 
sensitivity inducing factor (DSIF) are present at the MAD1 promoter by ChIP. All three factors 
are involved in the regulation of Pol II pausing and productive elongation. Furthermore, it 
would be interesting to analyze the trimethylation status of H3K36 inside the gene, which is 
another hallmark of elongation (Guenther et al., 2007).   
 
4.8 The mechanisms of MAD1 induction 
The results obtained in this study revealed that several pathways are involved in the 
induction of MAD1 expression in response to TGFβ1. Upon TGFβ1 stimulation p38 is 
activated through a TRAF6/TAK1-dependent mechanism and enhances MAD1 expression 
(Figure 42), however additional signals are required because p38 activation appears not to 
be sufficient. The downstream targets of p38 in this context are presently unknown, possible 
candidates are C/EBPβ and SP1. A TRAF-p38-C/EBPβ pathway was identified to induce 
HIV-1 expression in monocytes and macrophages (Horie et al., 2007). Moreover, Seymoure 
and colleagues demonstrated that the xanthine oxidoreductase (XOR) expression is 
upregulated via a p38-C/EBPβ-dependent mechanism in response to cellular stress induced 
by cycloheximide (Seymour et al., 2006). These findings are in agreement with the p38-
dependent induction of MAD1 expression upon cycloheximide treatment (Figure 14). SP1 
was shown to be activated through the p38 pathway upon LPS stimulation in macrophages 
(Ma et al., 2001).  
In differentiating keratinocytes MAD1 expression is upregulated in a IKKα-SMAD3-dependent 
manner (Descargues et al., 2008). Whether TAK1 phosphorylation of IKKα plays a role in the 
induction of MAD1 expression upon TGFβ1 treatment in hematopoietic cells remains to be 
elucidated (Figure 42). Another direct downstream target of the TGFβ signalling is SMAD3, 
which activates the MAD1 promoter and co-operates with C/EBPα.  
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In conclusion the results support the hypothesis that the MAD1 promoter is assembled in a 
pre-activated state. The promoter is occupied by the gene specific transcription factors 
C/EBPα, C/EBPβ, SP1, MYC and MAX and Furthermore, by the Pol II complex in the 
absence of TGFβ1 stimulation (Figure 43). The phosphorylation on Ser-5 in the absence of 
phosphorylated Ser-2 on the CTD of Pol II indicates that transcriptional initiation is complete 
prior to TGFβ1 stimulation and that the Pol II complex is paused (Figure 43). The promoter-
proximal pausing is controlled by transcription elongation factors including DSIF and NELF 
(Price, 2008) (Saunders et al., 2006). Both factors are associated with the Pol II complex and 
repress the productive elongation (Figure 43). In response to TGFβ1 the repressive effect of 
DSIF and NELF is overcome by the recruitment of activated P-TEFb. The P-TEFb subunit 
CDK9 phosphorylates different components of the transcription machinery including DSIF, 
NELF and CTD Ser-2 (Saunders et al., 2006). This phosphorylation induces the dissociation 
of NELF and converts DSIF into a positive elongation factor. These changes together with 
the phosphorylation at Ser-2 initiate the transition of the Pol II complex to the state of 
productive elongation. Central to this mechanism is the recruitment of P-TEFb, which is 
involved in the sequential phosphorylation of the CTD. It remains to be elucidated how  
P-TEFb is recruited to the promoter in response to TGFβ1. Two possible mechanisms are 
illustrated in Figure 43B and C. First, TGFβ1 stimulation induces the nuclear translocation of 
SMAD3, whether this is dependent on IKKα signalling and/or occurs via dimerization with 
SMAD2 needs to be addressed. Following the nuclear translocation SMAD3 binds either 
directly to the DNA or is indirectly recruited by C/EBPα. The association of SMAD3 with the 
promoter region initiates, in co-operation with C/EBPα, the recruitment of the activated P-
TEFb complex to the promoter (Figure 43). Previous studies demonstrated the recruitment of 
P-TEFb by gene-specific transcription factors, which are either bound to the proximal 
Figure 42: Schematic summary 
of TGFβ-associated signalling 
pathway involved in the 
induction of MAD1 expression.  
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promoter or to enhancer regions. This was shown for instance for NFκB and c-MYC 
(Barboric et al., 2001) (Eberhardy and Farnham, 2002).  
 
 
 
 
 
 
 
Figure 43: Model for the transcriptional activation of MAD1 expression in response to TGFβ1. A. In the 
absence of TGFβ treatment the MAD1 promoter is assembled in a pre-activated state. The gene specific 
transcription factors C/EBPα, C/EBPβ, SP1, MYC, and MAX and the Pol II complex are bound to the MAD1 
promoter. The Pol II complex is paused by the elongation factors NELF and DSIF, which inhibit the productive 
elongation of Pol II. B. In response to TGFβ1, C/EBPs and SMADs are activated and recruited respectively, 
resulting in the recruitment of P-TEFb, which phosphorylates CTD Ser-2, NELF and DSIF. C. Alternatively  
P-TEFb interacts with the Mediator complex, which is recruited by activated C/EBPβ and/or SP1.  
 
The second proposed mechanism bases on the interaction with the promoter bound Mediator 
complex. This interaction is mediated through the double bromodomain containing protein 
Brd4, which preferentially binds to acetylated chromatin (Yang et al., 2005). The recruitment 
of the Mediator complex may occur in a C/EBPβ-SP1-dependent manner. p38 signalling 
might induce post-translational modifications on C/EBPβ and/or SP1 accompanied by 
conformational changes, which allow the direct binding of components of the Mediator 
complex. C/EBPβ was described to switch from a repressive to an active conformation in 
response to phosphorylation by ERK1/2 facilitating the interaction with co-factor complexes 
A 
B 
C 
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(Kowenz-Leutz et al., 1994) (Nakajima et al., 1993). Furthermore, the phosphorylation of 
C/EBPβ initiates an exchange of components of the Mediator complex, which converts the 
Mediator complex into the active state. Several subunits of the Mediator complex have been 
reported to directly interact with C/EBPβ including Med1 and CRSP130/Sur2  (Li et al., 2008) 
(Mo et al., 2004). The p38 phosphorylation sites and the influence of this modification on 
C/EBPβ and SP1 remain to be examined in future studies. However, in addition it is 
conceivable that both mechanisms co-operate in the regulation of MAD1 expression.  
c-MYC may play a role in the regulation of MAD1 expression by determining the amount of 
promoter-bound C/EBPα and C/EBPβ. In TGFβ1 treated cells c-MYC expression is 
downregulated, which in turn would lead to an increased binding of C/EBPα and C/EBPβ to 
the promoter. The fact that no differences were detectable suggests that maybe only slight 
differences appear in response to TGFβ signalling. Also the tumour cells used in the studies 
summarized here may not be an adequate cell system. Instead the response to TGFβ1 
should also be addressed in non-transformed cells. 
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6.2 Abbreviations 
 
°C   Degree Celsius 
A  Ampere 
aa  Amino acid 
Ab   Antibody 
Ad5   Adenovirus 5 
A.dest.  Destilled water 
ADP  Adenosine diphosphate 
Amp   Ampicillin 
APS   Ammonium persulfate 
ATCC   American Type Culture Collection 
ATP   Adenosine triphosphate 
ß-ME   ß-Mercaptoethanol 
bHLH   Basic helix-loop-helix 
b  Basic region 
bp   Base pair(s) 
BPB   Bromophenole blue 
Bq   Bequerel 
BSA   Bovine serum albumin 
ca.   Circa 
CBP  CREB binding factor 
CDK   Cyclin-dependent kinase 
cDNA  Complementary DNA 
ChIP   Chromatin immunoprecipitation 
Ci   Curie 
cm2   Square centimeter 
CMV   Cytomegalie virus 
CT  car 
Da   Dalton 
DBD   DNA binding domain 
DMEM  Dulbecco’s modified Eagle’s medium 
DMSO   Dimethyl sulfoxide 
DNA   Desoxyribonucleic acid 
dNTP  Desoxynucleosidtriphosphat 
DRE   Dioxin response elements 
DTT   Dithiothreitol 
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ECL   Enhanced chemoluminescens 
E. coli  Escherichia coli 
EDTA   Ethylenediaminetetraacetic acid 
e.g.   for example 
EGTA   Ethyleneglycol-bis(2-aminoethylether)-N,N,N’,N’-tetraacetic acid 
et.al.   et alii 
FCS   Fetal calf serum 
g   Gramm 
g   gravitation constant ( g = 9,81 m / s2) 
G-CSF  Granulocyte colony stimulationg factor 
GSK   Glycogen synthase kinase 
h   h(s) 
HA  Hemaglutenin 
HAT  Histone acetytransferase 
HLHLZip helix-loop-helix-leucine zipper 
Hebs   Hepes buffered saline 
HEK   Human Embryo Kidney 
HEPES  4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
HMT   Histone methyltransferase 
HRP   Horseradish peroxidase 
i.e.   that is 
IgG   Immunoglobulin G 
INR  Initiator element 
IP   Immunoprecipitation 
l   Litre 
LB   Luria Broth 
LPS   Lipopolysaccharide 
JAK  Janus tyrosine kinase 
KLF  Krueppel-like factor 
µ   Micro 
m   Meter 
mm   Milli 
M   Mega 
M   Molar (mol / l) 
MAPK  Mitogen activated protein kinases 
MCS   Multiple cloning site 
Min  Minute(s) 
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mRNA  messenger RNA 
n   Nano 
NEB   New England Biolabs 
NES   Nuclear export signal 
NLS   Nuclear localisation signal 
NP-40   Nonidet P-40 
OD   Optical density 
ODC  Ornithin decarboxylase 
PAGE   Polyacrylamide gel electrophoresis 
PBS   Phospate buffered saline 
PCR  Polymerase chain reaction 
PI3K  Phosphatidyinositol 3-kinase 
PIP3  Phosphatidyinositol-3,4,5-triphosphat 
RNA   Ribonucleic acid 
Pol  Polymerase 
RPMI   Roswell Park Memorial Institute 
rpm   rounds per minute 
SDS   Sodium dodecyl sulfate 
shRNA  short hairpin RNA 
TAD  Transactivation domain 
TCA   Trichloroacetic acid 
TE   Tris-EDTA 
TPA  12-O-tetradecanoylphorbol-13-acetat 
U   Unit 
v/v  volume per volume 
Vol.   Volume 
w/v   weight per volume 
WB   Western Blot 
WT   Wild-type 
X  times / -fold 
XC   Xylene cyanol 
YFP   Yellow fluorescent protein 
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